

# Specific Genetic Predictors of Chemotherapeutic Response in Anaplastic Oligodendrogliomas

Journal of the National Cancer Institute

90, 1473-1479

DOI: [10.1093/jnci/90.19.1473](https://doi.org/10.1093/jnci/90.19.1473)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Low-grade gliomas. , 0, , 142-155.		3
2	Radiotherapy with concurrent and adjuvant temozolomide: a new standard of care for glioblastoma multiforme. , 0, , 37-52.		1
3	Rate of Fat Uptake by Intestinal Lymphatics.. Experimental Biology and Medicine, 1961, 108, 278-282.	1.1	75
4	Chemisorption Theory. Progress in Surface and Membrane Science, 1975, 9, 71-161.	0.9	46
5	Chemoradiation strategies for patients with malignant glioma. Seminars in Radiation Oncology, 1997, 7, 33-36.	1.0	1
6	Current Treatment of Oligodendrogliomas. Archives of Neurology, 1999, 56, 434.	4.9	41
7	Dysferlin is a surface membrane-associated protein that is absent in Miyoshi myopathy. Neurology, 1999, 53, 1119-1119.	1.5	133
8	Morphologic and molecular genetic aspects of oligodendroglial neoplasms. Neuro-Oncology, 1999, 1, 52-60.	0.6	49
9	Clinical Presentation, Diagnosis, and Pharmacotherapy of Patients with Primary Brain Tumors. Annals of Pharmacotherapy, 1999, 33, 816-832.	0.9	52
10	Expression of oligodendrocyte progenitor cell antigens by gliomas: Implications for the histogenesis of brain tumors. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 10361-10366.	3.3	175
11	BUdR radiosensitization in anaplastic astrocytoma. International Journal of Radiation Oncology Biology Physics, 1999, 45, 1105-1106.	0.4	1
12	Homozygous Deletions of the <i>CDKN2C</i> / <i>p18<sup>INK4C</sup></i> Gene on the Short Arm of Chromosome 1 in Anaplastic Oligodendrogliomas. Brain Pathology, 1999, 9, 639-643.	2.1	41
13	Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene, 1999, 18, 4144-4152.	2.6	354
14	Primary central nervous system tumors in adults. Current Treatment Options in Neurology, 1999, 1, 377-394.	0.7	14
15	Molecular Genetic Aspects of Oligodendrogliomas Including Analysis by Comparative Genomic Hybridization. American Journal of Pathology, 1999, 155, 375-386.	1.9	259
16	Molecular Genetic Analysis of Ependymal Tumors. American Journal of Pathology, 1999, 155, 627-632.	1.9	226
17	Oligodendroglioma: An Appraisal of Recent Data Pertaining to Diagnosis and Treatment. Neurosurgery, 1999, 45, 1279-1291.	0.6	143
19	Alterations of Chromosome Arms 1p and 19q as Predictors of Survival in Oligodendrogliomas, Astrocytomas, and Mixed Oligoastrocytomas. Journal of Clinical Oncology, 2000, 18, 636-636.	0.8	1,027

#	ARTICLE	IF	CITATIONS
20	Understanding low-grade glioma. <i>Neurology</i> , 2000, 54, 1402-1403.	1.5	24
21	Magnetic Source Imaging. <i>Journal of Neurosurgery</i> , 2000, 92, 1079-80.	0.9	1
22	Amplification of the Platelet-Derived Growth Factor Receptor- $\alpha$ (PDGFRA) Gene Occurs in Oligodendrogliomas with Grade IV Anaplastic Features. <i>Journal of Neuropathology and Experimental Neurology</i> , 2000, 59, 495-503.	0.9	118
23	Loss of Heterozygosity on Chromosome 19 in Secondary Glioblastomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2000, 59, 539-543.	0.9	118
24	<i>p18</i> tumor suppressor gene and progression of oligodendrogliomas to anaplasia. <i>Neurology</i> , 2000, 55, 867-869.	1.5	19
25	Advances in pediatric neuro-oncology. <i>Current Opinion in Neurology</i> , 2000, 13, 627-634.	1.8	5
26	Identification of transforming growth factor- $\beta$ 1-binding protein overexpression in carmustine-resistant glioma cells by mRNA differential display. <i>Cancer</i> , 2000, 89, 850-862.	2.0	8
27	CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas. <i>International Journal of Cancer</i> , 2000, 88, 554-557.	2.3	53
28	Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. <i>Genes Chromosomes and Cancer</i> , 2000, 29, 16-25.	1.5	13
29	Central neurocytomas are genetically distinct from oligodendrogliomas and neuroblastomas. <i>Histopathology</i> , 2000, 37, 160-165.	1.6	54
30	Molecular genetic analysis of archival gliomas using diagnostic smears. <i>Neuropathology and Applied Neurobiology</i> , 2000, 26, 441-447.	1.8	7
31	Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 48, 825-830.	0.4	198
32	Loss of heterozygosity at 1p, 8p, 10p, 13q, and 17p in advanced urothelial cancer and lack of relation to chemotherapy response and outcome. <i>Cancer Genetics and Cytogenetics</i> , 2000, 123, 109-113.	1.0	9
33	Allelic Loss at Chromosome Band 6q14 Correlates with Favorable Prognosis in Hepatocellular Carcinoma. <i>Cancer Genetics and Cytogenetics</i> , 2000, 116, 23-27.	1.0	10
34	Malignant gliomas. <i>Current Treatment Options in Oncology</i> , 2000, 1, 459-468.	1.3	104
35	Application of advances in molecular biology to the treatment of brain tumors. <i>Current Oncology Reports</i> , 2000, 2, 425-433.	1.8	7
36	A neurosurgeon's perspective on the neuropathology of low-grade gliomas. <i>Brain Tumor Pathology</i> , 2000, 17, 85-88.	1.1	0
37	A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors. <i>Journal of Neurology</i> , 2000, 247, 297-302.	1.8	51

#	ARTICLE	IF	CITATIONS
38	Long-term survival of glioblastoma multiforme: importance of histopathological reevaluation. <i>Journal of Neurology</i> , 2000, 247, 455-460.	1.8	57
39	Spinal cord astrocytoma: Response to PCV chemotherapy. <i>Neurology</i> , 2000, 54, 518-518.	1.5	25
40	Genetic alterations in adult diffuse glioma occurrence significance and prognostic implications. <i>Frontiers in Bioscience - Landmark</i> , 2000, 5, d213-231.	3.0	9
41	Neuro-oncology: Diagnosis and Management of Cerebral Gliomasâ€”Past, Present, and Future. <i>Neurosurgery</i> , 2000, 47, 1-8.	0.6	20
42	Ataxias on the march from Quebec to Tunisia. <i>Neurology</i> , 2000, 54, 1400-1401.	1.5	8
43	Myeloablative chemotherapy for recurrent aggressive oligodendroglioma. <i>Neuro-Oncology</i> , 2000, 2, 114-119.	0.6	25
44	Comprehensive Allelotype and Genetic Analysis of 466 Human Nervous System Tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2000, 59, 544-558.	0.9	137
45	Current status of viral gene therapy for brain tumours. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 713-726.	1.9	11
46	Genetic reflection of glioblastoma biopsy material in xenografts: characterization of 11 glioblastoma xenograft lines by comparative genomic hybridization. <i>Journal of Neurosurgery</i> , 2000, 92, 652-658.	0.9	23
47	Long survival and therapeutic responses in patient histologically disparate high-grade gliomas demonstrating chromosome 1p loss. <i>Journal of Neurosurgery</i> , 2000, 92, 983-990.	0.9	133
48	Long-term outcome of low-grade oligodendroglioma and mixed glioma. <i>Neurology</i> , 2000, 54, 1442-1448.	1.5	319
49	A Transcript Map of the Chromosome 19q-Arm Glioma Tumor Suppressor Region. <i>Genomics</i> , 2000, 64, 44-50.	1.3	116
50	Telomere length and Telomerase catalytic subunit expression in non-astrocytic gliomas. <i>Pathology Research and Practice</i> , 2000, 196, 691-699.	1.0	6
51	â€”Chemotherapy is useful in treatment of gliomasâ€™. <i>Journal of Clinical Neuroscience</i> , 2000, 7, 465-466.	0.8	1
52	Clinicopathologic study of forty-four histologically pure supratentorial oligodendrogliomas. <i>Annals of Diagnostic Pathology</i> , 2000, 4, 218-227.	0.6	29
53	Chemotherapy of low-grade gliomas. <i>Seminars in Radiation Oncology</i> , 2001, 11, 138-144.	1.0	23
54	Losses of Chromosomal Arms 1p and 19q in the Diagnosis of Oligodendroglioma. A Study of Paraffin-Embedded Sections. <i>Modern Pathology</i> , 2001, 14, 842-853.	2.9	110
55	CÃ¡ncer del sistema nervioso central. <i>Medicine</i> , 2001, 8, 3014-3023.	0.0	0

#	ARTICLE	IF	CITATIONS
56	PTEN Is a Target of Chromosome 10q Loss in Anaplastic Oligodendrogliomas and PTEN Alterations Are Associated with Poor Prognosis. American Journal of Pathology, 2001, 159, 359-367.	1.9	147
57	Glioma Classification. American Journal of Pathology, 2001, 159, 779-786.	1.9	265
58	Detection of 1p and 19q Loss in Oligodendroglioma by Quantitative Microsatellite Analysis, a Real-Time Quantitative Polymerase Chain Reaction Assay. American Journal of Pathology, 2001, 158, 1253-1262.	1.9	156
59	Pediatric High-Grade Astrocytomas Show Chromosomal Imbalances Distinct from Adult Cases. American Journal of Pathology, 2001, 158, 1525-1532.	1.9	121
60	Brain Tumors. New England Journal of Medicine, 2001, 344, 114-123.	13.9	1,597
61	Anticancer drug resistance in primary human brain tumors. Brain Research Reviews, 2001, 35, 161-204.	9.1	126
62	Malignant glioma: genetics and biology of a grave matter. Genes and Development, 2001, 15, 1311-1333.	2.7	1,064
63	Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncology, The, 2001, 2, 552-560.	5.1	493
64	Future trends in the treatment of brain tumours. European Journal of Cancer, 2001, 37, 2297-2301.	1.3	8
65	MOLECULAR BIOLOGY OF NERVOUS SYSTEM TUMORS. Hematology/Oncology Clinics of North America, 2001, 15, 979-1006.	0.9	6
66	NOVEL CHEMOTHERAPEUTIC APPROACHES TO BRAIN TUMORS. Hematology/Oncology Clinics of North America, 2001, 15, 1027-1052.	0.9	18
68	GENETICS OF NERVOUS SYSTEM TUMORS. Hematology/Oncology Clinics of North America, 2001, 15, 961-978.	0.9	15
69	Safety and Efficacy of Temozolomide in Patients With Recurrent Anaplastic Oligodendrogliomas After Standard Radiotherapy and Chemotherapy. Journal of Clinical Oncology, 2001, 19, 2449-2455.	0.8	164
71	PCV for Oligodendroglial Tumors: In Search of Prognostic Factors for Response and Survival. Canadian Journal of Neurological Sciences, 2001, 28, 215-223.	0.3	27
72	Pilot Evaluation of 1p and 19q Deletions in Anaplastic Oligodendrogliomas Collected by a National Cooperative Cancer Treatment Group. American Journal of Clinical Oncology: Cancer Clinical Trials, 2001, 24, 506-508.	0.6	36
73	Oligodendrogliomas: The Achilles' Heel of Malignant Gliomas. Canadian Journal of Neurological Sciences, 2001, 28, 187-188.	0.3	0
74	Constitutive Expression of Growth-related Oncogene and Its Receptor in Oligodendrogliomas. Neurosurgery, 2001, 48, 864-874.	0.6	4
75	Response of short-term cultures derived from human malignant glioma to aziridinylbenzoquinone, etoposide and doxorubicin: an in vitro phase II trial. Anti-Cancer Drugs, 2001, 12, 753-760.	0.7	10

#	ARTICLE	IF	CITATIONS
76	Combined Oligodendroglioma/Pleomorphic Xanthoastrocytoma: A Probable Collision Tumor: Case Report. <i>Neurosurgery</i> , 2001, 48, 1358-1361.	0.6	0
77	Clinical trials in neuro-oncology. <i>Current Opinion in Neurology</i> , 2001, 14, 689-694.	1.8	7
78	Oligodendroglial Neoplasms: Current Concepts, Misconceptions, and Folklore. <i>Advances in Anatomic Pathology</i> , 2001, 8, 183-199.	2.4	53
79	Constitutive Expression of Growth-related Oncogene and Its Receptor in Oligodendrogliomas. <i>Neurosurgery</i> , 2001, 48, 864-874.	0.6	43
80	Oligodendrogliomas: Reproducibility and Prognostic Value of Histologic Diagnosis and Grading. <i>Journal of Neuropathology and Experimental Neurology</i> , 2001, 60, 248-262.	0.9	186
81	Combined Oligodendroglioma/Pleomorphic Xanthoastrocytoma: A Probable Collision Tumor: Case Report. <i>Neurosurgery</i> , 2001, 48, 1358-1361.	0.6	35
82	Oligodendrogliomas: clinical and genetic correlations. <i>Current Opinion in Neurology</i> , 2001, 14, 705-710.	1.8	28
83	Oligodendroglioma. <i>Current Treatment Options in Neurology</i> , 2001, 3, 59-66.	0.7	9
84	Low-grade gliomas. <i>Current Treatment Options in Oncology</i> , 2001, 2, 495-506.	1.3	52
85	Adults with newly diagnosed high-grade gliomas. <i>Current Treatment Options in Oncology</i> , 2001, 2, 507-515.	1.3	20
86	Promoter hypermethylation and homozygous deletion of the p14 ARF and p16 INK4a genes in oligodendrogliomas. <i>Acta Neuropathologica</i> , 2001, 101, 185-189.	3.9	79
87	Chemotherapy for malignant brain tumors of astrocytic and oligodendroglial lineage. <i>Journal of Cancer Research and Clinical Oncology</i> , 2001, 127, 91-95.	1.2	28
88	Replicative Mcm2 protein as a novel proliferation marker in oligodendrogliomas and its relationship to Ki67 labelling index, histological grade and prognosis. <i>Neuropathology and Applied Neurobiology</i> , 2001, 27, 305-313.	1.8	94
89	Subtyping of oligo-astrocytic tumours by comparative genomic hybridization. <i>Journal of Pathology</i> , 2001, 194, 81-87.	2.1	55
90	Chromosomal imbalances associated with response to chemotherapy and cytotoxic cytokines in human malignant glioma cell lines. <i>International Journal of Cancer</i> , 2001, 91, 213-218.	2.3	5
91	Genetically engineered mouse models of astrocytoma: GEMs in the rough?. <i>Seminars in Cancer Biology</i> , 2001, 11, 177-190.	4.3	28
92	Prostate cancer susceptibility genes: many studies, many results, no answers. <i>Cancer and Metastasis Reviews</i> , 2001, 20, 155-164.	2.7	26
93	Molecular genetic alterations in glioblastomas with oligodendroglial component. <i>Acta Neuropathologica</i> , 2001, 101, 311-320.	3.9	101

#	ARTICLE	IF	CITATIONS
94	Genetic abnormalities in oligodendroglial and ependymal tumours. <i>Journal of Neurology</i> , 2001, 248, 1030-1035.	1.8	6
95	A novel member of the WD-repeat gene family, WDR11, maps to the 10q26 region and is disrupted by a chromosome translocation in human glioblastoma cells. <i>Oncogene</i> , 2001, 20, 5378-5392.	2.6	47
96	Comparative genomic hybridization analysis identifies gains of 1p35 <sup>~</sup> 1/4p36 and chromosome 19 in osteosarcoma. <i>Cancer Genetics and Cytogenetics</i> , 2001, 130, 14-21.	1.0	69
97	Chemotherapy for the treatment of oligodendroglial tumors. <i>Seminars in Oncology</i> , 2001, 28, 13-18.	0.8	39
98	Pathology of low- and intermediate-grade gliomas. <i>Seminars in Radiation Oncology</i> , 2001, 11, 95-102.	1.0	8
99	Multidisciplinary management of adult anaplastic astrocytomas. <i>Seminars in Radiation Oncology</i> , 2001, 11, 163-169.	1.0	10
100	Multidisciplinary management of adult anaplastic oligodendrogliomas and anaplastic mixed oligo-astrocytomas. <i>Seminars in Radiation Oncology</i> , 2001, 11, 170-180.	1.0	19
101	Multiple sclerosis and oligodendroglioma. <i>Multiple Sclerosis Journal</i> , 2001, 7, 269-273.	1.4	26
102	Concurrent Inactivation of RB1 and TP53 Pathways in Anaplastic Oligodendrogliomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2001, 60, 1181-1189.	0.9	92
103	Glioblastomas with an Oligodendroglial Component: A Pathological and Molecular Study. <i>Journal of Neuropathology and Experimental Neurology</i> , 2001, 60, 863-871.	0.9	120
104	Oligodendroglial Tumors Frequently Demonstrate Hypermethylation of the <i>CDKN2A</i> ( <i>MTS1</i> ), <i>INK4b</i> ( <i>p15</i> ) and <i>CDKN2B</i> ( <i>MTS2</i> ) Tumor Suppressor Genes. <i>Journal of Neuropathology and Experimental Neurology</i> , 2001, 60, 1170-1180.	0.9	81
105	Concurrent Hypermethylation of Multiple Genes Is Associated with Grade of Oligodendroglial Tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2001, 60, 808-816.	0.9	100
106	Distinct Expression Pattern of Microtubule-Associated Protein-2 in Human Oligodendrogliomas and Glial Precursor Cells. <i>Journal of Neuropathology and Experimental Neurology</i> , 2001, 60, 984-993.	0.9	93
107	Temozolomide chemotherapy in recurrent oligodendroglioma. <i>Neurology</i> , 2001, 57, 340-342.	1.5	89
108	Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. <i>Neurology</i> , 2001, 57, 1278-1281.	1.5	119
109	Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 10851-10856.	3.3	159
110	PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. <i>Genes and Development</i> , 2001, 15, 1913-1925.	2.7	611
111	Controversies in the therapy of low-grade glioma: when and how to treat. <i>Expert Review of Anticancer Therapy</i> , 2002, 2, 529-536.	1.1	3

#	ARTICLE	IF	CITATIONS
112	Influence of Unrecognized Molecular Heterogeneity on Randomized Clinical Trials. <i>Journal of Clinical Oncology</i> , 2002, 20, 2495-2499.	0.8	160
113	Molecular and Functional Imaging Technology for the Development of Efficient Treatment Strategies for Gliomas. <i>Technology in Cancer Research and Treatment</i> , 2002, 1, 187-204.	0.8	31
114	Chromosome 1p Allelic Loss by Fluorescence In Situ Hybridization Is Not Observed in Dysembryoplastic Neuroepithelial Tumors. <i>American Journal of Clinical Pathology</i> , 2002, 118, 512-517.	0.4	36
115	Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral contraceptives containing low-androgenic progestin. <i>Human Reproduction</i> , 2002, 17, 76-82.	0.4	44
116	Histopathological-Molecular Genetic Correlations in Referral Pathologist-Diagnosed Low-Grade Oligodendroglioma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2002, 61, 58-63.	0.9	134
117	High-Throughput Molecular Profiling of High-Grade Astrocytomas: The Utility of Fluorescence In Situ Hybridization on Tissue Microarrays (TMA-FISH). <i>Journal of Neuropathology and Experimental Neurology</i> , 2002, 61, 1078-1084.	0.9	40
118	Localization of the Neuronal Class III $\beta$ -Tubulin in Oligodendrogliomas: Comparison with Ki-67 Proliferative Index and 1p/19q Status. <i>Journal of Neuropathology and Experimental Neurology</i> , 2002, 61, 307-320.	0.9	63
119	Chromosomal imbalances in primary oligodendroglial tumors and their recurrences: clues about malignant progression detected using comparative genomic hybridization. <i>Journal of Neurosurgery</i> , 2002, 96, 559-564.	0.9	47
120	Analysis of loss of chromosome 10q, DMBT1 homozygous deletions, and PTEN mutations in oligodendrogliomas. <i>Journal of Neurosurgery</i> , 2002, 97, 1397-1401.	0.9	30
121	Current diagnosis and treatment of oligodendroglioma. <i>Neurosurgical Focus</i> , 2002, 12, 1-7.	1.0	20
122	Integrating pharmacogenomics into drug development. <i>Pharmacogenomics</i> , 2002, 3, 453-467.	0.6	32
123	Genetic differences between neurocytoma and dysembryoplastic neuroepithelial tumor and oligodendroglial tumors. <i>Journal of Neurosurgery</i> , 2002, 97, 1350-1355.	0.9	74
124	Genetic and Biologic Progression in Astrocytomas and Their Relation to Angiogenic Dysregulation. <i>Advances in Anatomic Pathology</i> , 2002, 9, 24-36.	2.4	88
125	Low-grade gliomas in adults. <i>Current Opinion in Neurology</i> , 2002, 15, 657-661.	1.8	22
126	Management of Glioblastoma Multiforme in Patients Presenting With Poor Functional Status. <i>Contemporary Neurosurgery</i> , 2002, 24, 1-5.	0.2	0
127	Genetic Alterations in Brain Tumors. , 2002, , 267-272.		0
128	Oligodendrogliomas with Neurocytic Differentiation. A Report of 4 Cases with Diagnostic and Histogenetic Implications. <i>Journal of Neuropathology and Experimental Neurology</i> , 2002, 61, 947-955.	0.9	147
129	The WHO Classification of Tumors of the Nervous System. <i>Journal of Neuropathology and Experimental Neurology</i> , 2002, 61, 215-225.	0.9	1,615



#	ARTICLE	IF	CITATIONS
130	Impact of Genotype and Morphology on the Prognosis of Glioblastoma. Journal of Neuropathology and Experimental Neurology, 2002, 61, 321-328.	0.9	184
131	Genetic Signature of Oligoastrocytomas Correlates with Tumor Location and Denotes Distinct Molecular Subsets. American Journal of Pathology, 2002, 161, 313-319.	1.9	171
132	Oligodendroglioma: pathology and molecular biology. World Neurosurgery, 2002, 58, 111-117.	1.3	76
133	Immunohistochemical markers for prognosis of oligodendroglial neoplasms. Journal of Neuro-Oncology, 2002, 58, 237-253.	1.4	18
134	Congenital oligodendroglioma with initial manifestation of jaundice. Pediatric Neurology, 2002, 27, 230-233.	1.0	10
135	Brain-tumour drug resistance: the bare essentials. Lancet Oncology, The, 2002, 3, 397-406.	5.1	90
136	Focus on central nervous system neoplasia. Cancer Cell, 2002, 1, 125-128.	7.7	130
137	Intersections between neurobiology and oncology: tumor origin, treatment and repair of treatment-associated damage. Trends in Neurosciences, 2002, 25, 103-107.	4.2	37
138	Diagnostic molecular genetics and its application to clinical decision in brain tumors. International Congress Series, 2002, 1247, 221-229.	0.2	0
139	Molecular abnormalities and correlations with tumor response and outcome in glioma patients. Neuroimaging Clinics of North America, 2002, 12, 627-639.	0.5	8
140	Low-grade gliomas in adults. Current Opinion in Neurology, 2002, 15, 657-661.	1.8	14
141	Prostate cancer susceptibility genes: Many studies, many results, no answers. , 2002, , 19-28.		0
142	Chemotherapy for Malignant Gliomas. Japanese Journal of Neurosurgery, 2002, 11, 347-354.	0.0	0
143	Quantitatively Determined Survivin Expression Levels Are of Prognostic Value in Human Gliomas. Journal of Clinical Oncology, 2002, 20, 1063-1068.	0.8	257
144	Molecular Imaging of Gliomas. Molecular Imaging, 2002, 1, 153535002002213.	0.7	12
145	Adenine nucleotide translocator 1 deficiency associated with Sengers syndrome. Annals of Neurology, 2002, 52, 95-99.	2.8	75
146	Angiostrongylus cantonensis infection mimicking a spinal cord tumor. Annals of Neurology, 2002, 52, 99-101.	2.8	15
147	Microscopic R2* mapping of reduced brain iron in the Belgrade rat. Annals of Neurology, 2002, 52, 102-105.	2.8	25

#	ARTICLE	IF	CITATIONS
148	Preferential loss of paternal 19q, but not 1p, alleles in oligodendrogliomas. <i>Annals of Neurology</i> , 2002, 52, 105-107.	2.8	21
149	Creutzfeldt-Jakob disease cluster in an Australian rural city. <i>Annals of Neurology</i> , 2002, 52, 115-118.	2.8	23
150	Anti-Hu antibodies in Merkel cell carcinoma. <i>Annals of Neurology</i> , 2002, 52, 111-115.	2.8	24
151	Minicolumnar pathology in dyslexia. <i>Annals of Neurology</i> , 2002, 52, 108-110.	2.8	64
152	In vivo study indicating loss of intracortical inhibition in tumor-associated epilepsy. <i>Annals of Neurology</i> , 2002, 52, 119-122.	2.8	16
153	Germline mosaicism of a novel mutation in lysosome-associated membrane protein-2 deficiency (Danon) Tj ETQq1 1,0.784314.rgBT /Ov 2.8 25	2.8	25
154	Association of chromosome 10 losses and negative prognosis in oligoastrocytomas. <i>Annals of Neurology</i> , 2002, 52, 842-845.	2.8	32
155	N-acetylglutamate synthase deficiency and the treatment of hyperammonemic encephalopathy. <i>Annals of Neurology</i> , 2002, 52, 845-849.	2.8	42
156	Transcriptional inactivation of TP73 expression in oligodendroglial tumors. <i>International Journal of Cancer</i> , 2002, 98, 370-375.	2.3	50
157	Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. <i>Cancer</i> , 2002, 95, 641-655.	2.0	104
158	Studying the heterogeneity of brain tumors using medium throughput LOH analysis. <i>Cytometry</i> , 2002, 47, 52-55.	1.8	2
159	Identification of the small interstitial deletion at chromosome band 1p34-p35 and its association with poor outcome in oligodendroglial tumors. <i>Genes Chromosomes and Cancer</i> , 2002, 35, 170-175.	1.5	39
160	Recurrent malignant glioma in adults. <i>Current Treatment Options in Oncology</i> , 2002, 3, 509-524.	1.3	43
161	Loss of heterozygosity on chromosome 22 in human ependymomas. <i>Acta Neuropathologica</i> , 2002, 103, 415-420.	3.9	33
162	Methylation of the p73 gene in gliomas. <i>Acta Neuropathologica</i> , 2002, 104, 357-362.	3.9	43
163	Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. <i>Acta Neuropathologica</i> , 2002, 103, 267-275.	3.9	126
164	Intensified PCV-chemotherapy with optional stem cell support in recurrent malignant oligodendroglioma. <i>Journal of Neurology</i> , 2002, 249, 1055-1057.	1.8	8
165	OLIG-1 and 2 gene expression and oligodendroglial tumours. <i>Neuropathology and Applied Neurobiology</i> , 2002, 28, 89-94.	1.8	22

#	ARTICLE	IF	CITATIONS
166	Classifying the medulloblastoma: insights from morphology and molecular genetics. <i>Neuropathology and Applied Neurobiology</i> , 2002, 28, 257-282.	1.8	195
167	PAI-1 and EGFR expression in adult glioma tumors: toward a molecular prognostic classification. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 592-598.	0.4	342
168	Multiplexed Analysis of Post-PCR Fluorescence-labeled Microsatellite Alleles and Statistical Evaluation of Their Imbalance in Brain Tumors. <i>Japanese Journal of Cancer Research</i> , 2002, 93, 284-290.	1.7	18
169	Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p. <i>Oncogene</i> , 2002, 21, 3961-3968.	2.6	80
170	Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum. <i>Oncogene</i> , 2002, 21, 7453-7463.	2.6	66
172	Extreme drug resistance in primary brain tumors: in vitro analysis of 64 resection specimens. <i>Journal of Neuro-Oncology</i> , 2002, 58, 115-123.	1.4	19
173	Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomas. <i>Journal of Neuro-Oncology</i> , 2002, 59, 157-163.	1.4	22
174	Human esophageal cancer is distinguished from adjacent esophageal tissue by tissue cysteine concentrations. <i>Digestive Diseases and Sciences</i> , 2002, 47, 2743-2750.	1.1	12
175	Neuropathology and Molecular Genetics of Diffusely Infiltrating Cerebral Gliomas. <i>Medical Laser Application: International Journal for Laser Treatment and Research</i> , 2002, 17, 133-146.	0.4	2
176	Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity. <i>Journal of Neuro-Oncology</i> , 2003, 64, 271-278.	1.4	65
177	A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma. <i>Investigational New Drugs</i> , 2003, 21, 473-480.	1.2	8
178	High-dose Chemotherapy with Stem Cell Rescue as Initial Therapy for Anaplastic Oligodendroglioma. <i>Journal of Neuro-Oncology</i> , 2003, 65, 127-134.	1.4	29
179	Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. <i>Journal of Neuro-Oncology</i> , 2003, 61, 267-273.	1.4	64
180	Oligodendroglioma. <i>Current Treatment Options in Oncology</i> , 2003, 4, 479-490.	1.3	12
181	Oligodendrogliomas: An update on basic and clinical research. <i>Current Neurology and Neuroscience Reports</i> , 2003, 3, 223-228.	2.0	4
182	Radiochemotherapy of Malignant Glioma in Adults. <i>Strahlentherapie Und Onkologie</i> , 2003, 179, 219-232.	1.0	57
184	Supratentorial grade II astrocytoma: biological features and clinical course. <i>Lancet Neurology</i> , The, 2003, 2, 395-403.	4.9	149
185	Can chemotherapy replace radiotherapy in low-grade gliomas? Time for randomized studies. <i>Seminars in Oncology</i> , 2003, 30, 39-44.	0.8	16

#	ARTICLE	IF	CITATIONS
186	Prognostic factors for low-grade gliomas. <i>Seminars in Oncology</i> , 2003, 30, 23-28.	0.8	52
187	Factors influencing survival in high-grade gliomas. <i>Seminars in Oncology</i> , 2003, 30, 10-14.	0.8	371
188	New frontiers in the treatment of malignant glioma. <i>Seminars in Oncology</i> , 2003, 30, 72-76.	0.8	18
189	Combined modality treatment for central nervous system malignancies. <i>Seminars in Oncology</i> , 2003, 30, 11-22.	0.8	15
190	Grade II astrocytomas are subgrouped by chromosome aberrations. <i>Cancer Genetics and Cytogenetics</i> , 2003, 142, 1-7.	1.0	51
191	Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas. <i>Cancer Genetics and Cytogenetics</i> , 2003, 144, 134-142.	1.0	107
192	Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. <i>Cancer</i> , 2003, 97, 1063-1071.	2.0	142
193	Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. <i>Cancer</i> , 2003, 97, 1276-1284.	2.0	184
194	Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p. <i>Cancer</i> , 2003, 97, 2254-2261.	2.0	45
195	Cyclooxygenase-2 in oligodendroglial neoplasms. <i>Cancer</i> , 2003, 98, 1465-1472.	2.0	29
196	No preferential loss of paternal 19q alleles in oligodendroglial tumors. <i>Annals of Neurology</i> , 2003, 54, 256-258.	2.8	10
197	Conformal irradiation for pure and mixed oligodendroglioma: The experience of Centre Leon Berard Lyon. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 56, 296-303.	0.4	10
198	Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q -deleted oligodendrogliomas. <i>Neuropathology and Applied Neurobiology</i> , 2003, 29, 462-471.	1.8	31
199	Age-related differences in 1p and 19q deletions in oligodendrogliomas. <i>BMC Clinical Pathology</i> , 2003, 3, 6.	1.8	13
200	Expression of cyclin A and topoisomerase III $\pm$ of oligodendrogliomas is correlated with tumour grade, MIB-1 labelling index and survival. <i>Histopathology</i> , 2003, 42, 395-402.	1.6	9
201	Genetic alterations of human brain tumors as molecular prognostic factors. <i>Neuropathology</i> , 2003, 23, 95-108.	0.7	14
202	Rapid detection of allelic losses in brain tumours using microsatellite repeat markers and high-performance liquid chromatography. <i>British Journal of Cancer</i> , 2003, 88, 1889-1893.	2.9	11
203	Molecular Diagnosis of Oligodendroglioma in Paraffin Sections. <i>Laboratory Investigation</i> , 2003, 83, 419-428.	1.7	61

#	ARTICLE	IF	CITATIONS
204	Fluorescent In Situ Hybridization on Isolated Tumor Cell Nuclei: A Sensitive Method for 1p and 19q Deletion Analysis in Paraffin-Embedded Oligodendroglial Tumor Specimens. <i>Modern Pathology</i> , 2003, 16, 708-715.	2.9	53
205	Progress and challenges for cell encapsulation in brain tumour therapy. <i>Expert Opinion on Biological Therapy</i> , 2003, 3, 551-561.	1.4	26
206	Targeted therapy in non-small cell lung cancer: myth or reality. <i>Lung Cancer</i> , 2003, 41, 3-8.	0.9	33
207	Oligodendroglioma and anaplastic oligodendroglioma. <i>World Neurosurgery</i> , 2003, 60, 443-456.	1.3	127
208	Primary brain tumours in adults. <i>Lancet, The</i> , 2003, 361, 323-331.	6.3	709
209	Association between Chromosome 1p and 19q Loss and Outcome in Pediatric Malignant Gliomas: Results from the CCG-945 Cohort. <i>Pediatric Neurosurgery</i> , 2003, 39, 114-121.	0.4	61
210	p190RhoGAP can act to inhibit PDGF-induced gliomas in mice: a putative tumor suppressor encoded on human Chromosome 19q13.3. <i>Genes and Development</i> , 2003, 17, 476-487.	2.7	82
211	Promises and controversies in the management of low-grade glioma. <i>Annals of Oncology</i> , 2003, 14, 1695-1696.	0.6	17
212	Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. <i>Journal of Clinical Oncology</i> , 2003, 21, 2525-2528.	0.8	288
213	Thallium-201 Single-Photon Emission Computed Tomography As an Early Predictor of Outcome in Recurrent Glioma. <i>Journal of Clinical Oncology</i> , 2003, 21, 3559-3565.	0.8	44
214	Correlation between genetic alterations and growth of human malignant glioma xenografted in nude mice. <i>British Journal of Cancer</i> , 2003, 89, 2327-2332.	2.9	15
215	Phase II Trial of Procarbazine, Lomustine, and Vincristine as Initial Therapy for Patients With Low-Grade Oligodendroglioma or Oligoastrocytoma: Efficacy and Associations With Chromosomal Abnormalities. <i>Journal of Clinical Oncology</i> , 2003, 21, 251-255.	0.8	236
216	Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. <i>Annals of Oncology</i> , 2003, 14, 1722-1726.	0.6	245
217	Trochleitis and migraine headache. <i>Neurology</i> , 2003, 61, 425-425.	1.5	17
218	Dramatic response to chemotherapy in oligodendroglial gliomatosis cerebri. <i>Neurology</i> , 2003, 60, 151-151.	1.5	23
219	Pure spastic paraparesis associated with a novel presenilin 1 R278K mutation. <i>Neurology</i> , 2003, 60, 150-150.	1.5	35
220	Analysis of a molecular genetic neuro-oncology study with partially biased selection. <i>Biostatistics</i> , 2003, 4, 167-178.	0.9	2
221	Preliminary observations on genetic alterations in pilocytic astrocytomas associated with neurofibromatosis 1. <i>Neuro-Oncology</i> , 2003, 5, 228-234.	0.6	33

#	ARTICLE	IF	CITATIONS
222	Dramatic response to chemotherapy in oligodendroglial gliomatosis cerebri. <i>Neurology</i> , 2003, 61, 425-425.	1.5	1
223	Recent developments in the molecular characterization and treatment of oligodendroglial tumors. <i>Neuro-Oncology</i> , 2003, 5, 128-138.	0.6	64
224	Anaplastic Oligodendrogliomas: Prognostic Factors for Tumor Recurrence and Survival. <i>Oncology</i> , 2003, 65, 259-266.	0.9	72
225	High-Resolution Analysis of Genetic Events in Cancer Cells Using Bacterial Artificial Chromosome Arrays and Comparative Genome Hybridization. <i>Advances in Cancer Research</i> , 2003, 90, 91-125.	1.9	44
226	Expression of the Oligodendroglial Lineage-Associated Markers Olig1 and Olig2 in Different Types of Human Gliomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2003, 62, 1052-1059.	0.9	70
227	Alterations in molecular pathways of diffusely infiltrating glial neoplasms: application to tumor classification and anti-tumor therapy (Review). <i>International Journal of Oncology</i> , 2003, 23, 857.	1.4	13
228	Clinical Utility of Fluorescence In Situ Hybridization (FISH) in Morphologically Ambiguous Gliomas with Hybrid Oligodendroglial/Astrocytic Features. <i>Journal of Neuropathology and Experimental Neurology</i> , 2003, 62, 1118-1128.	0.9	100
230	Relative survival rates and patterns of diagnosis analyzed by time period for individuals with primary malignant brain tumor, 1973-1997. <i>Journal of Neurosurgery</i> , 2003, 99, 458-466.	0.9	76
231	Pathology of low-grade gliomas: An update of emerging concepts. <i>Neuro-Oncology</i> , 2003, 5, 168-178.	0.6	43
232	Oligodendroglioma: Toward Molecular Definitions in Diagnostic Neuro-Oncology. <i>Journal of Neuropathology and Experimental Neurology</i> , 2003, 62, 111-126.	0.9	280
233	Pediatric Oligodendrogliomas: A Study of Molecular Alterations on 1p and 19q Using Fluorescence In Situ Hybridization. <i>Journal of Neuropathology and Experimental Neurology</i> , 2003, 62, 530-537.	0.9	100
234	Human Glioma Diagnosis from Gene Expression Data. , 2003, , 241-256.		1
235	Adjuvant Treatment for Gliomas. <i>Contemporary Neurosurgery</i> , 2003, 25, 1-9.	0.2	7
236	Classification of Glioblastoma Multiforme in Adults by Molecular Genetics. <i>Cancer Journal (Sudbury, Mass )</i> , 2003, 9, 214-221.	1.0	51
237	Title is missing!. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, e60-e66.	0.6	3
239	Current Chemotherapy for Glioblastoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2003, 9, 149-156.	1.0	80
240	Genetic Markers in Glioblastoma: Prognostic Significance and Future Therapeutic Implications. <i>Advances in Anatomic Pathology</i> , 2003, 10, 212-217.	2.4	75

#	ARTICLE	IF	CITATIONS
241	Oligodendroglioma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, e60-e66.	0.6	15
242	Advanced Cancer Genetics in Neurosurgical Research. Neurosurgery, 2003, 53, 1168-1178.	0.6	2
243	Malignant Glioma Physiology: Cellular Response to Hypoxia and Its Role in Tumor Progression. Annals of Internal Medicine, 2003, 138, 659.	2.0	98
244	Development of Secondary Anaplastic Oligoastrocytoma after Matched Unrelated Bone Marrow Transplantation in a Child with Acute Myeloid Leukemia. Acta Haematologica, 2003, 109, 196-198.	0.7	5
245	Ancillary fish analysis for 1p and 19q status preliminary observations in 287 gliomas and oligodendroglioma mimics. Frontiers in Bioscience - Landmark, 2003, 8, A1-9.	3.0	123
246	Initial chemotherapy in gliomatosis cerebri. Neurology, 2004, 63, 270-275.	1.5	106
247	Gliomatosis cerebri. Neurology, 2004, 63, 204-205.	1.5	11
248	Prognostic value of allelic losses and telomerase activity in meningiomas. Journal of Neurosurgery, 2004, 100, 303-309.	0.9	43
249	The influence of sex and the presence of giant cells on postoperative long-term survival in adult patients with supratentorial glioblastoma multiforme. Journal of Neurosurgery, 2004, 101, 219-226.	0.9	81
250	Therapy for recurrent malignant glioma in adults. Expert Review of Anticancer Therapy, 2004, 4, 759-782.	1.1	29
251	Case 33-2004. New England Journal of Medicine, 2004, 351, 1875-1882.	13.9	3
252	Imaging Molecular Signatures in Oligodendroglioma: Fig. 1.. Clinical Cancer Research, 2004, 10, 7109-7111.	3.2	9
253	Treatment of low-grade oligodendroglial tumors without radiotherapy. Neurology, 2004, 63, 2384-2386.	1.5	30
254	Molecular-genetic characterisation of gliomas that recur as same grade or higher grade tumours. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 723-726.	0.9	19
255	Imaging Correlates of Molecular Signatures in Oligodendrogliomas. Clinical Cancer Research, 2004, 10, 4303-4306.	3.2	142
256	Rapid generation of detailed loss of heterozygosity profiles for routine diagnosis of gliomas. Clinical Chemistry and Laboratory Medicine, 2004, 42, 595-601.	1.4	3
257	The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human Gliomas. Journal of Clinical Oncology, 2004, 22, 1926-1933.	0.8	347
258	Distinct Responses of Xenografted Gliomas to Different Alkylating Agents Are Related to Histology and Genetic Alterations. Cancer Research, 2004, 64, 4648-4653.	0.4	29



#	ARTICLE	IF	CITATIONS
259	Correlation of Molecular Genetics with Molecular and Morphological Imaging in Gliomas with an Oligodendroglial Component. <i>Clinical Cancer Research</i> , 2004, 10, 7182-7191.	3.2	60
260	Molecular Stratification of Diagnostically Challenging High-Grade Gliomas Composed of Small Cells. <i>Clinical Cancer Research</i> , 2004, 10, 7820-7826.	3.2	35
261	Detrended fluctuation analysis of genome-wide copy number profiles of glioblastomas using array-based comparative genomic hybridization. <i>Neuro-Oncology</i> , 2004, 6, 281-289.	0.6	23
262	Temozolomide As Initial Treatment for Adults With Low-Grade Oligodendrogliomas or Oligoastrocytomas and Correlation With Chromosome 1p Deletions. <i>Journal of Clinical Oncology</i> , 2004, 22, 3133-3138.	0.8	336
263	High-Dose Chemotherapy in Childhood Brain Tumors. <i>Oncology Research and Treatment</i> , 2004, 27, 239-245.	0.8	20
264	Current and Future Trials of the EORTC Brain Tumor Group. <i>Oncology Research and Treatment</i> , 2004, 27, 246-250.	0.8	16
265	Prognostic Value of 1p, 19q, 9p, 10q, and EGFR-FISH Analyses in Recurrent Oligodendrogliomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2004, 63, 314-322.	0.9	185
266	Characterization of the 1p/19q Chromosomal Loss in Oligodendrogliomas Using Comparative Genomic Hybridization Arrays (CGHa). <i>Journal of Neuropathology and Experimental Neurology</i> , 2004, 63, 151-158.	0.9	49
267	Immunolocalization of the Oligodendrocyte Transcription Factor 1 (Olig1) in Brain Tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2004, 63, 170-179.	0.9	32
268	Expression of Hypoxia-related Tissue Factors Correlates with Diminished Survival of Adjuvantly Treated Patients with Chromosome 1p Aberrant Oligodendroglial Neoplasms and Therapeutic Implications. <i>Clinical Cancer Research</i> , 2004, 10, 6567-6571.	3.2	12
269	The present and future management of malignant brain tumours: surgery, radiotherapy, chemotherapy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004, 75, ii24-ii30.	0.9	43
270	Delivery systems and molecular targets of mechanism-based therapies for GBM. <i>Expert Review of Neurotherapeutics</i> , 2004, 4, 649-663.	1.4	12
271	Age-Dependent Prognostic Effects of Genetic Alterations in Glioblastoma. <i>Clinical Cancer Research</i> , 2004, 10, 228-233.	3.2	161
272	Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials. <i>Neuro-Oncology</i> , 2004, 6, 96-103.	0.6	55
273	Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. <i>Neuro-Oncology</i> , 2004, 6, 134-144.	0.6	42
274	Diagnostic and prognostic significance of genetic regional heterogeneity in meningiomas. <i>Neuro-Oncology</i> , 2004, 6, 290-299.	0.6	44
275	Correlations between molecular profile and radiologic pattern in oligodendroglial tumors. <i>Neurology</i> , 2004, 63, 2360-2362.	1.5	72
276	Development of novel targeted therapies in the treatment of malignant glioma. <i>Nature Reviews Drug Discovery</i> , 2004, 3, 430-446.	21.5	214



#	ARTICLE	IF	CITATIONS
277	Gene expression profiling and subgroup identification of oligodendrogliomas. <i>Oncogene</i> , 2004, 23, 6012-6022.	2.6	56
278	DNA replication licensing and cell cycle kinetics of oligodendroglial tumours. <i>British Journal of Cancer</i> , 2004, 91, 262-269.	2.9	54
279	Identification of two contiguous minimally deleted regions on chromosome 1p36.31â€“p36.32 in oligodendroglial tumours. <i>British Journal of Cancer</i> , 2004, 91, 1105-1111.	2.9	36
280	Microdissection genotyping of gliomas: therapeutic and prognostic considerations. <i>Modern Pathology</i> , 2004, 17, 1346-1358.	2.9	5
281	Oligodendroglial Tumors: Refinement of Candidate Regions on Chromosome Arm 1p and Correlation of 1p/19q Status with Survival. <i>Brain Pathology</i> , 2004, 14, 121-130.	2.1	148
282	Selective Expression of a Subset of Neuronal Genes in Oligodendroglioma with Chromosome 1p Loss. <i>Brain Pathology</i> , 2004, 14, 34-42.	2.1	57
283	Altered molecular pathways in gliomas: An overview of clinically relevant issues. <i>Seminars in Oncology</i> , 2004, 31, 595-604.	0.8	79
284	Anaplastic astrocytoma: Diagnosis, prognosis, and management. <i>Seminars in Oncology</i> , 2004, 31, 618-634.	0.8	50
285	Diagnosis and management of oligodendroglioma. <i>Seminars in Oncology</i> , 2004, 31, 645-652.	0.8	34
286	Current controversies in the radiotherapeutic management of adult low-grade glioma. <i>Seminars in Oncology</i> , 2004, 31, 653-658.	0.8	34
287	Whatâ€™s new in neurological surgery1 1No competing interests declared.. <i>Journal of the American College of Surgeons</i> , 2004, 199, 109-113.	0.2	1
288	Application of bacterial artificial chromosome array-based comparative genomic hybridization and spectral karyotyping to the analysis of glioblastoma multiforme. <i>Cancer Genetics and Cytogenetics</i> , 2004, 151, 36-51.	1.0	58
289	Molecular Genetic Study of a Metastatic Oligodendroglioma. <i>Journal of Neuro-Oncology</i> , 2004, 66, 265-271.	1.4	27
290	Deletions of Chromosomes 1p and 19q are Detectable on Frozen Smears of Gliomas by FISH: Usefulness for Stereotactic Biopsies. <i>Journal of Neuro-Oncology</i> , 2004, 68, 141-149.	1.4	19
291	BCNU Down-Regulates Anti-Apoptotic Proteins Bcl-xL and Bcl-2 in Association with Cell Death in Oligodendroglioma-Derived Cells. <i>Journal of Neuro-Oncology</i> , 2004, 68, 233-241.	1.4	20
292	A Critical Review of the Clinical Effects of Therapeutic Irradiation Damage to the Brain: The Roots of Controversy. <i>Neuropsychology Review</i> , 2004, 14, 65-86.	2.5	123
293	Brain tumours: classification and genes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004, 75, ii2-ii11.	0.9	105
294	Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. <i>Acta Neuropathologica</i> , 2004, 108, 49-56.	3.9	288

#	ARTICLE	IF	CITATIONS
295	Microtubule-associated protein-2 immunoreactivity: a useful tool in the differential diagnosis of low-grade neuroepithelial tumors. <i>Acta Neuropathologica</i> , 2004, 108, 89-96.	3.9	66
296	The importance of genomic copy number changes in the prognosis of glioblastoma multiforme. <i>Neurosurgical Review</i> , 2004, 27, 58-64.	1.2	39
297	Chemoradiotherapy for brain tumors: current status and perspectives. <i>International Journal of Clinical Oncology</i> , 2004, 9, 471-474.	1.0	23
298	Genetic analysis of human glioblastomas using a genomic microarray system. <i>Brain Tumor Pathology</i> , 2004, 21, 27-34.	1.1	50
299	Molecular pathogenesis of oligodendroglial tumors. <i>Journal of Neuro-Oncology</i> , 2004, 70, 161-181.	1.4	99
300	Response of low-grade oligodendroglial tumors to temozolomide. <i>Journal of Neuro-Oncology</i> , 2004, 70, 279-280.	1.4	10
301	Pathology and molecular genetics of oligodendroglial tumors. <i>Journal of Molecular Medicine</i> , 2004, 82, 638-655.	1.7	44
302	Low-grade glioma: Supratentorial astrocytoma, oligodendroglioma, and oligoastrocytoma in adults. <i>Current Neurology and Neuroscience Reports</i> , 2004, 4, 211-217.	2.0	23
303	Malignant gliomas. <i>Current Neurology and Neuroscience Reports</i> , 2004, 4, 218-227.	2.0	30
304	Impact of location on outcome in children with low-grade oligodendroglioma. <i>Pediatric Blood and Cancer</i> , 2004, 43, 250-256.	0.8	42
305	Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy. <i>Cancer</i> , 2004, 100, 807-813.	2.0	39
306	Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. <i>Cancer</i> , 2004, 100, 2208-2214.	2.0	141
307	Small cell astrocytoma: An aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma. <i>Cancer</i> , 2004, 101, 2318-2326.	2.0	135
308	Combined treatment modality for anaplastic oligodendroglioma and oligoastrocytoma: a 10-year update of a Phase II study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 509-514.	0.4	13
309	Temozolomide treatment in glioma Experiences in two university hospitals in finland. <i>Acta Oncol³gica</i> , 2004, 43, 579-584.	0.8	3
310	Neuroimaging in glioma therapy. <i>Expert Review of Neurotherapeutics</i> , 2004, 4, 665-671.	1.4	7
311	Neuroâ€œOncology. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, 5, 34-35.	1.4	1
312	Gene Expression Profiling of Gliomas Strongly Predicts Survival. <i>Cancer Research</i> , 2004, 64, 6503-6510.	0.4	659

#	ARTICLE	IF	CITATIONS
314	Molecular Diagnosis of Metastasizing Oligodendroglioma. <i>Journal of Molecular Diagnostics</i> , 2004, 6, 52-57.	1.2	15
317	Genetic markers in the assessment of intrinsic brain tumours. <i>Current Diagnostic Pathology</i> , 2004, 10, 83-92.	0.4	7
318	Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas. <i>Brain Research Reviews</i> , 2004, 45, 143-163.	9.1	89
319	The infrared spectrum of human glioma cells is related to their in vitro and in vivo behavior. <i>Experimental Cell Research</i> , 2004, 297, 294-301.	1.2	33
320	The complex identity of brain tumors: emerging concerns regarding origin, diversity and plasticity. <i>Trends in Neurosciences</i> , 2004, 27, 148-154.	4.2	33
321	Cyclooxygenase-2, Bcl-2, and chromosome 1p analysis in protoplasmic astrocytomas. <i>Human Pathology</i> , 2004, 35, 317-321.	1.1	6
322	Atypical extraventricular neurocytoma with oligodendroglioma-like spread and an unusual pattern of chromosome 1p and 19q loss. <i>Human Pathology</i> , 2004, 35, 1156-1159.	1.1	47
326	Primary spinal oligoastrocytoma: a case report. <i>World Neurosurgery</i> , 2004, 61, 77-81.	1.3	15
328	Molecular changes in gliomas. <i>Current Opinion in Oncology</i> , 2004, 16, 607-613.	1.1	72
330	Physiology and Gene Expression Characteristics of Carcinogen-Initiated and Tumor-Transformed Glial Progenitor Cells Derived from the CNS of Methylnitrosourea (MNU)-Treated Sprague-Dawley Rats. <i>Journal of Neuropathology and Experimental Neurology</i> , 2004, 63, 1182-1199.	0.9	14
331	Neural development and the ontogeny of central nervous system tumors. <i>Neuron Glia Biology</i> , 2004, 1, 127-133.	2.0	4
332	Advances in the biology and treatment of oligodendrogliomas. <i>Current Opinion in Neurology</i> , 2004, 17, 675-680.	1.8	30
333	Bony Metastases of Anaplastic Oligodendroglioma Respond to Temozolomide. <i>Canadian Journal of Neurological Sciences</i> , 2004, 31, 102-108.	0.3	24
334	Staging Workup, Sentinel Node Biopsy, and Follow-up Tests for Melanoma. <i>Archives of Dermatology</i> , 2004, 140, 107-113.	1.7	44
335	State of the science in brain tumor classification. <i>Seminars in Oncology Nursing</i> , 2004, 20, 224-230.	0.7	19
336	Molecular genetics of oligodendrogliomas: a model for improved clinical management in the field of neurooncology. <i>Neurosurgical Focus</i> , 2005, 19, 1-9.	1.0	18
338	Molecular Diagnostic Techniques for the Clinical Evaluation of Gliomas. <i>Diagnostic Molecular Pathology</i> , 2005, 14, 1-8.	2.1	27
339	Oligodendroglioma: clinical study and survival analysis correlated with chromosomal anomalies. <i>Neurosurgical Focus</i> , 2005, 19, 1-9.	1.0	10

#	ARTICLE	IF	CITATIONS
340	An update on oligodendroglial neoplasms. <i>Current Opinion in Neurology</i> , 2005, 18, 639-644.	1.8	10
341	Molecular Diagnostics in Central Nervous System Tumors. <i>Advances in Anatomic Pathology</i> , 2005, 12, 180-194.	2.4	56
342	Validation of Intraoperative Diagnoses Using Smear Preparations from Stereotactic Brain Biopsies: Intraoperative versus Final Diagnosis—Influence of Clinical Factors. <i>Neurosurgery</i> , 2005, 56, 257-265.	0.6	112
343	Clinical and Radiological Prognostic Factors of Anaplastic Oligodendroglioma Treated by Combined Therapy. <i>Neurologia Medico-Chirurgica</i> , 2005, 45, 232-239.	1.0	15
344	PROGRESS IN CLINICAL NEUROSCIENCES: Advances in the Management of Low-Grade Gliomas. <i>Canadian Journal of Neurological Sciences</i> , 2005, 32, 18-26.	0.3	11
345	Fractionated stereotactic radiation therapy in the management of primary oligodendroglioma and oligoastrocytoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 797-802.	0.4	21
346	Genetic analyses for predictors of radiation response in glioblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 704-710.	0.4	20
347	First-line nitrosourea-based chemotherapy in symptomatic non-resectable supratentorial pure low-grade astrocytomas. <i>European Journal of Neurology</i> , 2005, 12, 685-690.	1.7	45
348	Oligodendroglioma: Impact of molecular biology on its definition, diagnosis and management. <i>Neuropathology</i> , 2005, 25, 247-253.	0.7	19
349	Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification. <i>Neuropathology and Applied Neurobiology</i> , 2005, 31, 62-69.	1.8	62
350	Molecular cytogenetic analysis of chromosomes 1 and 19 in glioma cell lines. <i>Cancer Genetics and Cytogenetics</i> , 2005, 160, 1-14.	1.0	54
351	No evidence of INI1hSNF5 (SMARCB1) and PARVG point mutations in oligodendroglial neoplasms. <i>Cancer Genetics and Cytogenetics</i> , 2005, 160, 169-173.	1.0	3
352	Surgery for malignant gliomas: mechanistic reasoning and slippery statistics. <i>Lancet Neurology</i> , The, 2005, 4, 413-422.	4.9	66
353	Low-grade gliomas: an update on pathology and therapy. <i>Lancet Neurology</i> , The, 2005, 4, 760-770.	4.9	113
354	Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas. <i>Genes Chromosomes and Cancer</i> , 2005, 42, 68-77.	1.5	89
355	Identification of consistent novel submegabase deletions in low-grade oligodendrogliomas using array-based comparative genomic hybridization. <i>Genes Chromosomes and Cancer</i> , 2005, 44, 85-96.	1.5	36
356	Frequent promoter hypermethylation and low expression of theMGMTgene in oligodendroglial tumors. <i>International Journal of Cancer</i> , 2005, 113, 379-385.	2.3	246
357	Molecular classification of human gliomas using matrix-based comparative genomic hybridization. <i>International Journal of Cancer</i> , 2005, 117, 95-103.	2.3	36

#	ARTICLE	IF	CITATIONS
358	Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. <i>Cancer</i> , 2005, 103, 329-338.	2.0	116
359	Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. <i>Cancer</i> , 2005, 103, 802-809.	2.0	123
360	Polymorphisms in <i>GLTSCR1</i> and <i>ERCC2</i> are associated with the development of oligodendrogliomas. <i>Cancer</i> , 2005, 103, 2363-2372.	2.0	60
361	The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. <i>Cancer</i> , 2005, 104, 1468-1477.	2.0	102
362	Molecular pathology and clinical characteristics of oligodendroglial neoplasms. <i>Annals of Neurology</i> , 2005, 57, 855-865.	2.8	64
363	Two types of chromosome 1p losses with opposite significance in gliomas. <i>Annals of Neurology</i> , 2005, 58, 483-487.	2.8	157
364	Grading of CNS neoplasms using continuous arterial spin labeled perfusion MR imaging at 3 Tesla. <i>Journal of Magnetic Resonance Imaging</i> , 2005, 22, 475-482.	1.9	156
365	Human gene therapy and imaging in neurological diseases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, S358-S383.	3.3	21
366	Losses of chromosomes 1p and 19q are rare in pediatric oligodendrogliomas. <i>Acta Neuropathologica</i> , 2005, 109, 387-392.	3.9	104
367	A distinct pattern of Olig2-positive cellular distribution in papillary glioneuronal tumors: a manifestation of the oligodendroglial phenotype?. <i>Acta Neuropathologica</i> , 2005, 110, 39-47.	3.9	56
368	Clinical, histological, and immunohistochemical features predicting 1p/19q loss of heterozygosity in oligodendroglial tumors. <i>Acta Neuropathologica</i> , 2005, 110, 27-38.	3.9	28
369	Molecular genetic alterations in gliomatosis cerebri: What can we learn about the origin and course of the disease?. <i>Acta Neuropathologica</i> , 2005, 110, 527-536.	3.9	34
370	Oligodendroglioma. <i>Current Treatment Options in Neurology</i> , 2005, 7, 305-314.	0.7	6
371	Optimal role of temozolomide in the treatment of malignant gliomas. <i>Current Neurology and Neuroscience Reports</i> , 2005, 5, 198-206.	2.0	168
372	Comparative genetic analysis of metachronous anaplastic oligoastrocytomas with extended recurrence-free interval. <i>Journal of Neuro-Oncology</i> , 2005, 72, 95-102.	1.4	4
373	Instability of mitochondrial DNA and MRI and clinical correlations in malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2005, 74, 87-90.	1.4	29
374	CXCL12 Expression is Predictive of a Shorter Time to Tumor Progression in Low-Grade Glioma: A Single-Institution Study in 50 Patients. <i>Journal of Neuro-Oncology</i> , 2005, 74, 287-293.	1.4	53
375	Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma. <i>Journal of Neuro-Oncology</i> , 2005, 71, 161-168.	1.4	36

#	ARTICLE	IF	CITATIONS
376	Postoperative radiotherapy and chemotherapy in the management of oligodendroglioma: single institutional review of 88 patients. <i>Journal of Neuro-Oncology</i> , 2005, 75, 189-193.	1.4	14
377	Allelic loss at 16q23.2 is associated with good prognosis in high grade prostate cancer. <i>Prostate</i> , 2005, 65, 341-346.	1.2	7
378	Comparison of Magnetic Resonance Spectroscopy and Perfusion-weighted Imaging in Presurgical Grading of Oligodendroglial Tumors. <i>Neurosurgery</i> , 2005, , .	0.6	30
381	Chemotherapy for Brain Tumors â€” A New Beginning. <i>New England Journal of Medicine</i> , 2005, 352, 1036-1038.	13.9	86
382	Single Nucleotide Polymorphisms (SNPs): History, Biotechnological Outlook and Practical Applications. <i>Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics</i> , 2005, 3, 237-245.	0.3	12
383	Gene Expression Profiles Associated with Treatment Response in Oligodendrogliomas. <i>Cancer Research</i> , 2005, 65, 11335-11344.	0.4	102
384	EMP3, a Myelin-Related Gene Located in the Critical 19q13.3 Region, Is Epigenetically Silenced and Exhibits Features of a Candidate Tumor Suppressor in Glioma and Neuroblastoma. <i>Cancer Research</i> , 2005, 65, 2565-2571.	0.4	154
386	YKL-40 Is a Differential Diagnostic Marker for Histologic Subtypes of High-Grade Gliomas. <i>Clinical Cancer Research</i> , 2005, 11, 2258-2264.	3.2	93
388	Drug Insight: temozolomide as a treatment for malignant gliomaâ€”impact of a recent trial. <i>Nature Clinical Practice Neurology</i> , 2005, 1, 88-95.	2.7	50
389	The molecular epidemiology of gliomas in adults. <i>Neurosurgical Focus</i> , 2005, 19, 1-11.	1.0	61
390	The Ki-67 labeling index as a prognostic factor in Grade II oligoastrocytomas. <i>Journal of Neurosurgery</i> , 2005, 102, 1033-1039.	0.9	15
391	Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 16759-16764.	3.3	270
392	Chemotherapy for low-grade gliomas. <i>Expert Review of Neurotherapeutics</i> , 2005, 5, 21-24.	1.4	3
393	Oligodendrogliomas: clinical significance of 1p and 19q chromosomal deletions. <i>Expert Review of Neurotherapeutics</i> , 2005, 5, 25-32.	1.4	8
394	Array Comparative Genomic Hybridization Identifies Genetic Subgroups in Grade 4 Human Astrocytoma. <i>Clinical Cancer Research</i> , 2005, 11, 2907-2918.	3.2	61
395	Oligodendroglioma and Its Variants: Radiologic-Pathologic Correlation. <i>Radiographics</i> , 2005, 25, 1669-1688.	1.4	114
396	Neoadjuvant temozolomide followed by complete resection of a 1p- and 19q-deleted anaplastic oligoastrocytoma: Case study. <i>Neuro-Oncology</i> , 2005, 7, 97-100.	0.6	17
397	Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1293-1302.	1.9	82

#	ARTICLE	IF	CITATIONS
398	A pseudolikelihood approach for simultaneous analysis of array comparative genomic hybridizations. <i>Biostatistics</i> , 2005, 7, 399-421.	0.9	45
399	Oligodendrogliomas Lacking O <sup>6</sup> -Methylguanine-DNA-Methyltransferase Expression. <i>Journal of Chemotherapy</i> , 2005, 17, 321-326.	0.7	8
400	Molecular Genetic Analysis of Oligodendroglial Tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2005, 64, 10-14.	0.9	49
401	MRI in treatment of adult gliomas. <i>Lancet Oncology</i> , The, 2005, 6, 167-175.	5.1	104
402	Clarifying the Diffuse Gliomas. <i>American Journal of Clinical Pathology</i> , 2005, 124, 755-768.	0.4	65
403	Patients with High-Grade Gliomas Harboring Deletions of Chromosomes 9p and 10q Benefit from Temozolomide Treatment. <i>Neoplasia</i> , 2005, 7, 883-893.	2.3	55
407	Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts. <i>Journal of Neurosurgery</i> , 2005, 102, 706-714.	0.9	36
408	Cerebellar oligodendroglioma in a young adult. <i>Journal of Clinical Neuroscience</i> , 2005, 12, 837-838.	0.8	10
409	Proximal migration of a lumboperitoneal unishunt system. <i>Journal of Clinical Neuroscience</i> , 2005, 12, 838-841.	0.8	11
410	What progress has been made in surgical management of patients with astrocytoma and oligodendroglioma in Australia over the last two decades?. <i>Journal of Clinical Neuroscience</i> , 2005, 12, 915-920.	0.8	9
411	Imaging in neurooncology. <i>NeuroRx</i> , 2005, 2, 333-347.	6.0	154
412	Genetic Pathways in the Evolution of Gliomas. , 2005, , 207-221.		0
415	Malignant Gliomas in 2005. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 615.	3.8	65
416	Multiplex Ligation-Dependent Probe Amplification. <i>Journal of Molecular Diagnostics</i> , 2006, 8, 433-443.	1.2	105
418	Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial. <i>Journal of Clinical Oncology</i> , 2006, 24, 2715-2722.	0.8	690
419	Chemotherapy in the treatment of malignant gliomas. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 755-767.	1.1	19
420	Oligodendroglial tumors. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 519-532.	1.4	8
421	Inroads in managing malignant gliomas renew hope. <i>Community Oncology</i> , 2006, 3, 684.	0.2	0



#	ARTICLE	IF	CITATIONS
423	Current Role of Radiation Therapy in the Management of Malignant Brain Tumors. Hematology/Oncology Clinics of North America, 2006, 20, 431-453.	0.9	7
424	Recent Advances in the Treatment of Malignant Astrocytoma. Journal of Clinical Oncology, 2006, 24, 1253-1265.	0.8	285
426	MOLECULAR PATHOLOGY OF MALIGNANT GLIOMAS. Annual Review of Pathology: Mechanisms of Disease, 2006, 1, 97-117.	9.6	566
427	High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: Long-term follow-up. Neuro-Oncology, 2006, 8, 183-188.	0.6	38
428	Glioma Test Array for Use with Formalin-Fixed, Paraffin-Embedded Tissue. Journal of Molecular Diagnostics, 2006, 8, 268-276.	1.2	43
429	Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. Journal of Clinical Oncology, 2006, 24, 2707-2714.	0.8	678
430	Recent developments in the use of chemotherapy in brain tumours. European Journal of Cancer, 2006, 42, 582-588.	1.3	108
431	Neural stem cells as novel cancer therapeutic vehicles. European Journal of Cancer, 2006, 42, 1298-1308.	1.3	45
432	1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. European Journal of Cancer, 2006, 42, 2499-2503.	1.3	111
433	Quantitation of chromosome 1p and 19q deletions in glial tumours by interphase FISH on formalin-fixed paraffin-embedded tissue. Journal of Clinical Neuroscience, 2006, 13, 96-101.	0.8	13
434	Clinical Pharmacology of Brain Tumor Chemotherapy. , 2006, , 21-43.		9
435	Chemotherapy of Oligodendrogliomas. , 2006, , 371-381.		1
436	Role of p16 and p14ARF in radio- and chemosensitivity of malignant gliomas. Oncology Reports, 2006, 16, 127.	1.2	8
437	Outcome-based profiling of astrocytic tumours identifies prognostic gene expression signatures which link molecular and morphology-based pathology. International Journal of Oncology, 2006, 29, 1183.	1.4	0
439	Glioma and Other Neuroepithelial Neoplasms. , 2006, , 674-694.		0
440	The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making. Journal of Neurosurgery, 2006, 104, 542-550.	0.9	43
441	DNA ???Fingerprint??? Evaluation of Clinical Specimen Contamination. , 2006, 11, 98-102.		6
442	Identification of der(1;19)(q10;p10) in Five Oligodendrogliomas Suggests Mechanism of Concurrent 1p and 19q Loss. Journal of Neuropathology and Experimental Neurology, 2006, 65, 988-994.	0.9	257



#	ARTICLE	IF	CITATIONS
443	The Role of Chemotherapy in the Treatment of Malignant Astrocytomas. Canadian Journal of Neurological Sciences, 2006, 33, 127-140.	0.3	14
444	Radiotherapy with Concurrent and Adjuvant Temozolomide: A New Standard of Care for Glioblastoma Multiforme. Progress in Neurotherapeutics and Neuropsychopharmacology, 2006, 1, 37-52.	0.0	2
445	Brain Tumor Imaging and Cancer Management. Topics in Magnetic Resonance Imaging, 2006, 17, 127-136.	0.7	16
446	Glioma Therapy in Adults. Neurologist, 2006, 12, 279-292.	0.4	121
447	Cimetidine, an unexpected anti-tumor agent, and its potential for the treatment of glioblastoma (review). International Journal of Oncology, 2006, 28, 1021.	1.4	16
448	Fluorescence In Situ Hybridization (FISH) on Touch Preparations: A Reliable Method for Detecting Loss of Heterozygosity at 1p and 19q in Oligodendroglial Tumors. American Journal of Surgical Pathology, 2006, 30, 828-837.	2.1	51
449	New approaches to primary brain tumor treatment. Anti-Cancer Drugs, 2006, 17, 1003-1016.	0.7	45
450	Perfusion Magnetic Resonance Imaging Predicts Patient Outcome as an Adjunct to Histopathology: A Second Reference Standard in the Surgical and Nonsurgical Treatment of Low-grade Gliomas. Neurosurgery, 2006, 58, 1009-1107.	0.6	98
451	Molecular changes in brain tumors: prognostic and therapeutic impact. Current Opinion in Oncology, 2006, 18, 623-630.	1.1	12
452	VARIANT OF THE CHEK2GENE AS A PROGNOSTIC MARKER IN GLIOBLASTOMA MULTIFORME. Neurosurgery, 2006, 59, 1078-1085.	0.6	19
453	Real-time Quantitative Polymerase Chain Reaction: A Potential Tool for Genetic Analysis in Neuropathology. Brain Pathology, 2002, 12, 54-66.	2.1	14
454	Fluorescence In Situ Hybridization (FISH) in Diagnostic and Investigative Neuropathology. Brain Pathology, 2002, 12, 67-86.	2.1	52
455	Molecular Classification of Human Diffuse Gliomas by Multidimensional Scaling Analysis of Gene Expression Profiles Parallels Morphology-Based Classification, Correlates with Survival, and Reveals Clinically Relevant Novel Glioma Subsets. Brain Pathology, 2002, 12, 108-116.	2.1	83
456	Novel <i>PLA2G4C</i> Polymorphism as a Molecular Diagnostic Assay for 19q Loss in Human Gliomas. Brain Pathology, 2002, 12, 178-182.	2.1	3
457	What is an Oligodendroglioma?. Brain Pathology, 2002, 12, 257-259.	2.1	97
458	Granular Cell Astrocytomas Show a High Frequency of Allelic Loss but are not a Genetically Defined Subset. Brain Pathology, 2003, 13, 185-194.	2.1	30
459	RE: MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION FOR THE DETECTION OF 1P AND 19Q LOSS IN OLIGODENDROGLIAL TUMORS. Brain Pathology, 2005, 15, 364-364.	2.1	3
460	Multiplex Ligation-Dependent Probe Amplification for the Detection of 1p and 19q Chromosomal Loss in Oligodendroglial Tumors. Brain Pathology, 2005, 15, 192-197.	2.1	36

#	ARTICLE	IF	CITATIONS
461	45- YEAR-OLD MALE WITH SYMPTOMATIC MASS IN THE FRONTAL LOBE. <i>Brain Pathology</i> , 2006, 16, 89-90.	2.1	5
462	Feature-Specific Penalized Latent Class Analysis for Genomic Data. <i>Biometrics</i> , 2006, 62, 1062-1070.	0.8	20
463	Lineage dependency and lineage-survival oncogenes in human cancer. <i>Nature Reviews Cancer</i> , 2006, 6, 593-602.	12.8	316
464	Genetic and metabolic predictors of chemosensitivity in oligodendroglial neoplasms. <i>British Journal of Cancer</i> , 2006, 95, 1424-1431.	2.9	9
465	Farnesylthiosalicylic acid induces caspase activation and apoptosis in glioblastoma cells. <i>Cell Death and Differentiation</i> , 2006, 13, 642-651.	5.0	11
466	Identification of novel genomic markers related to progression to glioblastoma through genomic profiling of 25 primary glioma cell lines. <i>Oncogene</i> , 2006, 25, 1571-1583.	2.6	96
467	Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma?. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 60, 99-111.	2.0	32
468	Comparative genomic hybridization pattern of non-anaplastic and anaplastic oligodendrogliomas " A meta-analysis. <i>Pathology Research and Practice</i> , 2006, 202, 23-30.	1.0	9
469	Gliomatosis Cerebri: A Review of 296 Cases from the ANOCEF Database and the Literature. <i>Journal of Neuro-Oncology</i> , 2006, 76, 201-205.	1.4	119
470	Oligodendroglial-specific Transcriptional Factor SOX10 is Ubiquitously Expressed in Human Gliomas. <i>Journal of Neuro-Oncology</i> , 2006, 76, 115-127.	1.4	63
471	Proposal of a scoring scale as a survival predictor in intracranial oligodendrogliomas. <i>Journal of Neuro-Oncology</i> , 2006, 79, 159-168.	1.4	6
472	Cystemustine in recurrent high grade glioma. <i>Journal of Neuro-Oncology</i> , 2006, 79, 33-37.	1.4	8
473	Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors. <i>Journal of Neuro-Oncology</i> , 2006, 79, 299-305.	1.4	13
474	The presence of necrosis and/or microvascular proliferation does not influence survival of patients with anaplastic oligodendroglial tumours: review of 98 patients. <i>Journal of Neuro-Oncology</i> , 2006, 80, 75-82.	1.4	20
475	Age at diagnosis and loss of heterozygosity on chromosome 1p and 19q in oligodendroglial tumors. <i>Journal of Neuro-Oncology</i> , 2006, 80, 215-217.	1.4	2
476	1p/19q chromosome deletions in metastatic oligodendrogloma. <i>Journal of Neuro-Oncology</i> , 2006, 80, 203-207.	1.4	25
478	Malignant glioma: Neuropathology and Neurobiology. <i>Wiener Medizinische Wochenschrift</i> , 2006, 156, 332-337.	0.5	46
479	Automatized assessment of 1p36-19q13 status in gliomas by interphase FISH assay on touch imprints of frozen tumours. <i>Acta Neuropathologica</i> , 2006, 111, 255-263.	3.9	14

#	ARTICLE	IF	CITATIONS
480	Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. <i>Neuroradiology</i> , 2006, 48, 703-713.	1.1	99
481	Thallium-201 SPECT: the optimal prediction of response in glioma therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 222-227.	3.3	13
482	Chemotherapeutic options for primary brain tumors. <i>Current Treatment Options in Oncology</i> , 2006, 7, 467-478.	1.3	15
483	Correlative studies in neuro-oncology trials: Should they influence treatment?. <i>Current Oncology Reports</i> , 2006, 8, 54-57.	1.8	5
484	Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. <i>Cancer Cell</i> , 2006, 9, 157-173.	7.7	2,706
485	Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas. <i>Cancer</i> , 2006, 106, 1358-1363.	2.0	200
486	Progressive low-grade oligodendrogliomas. <i>Cancer</i> , 2006, 106, 1759-1765.	2.0	131
487	Prognostic impact of molecular markers in a series of 220 primary glioblastomas. <i>Cancer</i> , 2006, 106, 2218-2223.	2.0	127
488	Prognostic stratification of patients with anaplastic gliomas according to genetic profile. <i>Cancer</i> , 2006, 107, 1891-1897.	2.0	63
489	Reclassification of oligoastrocytomas by loss of heterozygosity studies. <i>International Journal of Cancer</i> , 2006, 119, 84-90.	2.3	51
490	Identification of novel oligodendrogloma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling. <i>International Journal of Cancer</i> , 2006, 119, 792-800.	2.3	66
491	MGMT methylation: A marker of response to temozolomide in low-grade gliomas. <i>Annals of Neurology</i> , 2006, 60, 740-743.	2.8	196
492	The SHREW1 gene, frequently deleted in oligodendrogliomas, functions to inhibit cell adhesion and migration. <i>Cancer Biology and Therapy</i> , 2006, 5, 300-304.	1.5	41
493	Combination celecoxib and temozolomide in C6 rat glioma orthotopic model. <i>Oncology Reports</i> , 2006, 15, 7.	1.2	18
494	Using molecular information to guide brain tumor therapy. <i>Nature Clinical Practice Neurology</i> , 2006, 2, 232-233.	2.7	16
495	Management of malignant glioma: steady progress with multimodal approaches. <i>Neurosurgical Focus</i> , 2006, 20, E3.	1.0	65
496	Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. <i>Brain</i> , 2006, 129, 1884-1891.	3.7	150
497	Oligodendrogloma of the pineal region. <i>Journal of Neurosurgery</i> , 2006, 105, 461-464.	0.9	8

#	ARTICLE	IF	CITATIONS
498	Brain tumors: molecular biology and targeted therapies. <i>Annals of Oncology</i> , 2006, 17, x191-x197.	0.6	23
499	Low-Grade Gliomas in Adults. <i>Oncologist</i> , 2006, 11, 681-693.	1.9	128
500	Anaplastic Oligodendroglial Tumors: A Tale of Two Trials. <i>Journal of Clinical Oncology</i> , 2006, 24, 2689-2690.	0.8	18
501	Correlations Between O6-Methylguanine DNA Methyltransferase Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in Anaplastic and Recurrent Oligodendroglioma: A Prospective GICNO Study. <i>Journal of Clinical Oncology</i> , 2006, 24, 4746-4753.	0.8	171
502	A computationally tractable multivariate random effects model for clustered binary data. <i>Biometrika</i> , 2006, 93, 587-599.	1.3	6
503	Diffusely Infiltrative Low-Grade Gliomas in Adults. <i>Journal of Clinical Oncology</i> , 2006, 24, 1236-1245.	0.8	91
504	Changing Paradigms—An Update on the Multidisciplinary Management of Malignant Glioma. <i>Oncologist</i> , 2006, 11, 165-180.	1.9	357
505	Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area <sup>1</sup> . <i>Neuro-Oncology</i> , 2006, 8, 12-26.	0.6	70
506	Cytotoxic and molecular chemotherapy for high-grade glioma: an emerging strategy for the future. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 749-765.	0.9	4
507	Allelic Losses of Chromosome 10 in Glioma Tissues Detected by Quantitative Single-Strand Conformation Polymorphism Analysis. <i>Clinical Chemistry</i> , 2006, 52, 370-378.	1.5	31
508	Adjuvant treatment of high grade gliomas. <i>Annals of Oncology</i> , 2006, 17, x186-x190.	0.6	11
509	Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors. <i>Neurology</i> , 2006, 66, 1661-1667.	1.5	43
511	Molecular Diagnostics as a Tool to Personalize Treatment in Adult Glioma Patients. <i>Technology in Cancer Research and Treatment</i> , 2006, 5, 215-229.	0.8	19
512	Significance of Necrosis in Grading of Oligodendroglial Neoplasms: A Clinicopathologic and Genetic Study of Newly Diagnosed High-Grade Gliomas. <i>Journal of Clinical Oncology</i> , 2006, 24, 5419-5426.	0.8	158
513	A t(1;19)(q10;p10) Mediates the Combined Deletions of 1p and 19q and Predicts a Better Prognosis of Patients with Oligodendroglioma. <i>Cancer Research</i> , 2006, 66, 9852-9861.	0.4	678
514	Current Strategies in Treatment of Oligodendroglioma: Evolution of Molecular Signatures of Response. <i>Journal of Clinical Oncology</i> , 2006, 24, 1246-1252.	0.8	65
515	New treatment strategies for malignant gliomas. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1087-1104.	1.1	117
516	Present and potential future issues in glioblastoma treatment. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 719-732.	1.1	120

#	ARTICLE	IF	CITATIONS
517	Temozolomide: a milestone in neuro-oncology and beyond?. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1187-1204.	1.1	76
518	Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination. <i>Expert Review of Vaccines</i> , 2006, 5, 233-247.	2.0	48
519	Temozolomide for low-grade gliomas: Predictive impact of 1p/19q loss on response and outcome. <i>Neurology</i> , 2007, 68, 1831-1836.	1.5	282
520	Gene Expression-Based Molecular Diagnostic System for Malignant Gliomas Is Superior to Histological Diagnosis. <i>Clinical Cancer Research</i> , 2007, 13, 7341-7356.	3.2	68
521	Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. <i>Neuro-Oncology</i> , 2007, 9, 271-279.	0.6	144
522	The Application of Microarray Technology to the Analysis of the Cancer Genome. <i>Current Molecular Medicine</i> , 2007, 7, 103-120.	0.6	53
523	Chemotherapy for low-grade gliomas: Emerging consensus on its benefits. <i>Neurology</i> , 2007, 68, 1762-1763.	1.5	21
524	Proteomic comparison of oligodendrogliomas with and without 1pLOH. <i>Cancer Biology and Therapy</i> , 2007, 6, 391-396.	1.5	17
525	New developments in the treatment of malignant gliomas. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 1313-1326.	1.4	18
526	Association between fluorine-18 <sup>18</sup> F-labeled fluorodeoxyglucose uptake and 1p and 19q loss of heterozygosity in World Health Organization Grade II gliomas. <i>Journal of Neurosurgery</i> , 2007, 106, 633-637.	0.9	25
527	Cerebral Blood Volume Measurements and Proton MR Spectroscopy in Grading of Oligodendroglial Tumors. <i>American Journal of Roentgenology</i> , 2007, 188, 204-212.	1.0	106
528	Combined 1p/19q Loss in Oligodendroglial Tumors: Predictive or Prognostic Biomarker?. <i>Clinical Cancer Research</i> , 2007, 13, 6933-6937.	3.2	131
529	The 1p-Encoded Protein Stathmin and Resistance of Malignant Gliomas to Nitrosoureas. <i>Journal of the National Cancer Institute</i> , 2007, 99, 639-652.	3.0	49
530	Survey of treatment recommendations for anaplastic oligodendroglioma. <i>Neuro-Oncology</i> , 2007, 9, 314-318.	0.6	98
531	A Capsid-Modified, Conditionally Replicating Oncolytic Adenovirus Vector Expressing TRAIL Leads to Enhanced Cancer Cell Killing in Human Glioblastoma Models. <i>Cancer Research</i> , 2007, 67, 8783-8790.	0.4	62
532	Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 10974-10979.	3.3	65
533	Longitudinal Assessment of Genetic and Epigenetic Markers in Oligodendrogliomas. <i>Clinical Cancer Research</i> , 2007, 13, 1429-1437.	3.2	38
534	Mechanisms of Disease: genetic predictors of response to treatment in brain tumors. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 362-374.	4.3	36

#	ARTICLE	IF	CITATIONS
535	Correlation of chromosomal imbalances by comparative genomic hybridization and expression of EGFR, PTEN, p53, and MIB-1 in diffuse gliomas. <i>Oncology Reports</i> , 2007, 17, 1037.	1.2	3
536	Incorporating molecular tools into clinical trials and treatment for gliomas?. <i>Current Opinion in Neurology</i> , 2007, 20, 708-711.	1.8	9
537	Extracranial Relapse of an Anaplastic Oligodendroglioma in an Adolescent: Case Report and Review of the Literature. <i>Journal of Pediatric Hematology/Oncology</i> , 2007, 29, 319-322.	0.3	15
538	Gliosarcoma Arising in Oligodendroglial Tumors (âœOligosarcomaâœ). <i>American Journal of Surgical Pathology</i> , 2007, 31, 351-362.	2.1	50
539	Molecular targeted therapies and chemotherapy in malignant gliomas. <i>Current Opinion in Oncology</i> , 2007, 19, 598-605.	1.1	46
540	Molecular genetic markers as predictors of response to chemotherapy in gliomas. <i>Current Opinion in Oncology</i> , 2007, 19, 606-611.	1.1	56
541	GENETICALLY HETEROGENEOUS GLIOBLASTOMA RECURRING WITH DISAPPEARANCE OF 1P/19Q LOSSES. <i>Neurosurgery</i> , 2007, 61, E168-E169.	0.6	6
542	IQGAP1 and IGFBP2. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 405-417.	0.9	84
543	Intratumoral Distribution of 1p Loss in Oligodendroglial Tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 1118-1123.	0.9	9
544	Predictive and Prognostic Markers in Neuro-Oncology. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 1074-1081.	0.9	42
545	CLINICAL SIGNIFICANCE OF ABCA2, A POSSIBLE MOLECULAR MARKER FOR OLIGODENDROGLIOMAS. <i>Neurosurgery</i> , 2007, 60, 707-714.	0.6	11
546	Chemotherapy and Delivery in the Treatment of Primary Brain Tumors. <i>Current Clinical Pharmacology</i> , 2007, 2, 197-211.	0.2	9
547	Gene expression profile as a prognostic factor in high-grade gliomas. <i>International Journal of Oncology</i> , 2007, , .	1.4	5
548	Adjuvant Chemotherapy for Adults with Malignant Glioma: A Systematic Review. <i>Canadian Journal of Neurological Sciences</i> , 2007, 34, 402-410.	0.3	24
549	Diagnosis and pathogenesis of gliomas. <i>Current Diagnostic Pathology</i> , 2007, 13, 180-192.	0.4	12
550	High grade glioma: Imaging combined with pathological grade defines management and predicts prognosis. <i>Radiotherapy and Oncology</i> , 2007, 85, 371-378.	0.3	41
551	AnÃ¡lisis de la presencia de mutaciones por pÃ©rdida de heterocigocidad de 1p/19q en tumores cerebrales de estirpe glial. <i>Neurocirugia</i> , 2007, 18, 285-293.	0.2	3
552	Molecular Pathogenesis of Adult Brain Tumors and the Role of Stem Cells. <i>Neurologic Clinics</i> , 2007, 25, 891-924.	0.8	34

#	ARTICLE	IF	CITATIONS
553	Molecular Pathology in Clinical Practice. , 2007, , .		8
554	Loss of heterozygosity analysis in an anaplastic oligodendroglioma arising after radiation therapy. Neurological Research, 2007, 29, 723-726.	0.6	6
555	Temozolomide and Radiation in Low-Grade and Anaplastic Gliomas: Temoradiation. Cancer Investigation, 2007, 25, 776-784.	0.6	18
556	Anaplastic Oligodendroglioma and Oligoastrocytoma. Neurologic Clinics, 2007, 25, 1089-1109.	0.8	50
557	Tumors of the Central Nervous System. , 2007, , , 107-122.		5
558	Advanced MRI in the management of adult gliomas. British Journal of Neurosurgery, 2007, 21, 550-561.	0.4	71
560	EMP3 overexpression is associated with oligodendroglial tumors retaining chromosome arms 1p and 19q. International Journal of Cancer, 2007, 120, 947-950.	2.3	15
561	Identification of genomic aberrations associated with shorter overall survival in patients with oligodendroglial tumors. International Journal of Cancer, 2007, 120, 2368-2376.	2.3	35
562	Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound. International Journal of Cancer, 2007, 121, 901-907.	2.3	492
563	BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. International Journal of Cancer, 2008, 122, 1778-1786.	2.3	100
564	Candidate glioblastoma development gene identification using concordance between copy number abnormalities and gene expression level changes. Genes Chromosomes and Cancer, 2007, 46, 875-894.	1.5	26
565	High cerebral blood volume in human gliomas predicts deletion of chromosome 1p: Preliminary results of molecular studies in gliomas with elevated perfusion. Journal of Magnetic Resonance Imaging, 2007, 25, 1113-1119.	1.9	44
566	Central neurocytoma: Management recommendations based on a 35-year experience. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1145-1154.	0.4	132
567	Predicting Outcome of Patients with High-grade Gliomas After Radiotherapy using Quantitative Analysis of T1-weighted Magnetic Resonance Imaging. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1476-1483.	0.4	7
568	Outcome of children treated with preradiation chemotherapy for a high-grade glioma: Results of a French Society of Pediatric Oncology (SFOP) pilot study. Pediatric Blood and Cancer, 2007, 49, 803-807.	0.8	33
569	Hypermethylation and transcriptional downregulation of the CITED4 gene at 1p34.2 in oligodendroglial tumours with allelic losses on 1p and 19q. Oncogene, 2007, 26, 5010-5016.	2.6	43
570	Loss of Arf causes tumor progression of PDGFB-induced oligodendroglioma. Oncogene, 2007, 26, 6289-6296.	2.6	78
571	Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: A clinicopathological study using fluorescence in situ hybridization. Neuropathology, 2007, 27, 10-20.	0.7	46



#	ARTICLE	IF	CITATIONS
572	Human primary brain tumor cell growth inhibition in serum-free medium optimized for neuron survival. <i>Brain Research</i> , 2007, 1157, 156-166.	1.1	10
573	Metabolic and molecular imaging in neuro-oncology. <i>Lancet Neurology, The</i> , 2007, 6, 711-724.	4.9	100
574	Genomic alterations in low-grade, anaplastic astrocytomas and glioblastomas. <i>Pathology and Oncology Research</i> , 2007, 13, 39-46.	0.9	34
575	Objective Response to Radiation Therapy and Long-Term Survival of Patients with WHO Grade II Astrocytic Gliomas with Known LOH 1p/19q Status. <i>Strahlentherapie Und Onkologie</i> , 2007, 183, 517-522.	1.0	7
576	Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2007, 81, 323-325.	1.4	0
577	Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2007, 83, 53-60.	1.4	92
578	Cytogenetic analyses in 81 patients with brain gliomas: correlation with clinical outcome and morphological data. <i>Journal of Neuro-Oncology</i> , 2007, 84, 201-211.	1.4	11
579	Enhanced expression of DNA topoisomerase II genes in human medulloblastoma and its possible association with etoposide sensitivity. <i>Journal of Neuro-Oncology</i> , 2007, 84, 119-129.	1.4	19
580	Role of exclusive chemotherapy as first line treatment in oligodendroglioma. <i>Journal of Neuro-Oncology</i> , 2007, 85, 319-328.	1.4	10
581	Molecular Imaging of Brain Tumors: A Bridge Between Clinical and Molecular Medicine?. <i>Molecular Imaging and Biology</i> , 2007, 9, 60-71.	1.3	35
582	Predominant expression of OLIG2 over ID2 in oligodendroglial tumors. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2007, 450, 575-584.	1.4	8
583	Subtypes of oligodendroglioma defined by 1p,19q deletions, differ in the proportion of apoptotic cells but not in replication-licensed non-proliferating cells. <i>Acta Neuropathologica</i> , 2007, 113, 119-127.	3.9	16
584	FISH 1p/19q deletion/imbalance for molecular subclassification of glioblastoma. <i>Brain Tumor Pathology</i> , 2007, 24, 1-5.	1.1	26
585	Oligodendroglioma. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 262-272.	2.0	64
586	Prognostic and Predictive Markers in Glioma and Other Neuroepithelial Tumors. <i>Current Problems in Cancer</i> , 2008, 32, 97-123.	1.0	16
587	Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas. <i>Journal of Neuro-Oncology</i> , 2008, 88, 293-298.	1.4	49
588	Secondary anaplastic oligodendroglioma after cranial irradiation: a case report. <i>Journal of Neuro-Oncology</i> , 2008, 88, 299-303.	1.4	9
589	Chromosomal alterations in oligodendroglial tumours over multiple surgeries: is tumour progression associated with change in 1p/19q status?. <i>Journal of Neuro-Oncology</i> , 2008, 89, 37-45.	1.4	16



#	ARTICLE	IF	CITATIONS
590	Diagnosis of malignant glioma: role of neuropathology. <i>Journal of Neuro-Oncology</i> , 2008, 89, 287-311.	1.4	88
591	Methylation-specific multiplex ligation-dependent probe amplification in meningiomas. <i>Journal of Neuro-Oncology</i> , 2008, 90, 267-273.	1.4	9
592	Expression of glucose transporter 1 is associated with loss of heterozygosity of chromosome 1p in oligodendroglial tumors WHO grade II. <i>Journal of Molecular Histology</i> , 2008, 39, 553-560.	1.0	10
593	Molekular definierte Chemotherapien und zielgerichtete Therapien bei malignen Gliomen. <i>Onkopipeline</i> , 2008, 1, 11-16.	0.0	0
594	Anaplastic oligodendroglioma. <i>Current Treatment Options in Neurology</i> , 2008, 10, 295-307.	0.7	19
595	Glioblastomas: correlation between oligodendroglial components, genetic abnormalities, and prognosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008, 452, 481-490.	1.4	46
596	Brain tumor epidemiology: Consensus from the Brain Tumor Epidemiology Consortium. <i>Cancer</i> , 2008, 113, 1953-1968.	2.0	716
597	Frequent biallelic inactivation and transcriptional silencing of the <i>DIRAS3</i> gene at 1p31 in oligodendroglial tumors with 1p loss. <i>International Journal of Cancer</i> , 2008, 122, 2503-2510.	2.3	36
598	The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. <i>Oncogene</i> , 2008, 27, 2091-2096.	2.6	181
599	Can morphology predict 1p/19q loss in oligodendroglial tumours?. <i>Histopathology</i> , 2008, 53, 578-587.	1.6	26
600	Anaplastic Oligodendroglial Tumors: Refining the Correlation among Histopathology, 1p 19q Deletion and Clinical Outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. <i>Brain Pathology</i> , 2008, 18, 360-369.	2.1	125
601	The Evolution of Our Understanding on Glioma. <i>Brain Pathology</i> , 2008, 18, 455-463.	2.1	23
602	Phenotypic and Genotypic Characterization of Orthotopic Human Glioma Models and Its Relevance for the Study of Anti-Glioma Therapy. <i>Brain Pathology</i> , 2008, 18, 423-433.	2.1	67
603	Chromosome 1p loss evaluation in anaplastic oligodendrogliomas. <i>Neuropathology</i> , 2008, 28, 440-443.	0.7	29
604	Low grade diffuse gliomas: Shared cellular composition and morphometric differences. <i>Neuropathology</i> , 2008, 28, 455-465.	0.7	7
605	ATAD 3A and ATAD 3B are distal 1p-located genes differentially expressed in human glioma cell lines and present in vitro anti-oncogenic and chemoresistant properties. <i>Experimental Cell Research</i> , 2008, 314, 2870-2883.	1.2	42
606	Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors. <i>Brain Research</i> , 2008, 1198, 16-20.	1.1	11
607	Assessment of 1p/19q deletions by fluorescence in situ hybridization in gliomas. <i>Cancer Genetics and Cytogenetics</i> , 2008, 184, 77-86.	1.0	30

#	ARTICLE	IF	CITATIONS
608	Mutational analysis of the CITED4 gene in glioblastomas. <i>Cancer Genetics and Cytogenetics</i> , 2008, 185, 114-116.	1.0	4
609	Anaplastic Oligodendroglioma with Meningeal Infiltration in a Free-ranging Red Deer ( <i>Cervus</i> ) Tj ETQq1 1 0.784314,rgBT /Overlock 10	0.1	6
610	Neurological oncology. <i>Medicine</i> , 2008, 36, 609-615.	0.2	1
611	Biomarkers of Clinical Responsiveness in Brain Tumor Patients. <i>Molecular Diagnosis and Therapy</i> , 2008, 12, 199-208.	1.6	11
612	Malignant Gliomas in Adults. <i>New England Journal of Medicine</i> , 2008, 359, 492-507.	13.9	3,647
614	Ensayos de quimiosensibilidad en cultivos primarios de tumores cerebrales. <i>Neurocirugia</i> , 2008, 19, 5-10.	0.2	1
615	Contribution of DNA repair mechanisms to determining chemotherapy response in high-grade glioma. <i>Journal of Clinical Neuroscience</i> , 2008, 15, 1-8.	0.8	21
616	Comparative evaluation of radiochemotherapy with temozolomide versus standard-of-care postoperative radiation alone in patients with WHO grade III astrocytic tumors. <i>Radiotherapy and Oncology</i> , 2008, 88, 177-182.	0.3	27
619	Carmustine Implants for the Treatment of Newly Diagnosed High-Grade Gliomas. <i>Pharmacoeconomics</i> , 2008, 26, 33-44.	1.7	16
620	Metabolic Assessment of Gliomas Using <sup>11</sup> C-Methionine, [ <sup>18</sup> F] Fluorodeoxyglucose, and <sup>11</sup> C-Choline Positron-Emission Tomography. <i>American Journal of Neuroradiology</i> , 2008, 29, 1176-1182.	1.2	191
621	The Use of Magnetic Resonance Imaging to Noninvasively Detect Genetic Signatures in Oligodendroglioma. <i>Clinical Cancer Research</i> , 2008, 14, 2357-2362.	3.2	109
622	Histogram Analysis of MR Imagingâ€“Derived Cerebral Blood Volume Maps: Combined Glioma Grading and Identification of Low-Grade Oligodendroglial Subtypes. <i>American Journal of Neuroradiology</i> , 2008, 29, 1664-1670.	1.2	68
623	Identifying candidate genes involved in brain tumor formation. <i>Uppsala Journal of Medical Sciences</i> , 2008, 113, 1-38.	0.4	15
624	Time Trends in Oligodendroglial and Astrocytic Tumor Incidence. <i>Neuroepidemiology</i> , 2008, 30, 34-44.	1.1	41
625	Gliomatosis cerebri: growing evidence for diffuse gliomas with wide invasion. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 587-597.	1.4	17
626	Functional Diffusion Map As an Early Imaging Biomarker for High-Grade Glioma: Correlation With Conventional Radiologic Response and Overall Survival. <i>Journal of Clinical Oncology</i> , 2008, 26, 3387-3394.	0.8	264
627	Mechanisms of Disease: the role of stem cells in the biology and treatment of gliomas. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 393-404.	4.3	47
628	Molecular Imaging of Brain Tumors Personal Experience and Review of the Literature. <i>Current Molecular Medicine</i> , 2008, 8, 711-726.	0.6	33

#	ARTICLE	IF	CITATIONS
629	Genetic markers predictive of chemosensitivity and outcome in gliomatosis cerebri. <i>Neurology</i> , 2008, 70, 590-595.	1.5	44
630	Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomas. <i>Neuro-Oncology</i> , 2008, 10, 540-547.	0.6	27
631	Invited Article: The expanding impact of molecular biology on the diagnosis and treatment of gliomas. <i>Neurology</i> , 2008, 71, 365-373.	1.5	24
632	Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan. <i>Journal of Clinical Oncology</i> , 2008, 26, 271-278.	0.8	259
633	Molecular Predictors in Glioblastoma. <i>Archives of Neurology</i> , 2008, 65, 877-83.	4.9	62
634	Brain Tumor Imaging in Clinical Trials. <i>American Journal of Neuroradiology</i> , 2008, 29, 419-424.	1.2	157
635	Epigenetic markers in human gliomas: prospects for therapeutic intervention. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 1475-1496.	1.4	5
636	Neuroimaging in Patients with Gliomas. <i>Seminars in Neurology</i> , 2008, 28, 484-494.	0.5	35
637	Gliomas: Predicting Time to Progression or Survival with Cerebral Blood Volume Measurements at Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging. <i>Radiology</i> , 2008, 247, 490-498.	3.6	466
638	Emerging drugs for malignant glioma. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 81-94.	1.0	15
639	Leptomeningeal Disease from Oligodendroglioma: Clinical and Molecular Analysis. <i>Canadian Journal of Neurological Sciences</i> , 2008, 35, 204-209.	0.3	7
641	Dendritic Cell Immunotherapy for Malignant Gliomas. <i>Reviews on Recent Clinical Trials</i> , 2008, 3, 10-21.	0.4	21
642	Application of Serial Analysis of Gene Expression in Cancer Research. <i>Current Pharmaceutical Biotechnology</i> , 2008, 9, 375-384.	0.9	14
643	Low Grade Gliomas. Can We Predict Tumour Behaviour from Imaging Features?. <i>Neuroradiology Journal</i> , 2008, 21, 47-66.	0.6	2
644	Molecular Diagnostic Testing in Malignant Gliomas: A Practical Update on Predictive Markers. <i>Journal of Neuropathology and Experimental Neurology</i> , 2008, 67, 1-15.	0.9	84
645	The 2007 WHO classification of tumors of the central nervous system " what has changed?. <i>Current Opinion in Neurology</i> , 2008, 21, 720-727.	1.8	112
646	Editorial review: Targets for glioma treatment: from bench to bedside. <i>Current Opinion in Oncology</i> , 2008, 20, 650-651.	1.1	8
647	CLINICAL PROBLEM-SOLVING. <i>Neurosurgery</i> , 2008, 62, 920-929.	0.6	0

#	ARTICLE	IF	CITATIONS
648	Gliomas With 1p/19q Codeletion:a.k.a. Oligodendroglioma. Cancer Journal (Sudbury, Mass ), 2008, 14, 352-357.	1.0	81
649	6 Neurogenetic Basis of Pediatric Neurosurgical Conditions. , 2008, , .		0
651	Magnetic resonance perfusion imaging in neuro-oncology. Cancer Imaging, 2008, 8, 186-199.	1.2	23
654	Chromosome 1p and 19q evaluation in low-grade oligodendrogliomas: A descriptive study. International Journal of Molecular Medicine, 2009, 25, .	1.8	5
655	Long-Term Outcome of Postoperative Irradiation in Patients with Newly Diagnosed WHO Grade III Anaplastic Gliomas. Tumori, 2009, 95, 317-324.	0.6	10
656	Central Nervous System Tumors. , 2009, , 1984-2038.		1
658	Tumors of the Brain and the Spinal Cord. , 2009, , 1203-1206.		0
659	Neuro-Oncology. , 0, , 771-822.		1
660	Perfusion MR imaging in adult neoplasia. , 0, , 341-368.		0
661	NOTCH2 Is Neither Rearranged nor Mutated in t(1;19) Positive Oligodendrogliomas. PLoS ONE, 2009, 4, e4107.	1.1	19
662	Oligodendrogliomas: Molecular Biology and Treatment. Oncologist, 2009, 14, 155-163.	1.9	68
663	Î±-Internexin expression identifies 1p19q codeleted gliomas. Neurology, 2009, 72, 156-161.	1.5	49
664	Spinal cord oligodendroglioma with 1p and 19q deletions presenting with cerebral oligodendrogliomatosis. Journal of Neurosurgery: Spine, 2009, 10, 557-563.	0.9	20
665	IGFBP2 is a candidate biomarker for <i>Ink4a-Arf</i> status and a therapeutic target for high-grade gliomas. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 16675-16679.	3.3	52
666	Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro-Oncology, 2009, 11, 167-175.	0.6	55
667	Tenascin-C Is a Novel RBPJ <sup>Î±</sup> -Induced Target Gene for Notch Signaling in Gliomas. Cancer Research, 2009, 69, 458-465.	0.4	122
668	Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. Neuro-Oncology, 2009, 11, 737-746.	0.6	71
669	Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors. Neurology India, 2009, 57, 559.	0.2	9

#	ARTICLE	IF	CITATIONS
670	Solid tumors in children. , 2009, , 113-122.		0
671	Repeated Molecular Testing in Gliomas. American Journal of Clinical Pathology, 2009, 132, 118-124.	0.4	3
672	Current concepts in the pathology and genetics of gliomas. Indian Journal of Cancer, 2009, 46, 108.	0.2	11
673	Polysomy for Chromosomes 1 and 19 Predicts Earlier Recurrence in Anaplastic Oligodendrogliomas with Concurrent 1p/19q Loss. Clinical Cancer Research, 2009, 15, 6430-6437.	3.2	88
674	Molecular Neuropathology of Gliomas. International Journal of Molecular Sciences, 2009, 10, 184-212.	1.8	42
675	Does radiosurgery have a role in the management of oligodendrogliomas?. Journal of Neurosurgery, 2009, 110, 564-571.	0.9	23
676	Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology, 2009, 72, 1601-1606.	1.5	70
677	Beyond Grade: Molecular Pathology of Malignant Gliomas. Seminars in Radiation Oncology, 2009, 19, 142-149.	1.0	31
678	Chemotherapy for Malignant Gliomas. Seminars in Radiation Oncology, 2009, 19, 150-154.	1.0	16
679	Retrospective analysis of treatment outcome in 315 patients with oligodendroglial brain tumors. BMC Neurology, 2009, 9, 33.	0.8	9
680	Allelic status of 1p and 19q in oligodendrogliomas and glioblastomas: multiplex ligation-dependent probe amplification versus loss of heterozygosity. Cancer Genetics and Cytogenetics, 2009, 190, 93-96.	1.0	34
681	Is the 1p/19q deletion a diagnostic marker of oligodendrogliomas?. Cancer Genetics and Cytogenetics, 2009, 194, 12-22.	1.0	29
682	Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors. International Journal of Cancer, 2009, 124, 2872-2879.	2.3	32
683	Prognosis and patterns of care in elderly patients with glioma. Cancer, 2009, 115, 5534-5540.	2.0	51
684	Characterization and gene expression profiling in glioma cell lines with deletion of chromosome 19 before and after microcell-mediated restoration of normal human chromosome 19. Genes Chromosomes and Cancer, 2009, 48, 854-864.	1.5	7
685	Genomic aberrations in 80 cases of primary glioblastoma multiforme: Pathogenetic heterogeneity and putative cytogenetic pathways. Genes Chromosomes and Cancer, 2009, 48, 908-924.	1.5	38
686	Dendritic-cell- and peptide-based vaccination strategies for glioma. Neurosurgical Review, 2009, 32, 265-273.	1.2	38
687	Tumeurs oligodendrogiales anaplasiques. Oncologie, 2009, 11, 61-66.	0.2	0

#	ARTICLE	IF	CITATIONS
688	Lack of complete 1p19q deletion in a consecutive series of 12 WHO grade II gliomas involving the insula: a marker of worse prognosis?. <i>Journal of Neuro-Oncology</i> , 2009, 91, 1-5.	1.4	40
689	Chromosome 1p and 19q deletions in malignant glioneuronal tumors with oligodendroglioma-like component. <i>Journal of Neuro-Oncology</i> , 2009, 91, 33-38.	1.4	14
690	Genetic characterization of adult infratentorial gliomas. <i>Journal of Neuro-Oncology</i> , 2009, 91, 251-255.	1.4	11
691	Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma. <i>Journal of Neuro-Oncology</i> , 2009, 92, 57-63.	1.4	37
692	Cerebral glioblastoma with oligodendroglioma component: analysis of 36 cases. <i>Journal of Neuro-Oncology</i> , 2009, 94, 129-134.	1.4	45
693	Management of newly diagnosed glioblastoma: guidelines development, value and application. <i>Journal of Neuro-Oncology</i> , 2009, 93, 1-23.	1.4	42
694	Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status. <i>Journal of Neuro-Oncology</i> , 2009, 92, 373-386.	1.4	60
695	The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. <i>Journal of Neuro-Oncology</i> , 2009, 95, 401-411.	1.4	157
696	Loss of heterozygosity at 1p-19q induces a global change in oligodendroglial tumor gene expression. <i>Journal of Neuro-Oncology</i> , 2009, 95, 343-354.	1.4	25
697	Flow Cytometry Analysis of Neural Differentiation Markers Expression in Human Glioblastomas May Predict Their Response to Chemotherapy. <i>Cellular and Molecular Neurobiology</i> , 2009, 29, 845-858.	1.7	32
698	Low-Grade Gliomas. <i>Current Treatment Options in Oncology</i> , 2009, 10, 231-242.	1.3	37
699	Molecular profiling in glioblastoma: Prelude to personalized treatment. <i>Current Oncology Reports</i> , 2009, 11, 53-61.	1.8	17
700	Molecular profiling of oligodendrogliomas: Impact on prognosis, treatment, and future directions. <i>Current Oncology Reports</i> , 2009, 11, 62-67.	1.8	9
701	Decreased expression of the active subunit of the cystine/glutamate antiporter xCT is associated with loss of heterozygosity of 1p in oligodendroglial tumours WHO grade II. <i>Histopathology</i> , 2009, 54, 241-247.	1.6	4
702	Using gene expression profiling to identify a prognostic molecular spectrum in gliomas. <i>Cancer Science</i> , 2009, 100, 165-172.	1.7	26
703	Genetic alterations and signaling pathways in the evolution of gliomas. <i>Cancer Science</i> , 2009, 100, 2235-2241.	1.7	374
704	A Latent Class Model with Hidden Markov Dependence for Array CGH Data. <i>Biometrics</i> , 2009, 65, 1296-1305.	0.8	6
705	Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival. <i>Neuropathology</i> , 2009, 29, 242-247.	0.7	41

#	ARTICLE	IF	CITATIONS
706	Interphase Cytogenetics for 1p19q and t(1;19)(q10;p10) may Distinguish Prognostically Relevant Subgroups in Extraventricular Neurocytoma. <i>Brain Pathology</i> , 2009, 19, 623-629.	2.1	58
707	Genetically Engineered Mouse Models of Brain Cancer and the Promise of Preclinical Testing. <i>Brain Pathology</i> , 2009, 19, 132-143.	2.1	142
708	Robust Detection of EGFR Copy Number Changes and EGFR Variant III: Technical Aspects and Relevance for Glioma Diagnostics. <i>Brain Pathology</i> , 2009, 19, 661-671.	2.1	69
709	Molecular Pathology of Oligodendroglial Tumors. <i>Recent Results in Cancer Research</i> , 2009, 171, 25-49.	1.8	16
710	Pharmaceutical Perspectives of Cancer Therapeutics. , 2009, , .		15
711	Primary leptomeningeal anaplastic oligodendroglioma with a 1p36-19q13 deletion: Report of a unique case successfully treated with Temozolomide. <i>Journal of the Neurological Sciences</i> , 2009, 287, 267-270.	0.3	28
712	Gliomas. <i>Recent Results in Cancer Research</i> , 2009, , .	1.8	15
713	Magnolol Inhibits Human Glioblastoma Cell Proliferation through Upregulation of p21/Cip1. <i>Journal of Agricultural and Food Chemistry</i> , 2009, 57, 7331-7337.	2.4	54
714	Insights into pharmacotherapy of malignant glioma in adults. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2279-2290.	0.9	7
715	Tumores del sistema nervioso central. <i>Medicine</i> , 2009, 10, 1672-1686.	0.0	0
716	Retrospective review of prognostic factors, including 1p19q deletion, in low-grade oligodendrogliomas and a review of recent published works. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2009, 53, 305-309.	0.9	13
717	Targeted Therapies for Malignant Brain Tumors. , 2009, , 475-519.		0
718	Diagnostic and prognostic markers in gliomas. <i>Current Opinion in Oncology</i> , 2009, 21, 537-542.	1.1	40
719	Classification and management of anaplastic gliomas. <i>Current Opinion in Neurology</i> , 2009, 22, 650-656.	1.8	11
720	Novel insights into the pathogenesis of gliomas based on large-scale molecular profiling approaches. <i>Current Opinion in Neurology</i> , 2009, 22, 619-624.	1.8	8
721	Tumor Cells Can Mimic Vascular Endothelial Cells. <i>Advances in Small Animal Medicine and Surgery</i> , 2009, 22, 1-3.	0.0	0
723	Novel Genomic Alterations and Mechanisms Associated With Tumor Progression in Oligodendroglioma and Mixed Oligoastrocytoma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009, 68, 274-285.	0.9	13
724	Chromosome 1p and 19q Deletions in Glioblastoma Multiforme. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2009, 17, 512-516.	0.6	26



#	ARTICLE	IF	CITATIONS
725	Glioma Diagnosis: Immunohistochemistry and Beyond. <i>Advances in Anatomic Pathology</i> , 2010, 17, 187-201.	2.4	54
726	Extracranial Metastasis of Anaplastic Oligodendroglioma With 1p19q Loss of Heterozygosity -Case Report-. <i>Neurologia Medico-Chirurgica</i> , 2010, 50, 161-164.	1.0	22
727	Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors—towards individualized tumor treatment?. <i>Neuro-Oncology</i> , 2010, 12, 490-9.	0.6	21
729	Oligodendroglial neoplasms with ganglioglioma-like maturation: a diagnostic pitfall. <i>Acta Neuropathologica</i> , 2010, 120, 237-252.	3.9	49
730	Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective. <i>Acta Neuropathologica</i> , 2010, 120, 297-304.	3.9	439
731	Molecular diagnostics of gliomas: state of the art. <i>Acta Neuropathologica</i> , 2010, 120, 567-584.	3.9	243
732	Analysis of MGMT promoter methylation status on intraoperative fresh tissue section from frameless neuronavigation needle biopsy: a preliminary study of ten patients. <i>Acta Neurochirurgica</i> , 2010, 152, 1189-1196.	0.9	11
733	Leptomeningeal dissemination of a pediatric neoplasm with 1p19q deletion showing mixed immunohistochemical features of an oligodendroglioma and neurocytoma. <i>Acta Neurochirurgica</i> , 2010, 152, 1425-1429.	0.9	11
734	MR imaging characteristics of oligodendroglial tumors with assessment of 1p/19q deletion status. <i>Acta Neurochirurgica</i> , 2010, 152, 1827-1834.	0.9	19
735	Molecular genetics, imaging and treatment of oligodendroglial tumours. <i>Acta Neurochirurgica</i> , 2010, 152, 1815-1825.	0.9	8
736	Molecular markers in gliomas: impact for the clinician. <i>Targeted Oncology</i> , 2010, 5, 201-210.	1.7	21
737	Newly Diagnosed High-Grade Gliomas. <i>Current Treatment Options in Neurology</i> , 2010, 12, 309-320.	0.7	5
738	High rate of deletion of chromosomes 1p and 19q in insular oligodendroglial tumors. <i>Journal of Neuro-Oncology</i> , 2010, 99, 57-64.	1.4	14
739	Assessment of tumor angiogenesis as a prognostic factor of survival in patients with oligodendroglioma. <i>Journal of Neuro-Oncology</i> , 2010, 96, 277-285.	1.4	15
740	Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide. <i>Journal of Neuro-Oncology</i> , 2010, 100, 439-441.	1.4	15
741	Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. <i>Lancet Neurology</i> , The, 2010, 9, 717-726.	4.9	251
742	Daily intake of antioxidants in relation to survival among adult patients diagnosed with malignant glioma. <i>BMC Cancer</i> , 2010, 10, 215.	1.1	34
743	Genome-wide cDNA microarray screening to reveal gene-expression profiles correlated to chemosensitivity of oral squamous cell carcinoma cell lines. <i>Asian Journal of Oral and Maxillofacial Surgery</i> , 2010, 22, 7-11.	0.1	0



#	ARTICLE	IF	CITATIONS
744	Heterozygosity status of 1p and 19q and its correlation with p53 protein expression and EGFR amplification in patients with astrocytic tumors: novel series from India. <i>Cancer Genetics and Cytogenetics</i> , 2010, 198, 126-134.	1.0	9
746	Glutathione S-transferase polymorphisms are associated with survival in anaplastic glioma patients. <i>Cancer</i> , 2010, 116, 2242-2249.	2.0	32
747	Combined use of neuroradiology and <sup>1</sup> H-MR spectroscopy may provide an intervention limiting diagnosis of glioblastoma multiforme. <i>Journal of Magnetic Resonance Imaging</i> , 2010, 32, 1038-1044.	1.9	18
748	WHO grade-specific comparative genomic hybridization pattern of astrocytoma – A meta-analysis. <i>Pathology Research and Practice</i> , 2010, 206, 663-668.	1.0	11
749	Genomics boosts brain-cancer work. <i>Nature</i> , 2010, 463, 278-278.	13.7	12
750	Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. <i>Nature Reviews Cancer</i> , 2010, 10, 319-331.	12.8	660
751	Array-Based Genomics in Glioma Research. <i>Brain Pathology</i> , 2010, 20, 28-38.	2.1	13
752	Fixation of Brain Tumor Biopsy Specimens with RCL2 Results in Well-Preserved Histomorphology, Immunohistochemistry and Nucleic Acids. <i>Brain Pathology</i> , 2010, 20, 1010-1020.	2.1	22
753	KIAA0495/PDAM Is Frequently Downregulated in Oligodendroglial Tumors and Its Knockdown by siRNA Induces Cisplatin Resistance in Glioma Cells. <i>Brain Pathology</i> , 2010, 20, 1021-1032.	2.1	40
754	Utility of in situ demonstration of 1p loss and p53 overexpression in pathologic diagnosis of oligodendroglial tumors. <i>Neuropathology</i> , 2010, 30, 586-596.	0.7	8
755	Gliomas in Adults. <i>Deutsches Arzteblatt International</i> , 2010, 107, 799-807; quiz 808.	0.6	63
756	Troglitazone Reduces Glyoxalase I Protein Expression in Glioma and Potentiates the Effects of Chemotherapeutic Agents. <i>Journal of Oncology</i> , 2010, 2010, 1-7.	0.6	5
757	Gene Expression in Oligodendroglial Tumors. <i>Analytical Cellular Pathology</i> , 2010, 33, 81-94.	0.7	3
758	Glioblastomas with Oligodendroglial Component – Common Origin of the Different Histological Parts and Genetic Subclassification. <i>Analytical Cellular Pathology</i> , 2010, 33, 37-54.	0.7	16
759	Oligodendrogliomas. <i>Blue Books of Neurology</i> , 2010, 36, 132-149.	0.1	1
760	Pathology and Molecular Genetics of Common Brain Tumors. <i>Blue Books of Neurology</i> , 2010, 36, 1-36.	0.1	0
761	Prognostic markers in gliomas. <i>Future Oncology</i> , 2010, 6, 733-739.	1.1	17
762	Influence of blood-brain barrier efflux pumps on the distribution of vincristine in brain and brain tumors. <i>Neuro-Oncology</i> , 2010, 12, 1043-1049.	0.6	50

#	ARTICLE	IF	CITATIONS
763	Infratentorial oligodendrogliomas: Imaging findings in six patients. <i>Acta Radiologica</i> , 2010, 51, 213-217.	0.5	11
764	Differential proteome analysis of human gliomas stratified for loss of heterozygosity on chromosomal arms 1p and 19q. <i>Neuro-Oncology</i> , 2010, 12, 243-256.	0.6	32
765	Oligodendroglioma cell lines containing t(1;19)(q10;p10). <i>Neuro-Oncology</i> , 2010, 12, 745-755.	0.6	77
766	Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses. <i>Neuro-Oncology</i> , 2010, 12, 664-678.	0.6	71
767	Malignant Gliomas in Adults. <i>Blue Books of Neurology</i> , 2010, 36, 99-120.	0.1	6
768	1p19q LOH patterns and expression of p53 and Olig2 in gliomas: relation with histological types and prognosis. <i>Modern Pathology</i> , 2010, 23, 619-628.	2.9	22
770	Diagnostic and prognostic molecular markers in common adult gliomas. <i>Expert Review of Molecular Diagnostics</i> , 2010, 10, 637-649.	1.5	5
772	Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?. <i>Future Oncology</i> , 2010, 6, 1407-1414.	1.1	23
773	Health-related quality of life aspects in patients with low-grade glioma. <i>Advances and Technical Standards in Neurosurgery</i> , 2010, 35, 213-235.	0.2	24
774	Pathology and Classification of Tumors of the Nervous System. , 2010, , 3-75.		8
775	Low-Grade Astrocytomas. , 2010, , 119-134.		2
777	Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. <i>Molecular Cancer</i> , 2010, 9, 135.	7.9	247
779	Molecular Tools: Biology, Prognosis, and Therapeutic Triage. <i>Neuroimaging Clinics of North America</i> , 2010, 20, 273-282.	0.5	7
780	Quantitative Proteomic Analysis of Oligodendrogliomas With and Without 1p/19q Deletion. <i>Journal of Proteome Research</i> , 2010, 9, 2610-2618.	1.8	12
781	Coexpression Network Analysis Identifies Transcriptional Modules Related to Proastrocytic Differentiation and Sprouty Signaling in Glioma. <i>Cancer Research</i> , 2010, 70, 10060-10070.	0.4	82
782	Mouse models in neurological disorders: Applications of non-invasive imaging. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2010, 1802, 819-839.	1.8	42
783	Clinical significance of astrocyte elevated gene-1 expression in human oligodendrogliomas. <i>Clinical Neurology and Neurosurgery</i> , 2010, 112, 413-419.	0.6	34
784	All the 1p19q codeleted gliomas are mutated on <i>IDH1</i> or <i>IDH2</i> . <i>Neurology</i> , 2010, 74, 1886-1890.	1.5	240

#	ARTICLE	IF	CITATIONS
785	Practical molecular diagnostics in neuropathology: making a tough job a little easier. Seminars in Diagnostic Pathology, 2010, 27, 105-113.	1.0	17
786	Oligodendroglial tumors: diagnostic and molecular pathology. Seminars in Diagnostic Pathology, 2010, 27, 136-145.	1.0	17
790	Astrocytic and Oligodendroglial Tumors. , 2010, , 63-102.		4
791	Genomic Evaluation of Brain Tumors and Gliomas. , 2010, , 522-531.		0
792	Imaging of Brain Tumors: Perfusion/Permeability. Neuroimaging Clinics of North America, 2010, 20, 337-353.	0.5	38
793	Chemo Fog. Advances in Experimental Medicine and Biology, 2010, , .	0.8	9
794	Annual Report to the Nation on the Status of Cancer, 1975-2007, Featuring Tumors of the Brain and Other Nervous System. Journal of the National Cancer Institute, 2011, 103, 714-736.	3.0	597
795	Biology, genetics and imaging of glial cell tumours. British Journal of Radiology, 2011, 84, S90-S106.	1.0	59
796	Diagnostic Molecular Pathology in Practice. , 2011, , .		2
797	Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas. Journal of Neurosurgery, 2011, 114, 1617-1621.	0.9	96
798	Histomolecular classification of adult diffuse gliomas: The diagnostic value of immunohistochemical markers. Revue Neurologique, 2011, 167, 683-690.	0.6	26
799	Regulation of the MDM2-P53 pathway and tumor growth by PICT1 via nucleolar RPL11. Nature Medicine, 2011, 17, 944-951.	15.2	170
800	Molecular Abnormalities in Gliomas. , 2011, , 35-48.		1
801	Molecular Classification of Gliomas. , 2011, , 9-19.		0
803	Tumors of the Central Nervous System, Volume 2. , 2011, , .		3
804	Proteomic identification of glutamine synthetase as a differential marker for oligodendrogliomas and astrocytomas. Journal of Neurosurgery, 2011, 115, 789-795.	0.9	20
805	Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas. European Journal of Cancer, 2011, 47, 802-808.	1.3	39
806	The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20yearsâ€™ experience at a single centre. Journal of Clinical Neuroscience, 2011, 18, 329-333.	0.8	62

#	ARTICLE	IF	CITATIONS
807	Gliomatosis cerebri in a patient with Ollier disease. <i>Journal of Clinical Neuroscience</i> , 2011, 18, 1564-1566.	0.8	5
808	Anaplastic gliomas: an emerging entity. <i>European Journal of Cancer</i> , 2011, 47, S357-S358.	1.3	5
809	Molecular Hallmarks of Gliomas. , 0, , .		5
810	Evolution of Molecular Biomarkers in Targeted Therapy of Malignant Gliomas. , 2011, , .		1
811	Molecular Pathways of Glioblastoma and Glioblastoma Stem Cells. , 0, , .		0
812	Overview and recent advances in neuropathology. Part 1: Central nervous system tumours. <i>Pathology</i> , 2011, 43, 88-92.	0.3	14
813	Whole Genome Analysis From Microdissected Tissue Revealed Adult Supratentorial Grade II-III Gliomas Are Divided Into Clinically Relevant Subgroups by Genetic Profile. <i>Neurosurgery</i> , 2011, 69, 376-390.	0.6	17
814	Single-Copy Gain of Chromosome 1q Is a Negative Prognostic Marker in Pediatric Nonependymal, Nonpilocytic Gliomas. <i>Neurosurgery</i> , 2011, 68, 206-212.	0.6	21
815	Proton MR Spectroscopy Provides Relevant Prognostic Information in High-Grade Astrocytomas. <i>American Journal of Neuroradiology</i> , 2011, 32, 74-80.	1.2	33
816	Loss of Chromosome 1p/19q in Oligodendroglial Tumors: Refinement of Chromosomal Critical Regions and Evaluation of Internexin Immunostaining as a Surrogate Marker. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 177-182.	0.9	20
817	Perfusion CT Imaging of Brain Tumors: An Overview. <i>American Journal of Neuroradiology</i> , 2011, 32, 1570-1577.	1.2	79
818	Extraventricular neurocytomas: a morphological and histogenetic consideration. A study of six cases. <i>Pathology</i> , 2011, 43, 327-334.	0.3	23
819	Î±-Internexin in the Diagnosis of Oligodendroglial Tumors and Association With 1p/19q Status. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 970-978.	0.9	19
820	Advances in Translational Research in Neuro-oncology. <i>Archives of Neurology</i> , 2011, 68, 303-8.	4.9	4
821	Novel clinical trials in neuro-oncology. <i>Clinical Investigation</i> , 2011, 1, 781-794.	0.0	1
822	Central Nervous System Cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 352-400.	2.3	99
823	The Nature and Timing of Specific Copy Number Changes in the Course of Molecular Progression in Diffuse Gliomas: Further Elucidation of Their Genetic "Life Story". <i>Brain Pathology</i> , 2011, 21, 308-320.	2.1	19
824	The Use of Global Profiling in Biomarker Development for Gliomas. <i>Brain Pathology</i> , 2011, 21, 88-95.	2.1	19

#	ARTICLE	IF	CITATIONS
825	Recent advancements in multimodality treatment of gliomas. <i>Future Oncology</i> , 2011, 7, 1169-1183.	1.1	52
826	Predictive and prognostic factors for gliomas. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 781-789.	1.1	54
827	Molecular Pathogenesis. , 2011, , 27-44.		2
828	Molecular Subtypes of Gliomas. , 2011, , 25-29.		0
829	Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma. <i>Journal of Neuro-Oncology</i> , 2011, 101, 457-462.	1.4	26
830	Tumor vascular leakiness and blood volume estimates in oligodendrogliomas using perfusion CT: an analysis of perfusion parameters helping further characterize genetic subtypes as well as differentiate from astroglial tumors. <i>Journal of Neuro-Oncology</i> , 2011, 102, 287-293.	1.4	28
831	Prognosis of oligodendroglial tumor with ring enhancement showing central necrotic portion. <i>Journal of Neuro-Oncology</i> , 2011, 103, 103-110.	1.4	3
832	Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. <i>Journal of Neuro-Oncology</i> , 2011, 103, 221-230.	1.4	21
833	Spinal cord anaplastic oligodendroglioma with 1p deletion: report of a relapsing case treated with temozolomide. <i>Journal of Neuro-Oncology</i> , 2011, 104, 387-394.	1.4	15
834	Leptomeningeal disease in oligodendroglial tumors: a population-based study. <i>Journal of Neuro-Oncology</i> , 2011, 104, 811-815.	1.4	12
835	Rapid spontaneous regression of multicentric infantile myofibromatosis in the posterior fossa and lumbar vertebra. <i>Child's Nervous System</i> , 2011, 27, 491-496.	0.6	10
836	Genome-wide comparison of paired fresh frozen and formalin-fixed paraffin-embedded gliomas by custom BAC and oligonucleotide array comparative genomic hybridization: facilitating analysis of archival gliomas. <i>Acta Neuropathologica</i> , 2011, 121, 529-543.	3.9	15
837	Loss of heterozygosity analysis in malignant gliomas. <i>Brain Tumor Pathology</i> , 2011, 28, 191-196.	1.1	22
838	Molecular and clinical analysis of glioblastoma with an oligodendroglial component (GBMO). <i>Brain Tumor Pathology</i> , 2011, 28, 185-190.	1.1	26
839	Glioblastomas with oligodendroglial component-common origin of the different histological parts and genetic subclassification. <i>Cellular Oncology (Dordrecht)</i> , 2011, 34, 261-275.	2.1	20
840	Gene expression in oligodendroglial tumors. <i>Cellular Oncology (Dordrecht)</i> , 2011, 34, 355-367.	2.1	14
841	High-Grade Gliomas. <i>Current Treatment Options in Neurology</i> , 2011, 13, 386-399.	0.7	26
842	Tumor Profiling: Development of Prognostic and Predictive Factors to Guide Brain Tumor Treatment. <i>Current Oncology Reports</i> , 2011, 13, 26-36.	1.8	5

#	ARTICLE	IF	CITATIONS
843	Molecular subclassification of diffuse gliomas: Seeing order in the chaos. <i>Glia</i> , 2011, 59, 1190-1199.	2.5	201
844	Genomic aberrations in diffuse low-grade gliomas. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 409-420.	1.5	13
845	Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic?. <i>Clinical Cancer Research</i> , 2011, 17, 4588-4599.	3.2	179
846	Discovering neurosurgery: new frontiers. <i>Journal of Neurosurgery</i> , 2011, 115, 1053-1066.	0.9	1
847	Pleomorphic xanthoastrocytoma and oligodendroglioma: collision of 2 morphologically and genetically distinct anaplastic components. <i>Journal of Neurosurgery</i> , 2011, 114, 1648-1653.	0.9	11
848	Molecular profile of oligodendrogliomas in young patients. <i>Neuro-Oncology</i> , 2011, 13, 1099-1106.	0.6	43
849	Detection of Allelic Status of 1p and 19q by Microsatellite-based PCR Versus FISH. <i>Diagnostic Molecular Pathology</i> , 2011, 20, 40-47.	2.1	28
850	Extracranial Skeletal Metastasis in Anaplastic Oligodendroglioma: Case Report and Review of the Literature. <i>Journal of International Medical Research</i> , 2011, 39, 960-967.	0.4	11
851	Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 224-227.	0.9	52
852	International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. <i>Neuro-Oncology</i> , 2011, 13, 649-659.	0.6	138
853	Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications. <i>British Journal of Radiology</i> , 2011, 84, S179-S195.	1.0	3
854	A ribosomal tactic to halt cancer. <i>Nature Medicine</i> , 2011, 17, 930-931.	15.2	1
855	A Hypermethylated Phenotype Is a Better Predictor of Survival than <i>MGMT</i> Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951. <i>Clinical Cancer Research</i> , 2011, 17, 7148-7155.	3.2	107
856	Risk factors for oligodendroglial tumors: A pooled international study. <i>Neuro-Oncology</i> , 2011, 13, 242-250.	0.6	27
857	Classification and pathogenesis of brain tumors. , 2012, , 36-58.		2
858	Survival Analysis of Patients with High-Grade Gliomas Based on Data Mining of Imaging Variables. <i>American Journal of Neuroradiology</i> , 2012, 33, 1065-1071.	1.2	70
859	Molecular biology of brain tumors. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 104, 23-34.	1.0	11
860	The Impact of Extent of Resection and Histological Subtype on the Outcome of Adult Patients with High-grade Gliomas. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 270-277.	0.6	37

#	ARTICLE	IF	CITATIONS
861	Detection of Intratumoral Calcification in Oligodendrogliomas by Susceptibility-Weighted MR Imaging. <i>American Journal of Neuroradiology</i> , 2012, 33, 858-864.	1.2	56
862	Prime time for molecular marker diagnostics in neuro-oncology. <i>Current Opinion in Neurology</i> , 2012, 25, 743-744.	1.8	2
863	Management of Malignant Gliomas and Primary CNS Lymphoma. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2012, 18, 406-415.	0.4	10
864	Molecular predictors of outcome in low-grade glioma. <i>Current Opinion in Neurology</i> , 2012, 25, 767-773.	1.8	54
865	Chemotherapy with cytotoxic and cytostatic agents in brain cancer. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2012, 104, 229-254.	1.0	9
866	Chemotherapy for Brain Tumors. , 2012, , 94-104.		0
867	Design and use of biomarkers for the current and future clinical management of brain tumors. <i>Biomarkers in Medicine</i> , 2012, 6, 293-295.	0.6	2
868	Scission of the p53-MDM2 Loop by Ribosomal Proteins. <i>Genes and Cancer</i> , 2012, 3, 298-310.	0.6	65
869	Autocrine PDGF stimulation in malignancies. <i>Upsala Journal of Medical Sciences</i> , 2012, 117, 83-91.	0.4	62
870	Magnetic resonance imaging volumetric assessment of the extent of contrast enhancement and resection in oligodendroglial tumors. <i>Journal of Neurosurgery</i> , 2012, 116, 1172-1181.	0.9	27
871	Enhancing Diagnosis, Prognosis, and Therapeutic Outcome Prediction of Gliomas Using Genomics. <i>OMICS A Journal of Integrative Biology</i> , 2012, 16, 113-122.	1.0	27
872	Anaplastic oligodendroglial tumors. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2012, 105, 467-484.	1.0	4
873	LOW GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2012, 14, i69-i81.	0.6	5
874	Low-grade astrocytomas. , 2012, , 372-383.		0
876	Progenitor-like Traits Contribute to Patient Survival and Prognosis in Oligodendroglial Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 4122-4135.	3.2	16
877	Moving toward molecular classification of diffuse gliomas in adults. <i>Neurology</i> , 2012, 79, 1917-1926.	1.5	70
878	Detection of 1p19q Deletion by Real-Time Comparative Quantitative PCR. <i>Biomarker Insights</i> , 2012, 7, BMI.S9003.	1.0	24
879	Genomic Estimates of Aneuploid Content in Glioblastoma Multiforme and Improved Classification. <i>Clinical Cancer Research</i> , 2012, 18, 5595-5605.	3.2	34



#	ARTICLE	IF	CITATIONS
880	The Importance of 10q Status in an Outcomes-Based Comparison Between 1p/19q Fluorescence In Situ Hybridization and Polymerase Chain Reaction-Based Microsatellite Loss of Heterozygosity Analysis of Oligodendrogliomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2012, 71, 73-82.	0.9	30
881	Tumor-Specific Targeted Therapy in Pediatric Astrocytoma Demonstrated in a Murine Model. <i>Neurosurgery</i> , 2012, 71, N7.	0.6	0
882	Primary brain tumours in adults. <i>Lancet, The</i> , 2012, 379, 1984-1996.	6.3	723
883	Diagnostic neuropathology of tumors of the central nervous system. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 104, 77-107.	1.0	6
884	Molecular markers of glioma: an update on recent progress and perspectives. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 1971-1981.	1.2	51
885	Molecular characteristics of glioblastoma with 1p/19q co-deletion. <i>Brain Tumor Pathology</i> , 2012, 29, 148-153.	1.1	27
886	Nuclear karyopherin a2: a novel biomarker for infiltrative astrocytomas. <i>Journal of Neuro-Oncology</i> , 2012, 109, 545-553.	1.4	49
887	Improved Anti-Tumor Effect of Liposomal Doxorubicin After Targeted Blood-Brain Barrier Disruption by MRI-Guided Focused Ultrasound in Rat Glioma. <i>Ultrasound in Medicine and Biology</i> , 2012, 38, 1716-1725.	0.7	246
888	An Unusual Form of Superficially Disseminated Glioma in Children. <i>Journal of Child Neurology</i> , 2012, 27, 727-733.	0.7	24
889	Something Old and Something New About Molecular Diagnostics in Gliomas. <i>Surgical Pathology Clinics</i> , 2012, 5, 919-939.	0.7	12
890	Analysis of the BRAFV600E Mutation in Central Nervous System Tumors. <i>Translational Oncology</i> , 2012, 5, 430-436.	1.7	51
891	Clinical trials in neuro-oncology. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 104, 417-434.	1.0	1
892	IDH Mutation and Neuroglial Developmental Features Define Clinically Distinct Subclasses of Lower Grade Diffuse Astrocytic Glioma. <i>Clinical Cancer Research</i> , 2012, 18, 2490-2501.	3.2	127
893	Cytogenetic profile of locally advanced and metastatic schistosoma-related bladder cancer and response to chemotherapy. <i>Cancer Genetics</i> , 2012, 205, 156-162.	0.2	10
894	Co-Deletion of Chromosome 1p/19q and IDH1/2 Mutation in Glioma Subsets of Brain Tumors in Chinese Patients. <i>PLoS ONE</i> , 2012, 7, e32764.	1.1	43
895	Overview of Primary Brain Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 715-732.	0.9	29
896	Clinical Manifestations and Diagnostic Imaging of Brain Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 733-755.	0.9	12
897	Biomarkers Classification and Therapeutic Decision-Making for Malignant Gliomas. <i>Current Treatment Options in Oncology</i> , 2012, 13, 417-436.	1.3	25

#	ARTICLE	IF	CITATIONS
900	Anaplastic Gliomas. Hematology/Oncology Clinics of North America, 2012, 26, 811-823.	0.9	7
902	Glioblastoma and malignant astrocytoma. , 2012, , 384-407.		3
903	Clonal Analysis in Recurrent Astrocytic, Oligoastrocytic and Oligodendroglial Tumors Implicates IDH1- Mutation as Common Tumor Initiating Event. PLoS ONE, 2012, 7, e41298.	1.1	43
904	SNP Array Analysis Reveals Novel Genomic Abnormalities Including Copy Neutral Loss of Heterozygosity in Anaplastic Oligodendrogliomas. PLoS ONE, 2012, 7, e45950.	1.1	25
905	Clinical trials and chemotherapy. , 2012, , 306-315.		0
906	Oligodendroglioma. , 2012, , 408-423.		1
907	Concurrent <i>CIC</i> mutations, <i>IDH</i> mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. Journal of Pathology, 2012, 226, 7-16.	2.1	272
908	Clinically useful biomarkers in neurooncology. Memo - Magazine of European Medical Oncology, 2012, 5, 201-204.	0.3	1
909	Molecular Biology of Glioma. Advances in Experimental Medicine and Biology, 2012, 746, 2-11.	0.8	58
910	Emerging insights into the molecular and cellular basis of glioblastoma. Genes and Development, 2012, 26, 756-784.	2.7	463
911	The renal $\text{Na}^+\text{K}^+\text{ATPase}$ $\alpha 4$ subunit is expressed in specific subtypes of human gliomas. Glia, 2012, 60, 1004-1012.	2.5	22
912	Oligodendroglioma Models. Neuromethods, 2012, , 57-82.	0.2	0
913	1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth. Journal of Neuro-Oncology, 2012, 108, 69-75.	1.4	46
914	Anaplastic Glioma. Current Treatment Options in Neurology, 2012, 14, 381-390.	0.7	14
915	A huge intraventricular congenital anaplastic astrocytoma: case report with histopathological and genetic consideration. Brain Tumor Pathology, 2012, 29, 107-112.	1.1	5
916	Clinicopathological features in the recurrence of oligodendroglioma and diffuse astrocytoma. Brain Tumor Pathology, 2012, 29, 140-147.	1.1	0
917	Prognostic value of Ki67 index in anaplastic oligodendroglial tumours – a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Histopathology, 2012, 60, 885-894.	1.6	44
918	The role of glutathione in brain tumor drug resistance. Biochemical Pharmacology, 2012, 83, 1005-1012.	2.0	159

#	ARTICLE	IF	CITATIONS
919	A new PICTURE of nucleolar stress. <i>Cancer Science</i> , 2012, 103, 632-637.	1.7	51
920	Molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. <i>Neuropathology and Applied Neurobiology</i> , 2012, 38, 271-291.	1.8	97
921	The hypermethylation of the O <sup>6</sup> -methylguanine DNA methyltransferase gene promoter in gliomas correlation with array comparative genome hybridization results and IDH1 mutation. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 20-29.	1.5	13
922	Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience. <i>Journal of Neuro-Oncology</i> , 2013, 114, 85-91.	1.4	28
923	Differential molecular genetic analysis in glioblastoma multiforme of long- and short-term survivors: a clinical study in Chinese patients. <i>Journal of Neuro-Oncology</i> , 2013, 113, 251-258.	1.4	32
924	Neoadjuvant chemotherapy may optimize the extent of resection of World Health Organization grade II gliomas: a case series of 17 patients. <i>Journal of Neuro-Oncology</i> , 2013, 113, 267-275.	1.4	58
925	Contribution of Molecular Biology to the Classification of Low-Grade Diffuse Glioma. , 2013, , 61-72.		0
926	Actualización en tumores del sistema nervioso central. <i>Medicine</i> , 2013, 11, 1468-1483.	0.0	0
927	Discovery of structural alterations in solid tumor oligodendroglioma by single molecule analysis. <i>BMC Genomics</i> , 2013, 14, 505.	1.2	30
928	Proteomic and bioinformatic analysis of recurrent anaplastic oligodendroglioma. <i>Journal of Analytical Science and Technology</i> , 2013, 4, 6.	1.0	1
929	Primary Tumors of the Nervous System. , 2013, , 1-22.		0
930	Emerging Concepts in Neuro-Oncology. , 2013, , .		0
931	Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors. <i>Acta Neuropathologica</i> , 2013, 126, 277-289.	3.9	49
933	Anaplastic oligodendrogliomas value of early chemotherapy. <i>Nature Reviews Neurology</i> , 2013, 9, 7-8.	4.9	3
934	Intrinsic Molecular Subtypes of Glioma Are Prognostic and Predict Benefit From Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Combination With Other Prognostic Factors in Anaplastic Oligodendroglial Brain Tumors: A Report From EORTC Study 26951. <i>Journal of Clinical Oncology</i> , 2013, 31, 328-336.	0.8	99
935	Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402. <i>Journal of Clinical Oncology</i> , 2013, 31, 337-343.	0.8	968
936	Update in the Treatment of High-grade Gliomas. <i>Neurologic Clinics</i> , 2013, 31, 847-867.	0.8	9
938	Gene markers in brain tumors: What the epileptologist should know. <i>Epilepsia</i> , 2013, 54, 25-29.	2.6	18

#	ARTICLE	IF	CITATIONS
939	Chemotherapy and immunotherapy of brain tumors: What the epileptologist must know. <i>Epilepsia</i> , 2013, 54, 105-108.	2.6	8
940	cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome. <i>Journal of Neuro-Oncology</i> , 2013, 115, 249-259.	1.4	28
941	Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. <i>World Journal of Surgical Oncology</i> , 2013, 11, 284.	0.8	22
942	Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 14-26.	12.5	281
943	Genetics and pharmacogenomics of diffuse gliomas. , 2013, 137, 78-88.		7
944	Understanding high grade glioma: Molecular mechanism, therapy and comprehensive management. <i>Cancer Letters</i> , 2013, 331, 139-146.	3.2	228
945	The Role of MGMT Testing in Clinical Practice. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 539-555.	1.2	57
946	The molecular biology of WHO Grade II gliomas. <i>Neurosurgical Focus</i> , 2013, 34, E1.	1.0	16
947	Success at Last: A Molecular Factor That Informs Treatment. <i>Current Oncology Reports</i> , 2013, 15, 47-55.	1.8	6
948	On the Pathway to Success: Defining Subtypes of Gliomas for Better Treatment Selection and Refining the Meaning of Success. <i>Current Oncology Reports</i> , 2013, 15, 24-26.	1.8	1
949	Molecular diagnostics in paediatric glial tumours. <i>Lancet Oncology</i> , The, 2013, 14, e19-e27.	5.1	8
950	The Molecular Biology of Diffuse Low-Grade Gliomas. , 2013, , 99-115.		0
951	Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach. <i>Acta Neuropathologica</i> , 2013, 126, 21-37.	3.9	16
952	Subgrouping of gliomas on the basis of genetic profiles. <i>Brain Tumor Pathology</i> , 2013, 30, 203-208.	1.1	29
954	What underlies the diversity of brain tumors?. <i>Cancer and Metastasis Reviews</i> , 2013, 32, 5-24.	2.7	16
955	Diagnostic and prognostic markers in gliomas – an update. <i>British Journal of Neurosurgery</i> , 2013, 27, 311-315.	0.4	12
956	Exploitation of adaptive evolution in glioma treatment. <i>CNS Oncology</i> , 2013, 2, 171-179.	1.2	8
957	Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951. <i>Journal of Clinical Oncology</i> , 2013, 31, 344-350.	0.8	1,003

#	ARTICLE	IF	CITATIONS
958	Neuro-oncology: Five new things. <i>Neurology: Clinical Practice</i> , 2013, 3, 326-333.	0.8	3
959	Molecular genetics of low-grade gliomas: genomic alterations guiding diagnosis and therapeutic intervention. 11th Annual Frye-Halloran Brain Tumor Symposium. <i>Neurosurgical Focus</i> , 2013, 34, E9.	1.0	10
961	<i>MGMT</i> -STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951. <i>Clinical Cancer Research</i> , 2013, 19, 5513-5522.	3.2	106
962	Brain Tumors and Gliomas. , 2013, , 749-764.		0
963	Co-polysomy of chromosome 1q and 19p predicts worse prognosis in 1p/19q codeleted oligodendroglial tumors: FISH analysis of 148 consecutive cases. <i>Neuro-Oncology</i> , 2013, 15, 1244-1250.	0.6	17
964	The molecular landscape of diffuse glioma and prospects for biomarker development. <i>Expert Opinion on Medical Diagnostics</i> , 2013, 7, 573-587.	1.6	9
965	Predictive biomarkers in adult gliomas. <i>Current Opinion in Oncology</i> , 2013, 25, 689-694.	1.1	34
966	From genomics to the clinic: biological and translational insights of mutant <i>IDH1/2</i> in glioma. <i>Neurosurgical Focus</i> , 2013, 34, E2.	1.0	59
967	Differentiation between Oligodendroglioma Genotypes Using Dynamic Susceptibility Contrast Perfusion-Weighted Imaging and Proton MR Spectroscopy. <i>American Journal of Neuroradiology</i> , 2013, 34, 1542-1549.	1.2	76
968	Prediction of Response to Chemotherapy in Anaplastic Glioma: How Many Markers Does It Take?. <i>Journal of Clinical Oncology</i> , 2013, 31, 297-298.	0.8	5
969	1p/19q testing has no significance in the workup of glioblastomas. <i>Neuropathology and Applied Neurobiology</i> , 2013, 39, 706-717.	1.8	43
970	Minding the Ps and Qs: Perseverance and Quality Studies Lead to Major Advances in Patients With Anaplastic Oligodendroglioma. <i>Journal of Clinical Oncology</i> , 2013, 31, 299-300.	0.8	4
971	<i>PICT1</i> regulates TP53 via <i>RPL11</i> and is involved in gastric cancer progression. <i>British Journal of Cancer</i> , 2013, 109, 2199-2206.	2.9	32
972	Emerging biomarkers in anaplastic oligodendroglioma: implications for clinical investigation and patient management. <i>CNS Oncology</i> , 2013, 2, 351-358.	1.2	10
973	Central Nervous System Cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 1114-1151.	2.3	104
974	Survival and Prognostic Factors of Anaplastic Gliomas. <i>Neurosurgery</i> , 2013, 73, 458-465.	0.6	54
975	A Weighted Fluorescence In Situ Hybridization Strengthens the Favorable Prognostic Value of 1p/19q Codeletion in Pure and Mixed Oligodendroglial Tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013, 72, 432-441.	0.9	17
976	Chromogenic <i>in situ</i> Hybridization is a Reliable Alternative to Fluorescence <i>in situ</i> Hybridization for Diagnostic Testing of 1p and 19q Loss in Paraffin-Embedded Gliomas. <i>Brain Pathology</i> , 2013, 23, 311-318.	2.1	21

#	ARTICLE	IF	CITATIONS
977	A Novel, Diffusely Infiltrative Xenograft Model of Human Anaplastic Oligodendroglioma with Mutations in FUBP1, CIC, and IDH1. <i>PLoS ONE</i> , 2013, 8, e59773.	1.1	39
978	Laboratory Testing for Prognostic and Predictive Markers in Gliomas. , 0, , .		0
979	Genetic Profiling: Searching for Novel Genetic Aberrations in Glioblastoma. , 0, , .		0
980	Original article Loss of genetic material within 1p and 19q chromosomal arms in low grade gliomas of central nervous system. <i>Folia Neuropathologica</i> , 2013, 1, 26-32.	0.5	6
981	In Situ Hybridization. , 2014, , 699-704.		0
982	Molecular, histopathological, and genomic variants of glioblastoma. <i>Frontiers in Bioscience - Landmark</i> , 2014, 19, 1065.	3.0	17
983	Benefits of dynamic susceptibility-weighted contrast-enhanced perfusion MRI for glioma diagnosis and therapy. <i>CNS Oncology</i> , 2014, 3, 407-419.	1.2	30
984	Occipital anaplastic oligodendroglioma with multiple organ metastases after a short clinical course: a case report and literature review. <i>Diagnostic Pathology</i> , 2014, 9, 17.	0.9	27
985	Brain Tumors; Clinical Aspects. , 2014, , 527-531.		0
987	Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial. <i>Acta Neuropathologica Communications</i> , 2014, 2, 68.	2.4	29
988	The Cyclin-Like Protein Spy1 Regulates Growth and Division Characteristics of the CD133+ Population in Human Glioma. <i>Neurosurgery</i> , 2014, 74, N18-N19.	0.6	0
989	IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. <i>Neuro-Oncology</i> , 2014, 16, 81-91.	0.6	370
990	Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors. <i>Modern Pathology</i> , 2014, 27, 332-342.	2.9	45
991	Polysomy of chromosomes 1 and 19: an underestimated prognostic factor in oligodendroglial tumors. <i>Journal of Neuro-Oncology</i> , 2014, 120, 131-138.	1.4	17
992	Homozygous deletion of TNFRSF4, TP73, PPAP2B and DPYD at 1p and PDCD5 at 19q identified by multiplex ligation-dependent probe amplification (MLPA) analysis in pediatric anaplastic glioma with questionable oligodendroglial component. <i>Molecular Cytogenetics</i> , 2014, 7, 1.	0.4	30
993	Brain and Spinal Cord. , 2014, , 1384-1426.		0
994	Updates in the management of high-grade glioma. <i>Journal of Neurology</i> , 2014, 261, 651-654.	1.8	18
995	Short-term survivors in glioblastomas with oligodendroglioma component: a clinical study of 186 Chinese patients from a single institution. <i>Journal of Neuro-Oncology</i> , 2014, 116, 395-404.	1.4	13

#	ARTICLE	IF	CITATIONS
996	Methylation-specific multiplex ligation-dependent probe amplification and its impact on clinical findings in medulloblastoma. <i>Journal of Neuro-Oncology</i> , 2014, 116, 213-220.	1.4	8
997	Radiological features of supratentorial gliomas are associated with their genetic aberrations. <i>Neurosurgical Review</i> , 2014, 37, 291-300.	1.2	7
998	Alpha-internexin and altered CIC expression as a supportive diagnostic marker for oligodendroglial tumors with the 1p/19q co-deletion. <i>Brain Tumor Pathology</i> , 2014, 31, 257-264.	1.1	10
999	Activation of the tumor suppressor p53 upon impairment of ribosome biogenesis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 817-830.	1.8	130
1000	Incidence and relative survival of anaplastic astrocytomas. <i>Neuro-Oncology</i> , 2014, 16, 1400-1407.	0.6	33
1001	Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas. <i>Neuro-Oncology</i> , 2014, 16, 123-130.	0.6	23
1002	Molecular Testing in Cancer. , 2014, , .		2
1003	Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas. <i>Neuro-Oncology</i> , 2014, 16, 914-923.	0.6	69
1004	Pathology of Gliomas and Developments in Molecular Testing. <i>Clinical Oncology</i> , 2014, 26, 377-384.	0.6	5
1005	Update on treatment strategies for anaplastic glioma: a review of literature. <i>Neurological Sciences</i> , 2014, 35, 977-981.	0.9	14
1006	Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. <i>The Cochrane Library</i> , 2014, , CD007104.	1.5	20
1007	Loss of heterozygosity 1p/19q and survival in glioma: a meta-analysis. <i>Neuro-Oncology</i> , 2014, 16, 103-112.	0.6	60
1008	The Evolving Role of Molecular Markers in the Diagnosis and Management of Diffuse Glioma. <i>Clinical Cancer Research</i> , 2014, 20, 5601-5611.	3.2	53
1010	Genetic Markers in Adult High-Grade Gliomas. <i>Seminars in Radiation Oncology</i> , 2014, 24, 235-239.	1.0	2
1011	KPNA2 predicts long term survival in patients with anaplastic oligoastrocytomas. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1719-1724.	0.8	9
1012	Epidemiologic and Molecular Prognostic Review of Glioblastoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1985-1996.	1.1	933
1013	Is the absolute value of O6-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?. <i>Journal of Neurosurgery</i> , 2014, 121, 818-826.	0.9	10
1014	Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. <i>Neuro-Oncology</i> , 2014, 16, 1541-1546.	0.6	12



#	ARTICLE	IF	CITATIONS
1015	Applications of positron emission tomography in neuro-oncology: A clinical approach. Journal of the Royal College of Surgeons of Edinburgh, 2014, 12, 148-157.	0.8	26
1016	Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of <i>IDH1</i> . Journal of Clinical Oncology, 2014, 32, 783-790.	0.8	356
1017	An overview of current and future treatment options for adults anaplastic oligodendroglial tumors. Expert Opinion on Orphan Drugs, 2014, 2, 831-840.	0.5	0
1018	Clinical Discussion of the Management of Anaplastic Oligodendroglioma/Oligoastrocytoma (Both) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 665-672.	2.3	11
1020	Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas. Cancer Control, 2015, 22, 200-205.	0.7	10
1021	PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. Acta Neuropathologica Communications, 2015, 3, 88.	2.4	42
1022	<i>CDKN2A</i> Loss Is Associated With Shortened Overall Survival in Lower-Grade (World Health) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2015, 74, 442-452.	0.9	144
1023	Clinical management of grade III oligodendroglioma. Cancer Management and Research, 2015, 7, 213.	0.9	23
1024	Management of cancers of the central nervous system. , 0, , 473-484.		0
1025	Magnetic resonance imaging of primary spinal anaplastic oligoastrocytoma (World Health) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 0.1 1	0.1	1
1026	Modern Brain Tumor Imaging. Brain Tumor Research and Treatment, 2015, 3, 8.	0.4	157
1027	Metabolomic Screening of Tumor Tissue and Serum in Glioma Patients Reveals Diagnostic and Prognostic Information. Metabolites, 2015, 5, 502-520.	1.3	63
1029	Molecular biology techniques for loss of heterozygosity detection: the glioma example. Jornal Brasileiro De Patologia E Medicina Laboratorial, 2015, 51, 189-196.	0.3	8
1030	Malignant Glioma: Viewpoint "Chemotherapy. , 2015, , 279-293.		0
1031	Oligodendroglioma: pathology, molecular mechanisms and markers. Acta Neuropathologica, 2015, 129, 809-827.	3.9	162
1032	Automatic summarization of risk factors preceding disease progression an insight-driven healthcare service case study on using medical records of diabetic patients. World Wide Web, 2015, 18, 1163-1175.	2.7	4
1033	Diagnostic, prognostic and predictive relevance of molecular markers in gliomas. Neuropathology and Applied Neurobiology, 2015, 41, 694-720.	1.8	83
1034	Oligodendrogliomas: a short history of clinical developments. CNS Oncology, 2015, 4, 281-285.	1.2	4

#	ARTICLE	IF	CITATIONS
1035	Proposed therapeutic strategy for adult low-grade glioma based on aggressive tumor resection. <i>Neurosurgical Focus</i> , 2015, 38, E7.	1.0	73
1037	Oligodendroglial Tumors. <i>Molecular Pathology Library</i> , 2015, , 105-120.	0.1	0
1038	Practical Molecular Pathologic Diagnosis of Infiltrating Gliomas. <i>Surgical Pathology Clinics</i> , 2015, 8, 49-61.	0.7	3
1039	Survival and low-grade glioma: the emergence of genetic information. <i>Neurosurgical Focus</i> , 2015, 38, E6.	1.0	358
1040	Pattern of care of anaplastic oligodendroglioma and oligoastrocytoma in a Korean population: the Korean radiation oncology group study 13-12. <i>Journal of Neuro-Oncology</i> , 2015, 121, 531-539.	1.4	8
1041	The Biology of Primary Brain Tumors. , 2015, , 573-580.e1.		0
1042	Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study. <i>Journal of Neuro-Oncology</i> , 2015, 122, 111-119.	1.4	22
1043	The Cancer Genomics Resource List 2014. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 989-1008.	1.2	18
1044	The future of high-grade glioma: Where we are and where are we going. , 2015, 6, 9.		29
1045	Impact of oligodendroglial component in glioblastoma (GBM-O): Is the outcome favourable than glioblastoma?. <i>Clinical Neurology and Neurosurgery</i> , 2015, 135, 46-53.	0.6	8
1046	Input of molecular analysis in medical management of primary brain tumor patients. <i>Revue Neurologique</i> , 2015, 171, 457-465.	0.6	2
1047	Redox proteomics reveal stress responsive proteins linking peroxiredoxin-1 status in glioma to chemosensitivity and oxidative stress. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2015, 1854, 624-631.	1.1	24
1048	Indications for Treatment: Is Observation or Chemotherapy Alone a Reasonable Approach in the Management of Low-Grade Gliomas?. <i>Seminars in Radiation Oncology</i> , 2015, 25, 203-209.	1.0	12
1049	Prognostic value of volume-based measurements on 11C-methionine PET in glioma patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1071-1080.	3.3	57
1051	Cranial and spinal oligodendrogliomatosis: a case report and review of the literature. <i>Child's Nervous System</i> , 2015, 31, 147-153.	0.6	4
1052	Conventional and advanced (DTI/SWI) neuroimaging findings in pediatric oligodendroglioma. <i>Child's Nervous System</i> , 2015, 31, 885-891.	0.6	12
1053	IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II&III diffuse gliomas. <i>Acta Neuropathologica</i> , 2015, 129, 585-596.	3.9	272
1054	HDAC4, a prognostic and chromosomal instability marker, refines the predictive value of MGMT promoter methylation. <i>Journal of Neuro-Oncology</i> , 2015, 122, 303-312.	1.4	36

#	ARTICLE	IF	CITATIONS
1055	Change in radiotherapy treatment volumes with initial alkylating chemotherapy in anaplastic gliomas. <i>Journal of Radiation Oncology</i> , 2015, 4, 163-167.	0.7	0
1056	EPMA position paper in cancer: current overview and future perspectives. <i>EPMA Journal</i> , 2015, 6, 9.	3.3	86
1057	Anaplastic glioma: current treatment and management. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 601-620.	1.4	21
1058	Glioblastoma: pathology, molecular mechanisms and markers. <i>Acta Neuropathologica</i> , 2015, 129, 829-848.	3.9	503
1059	Chemotherapy in glioma. <i>CNS Oncology</i> , 2015, 4, 179-192.	1.2	58
1060	Next Generation Sequencing in Cancer Research, Volume 2. , 2015, , .		4
1061	Molecular Classification Defines 4 Prognostically Distinct Glioma Groups Irrespective of Diagnosis and Grade. <i>Journal of Neuropathology and Experimental Neurology</i> , 2015, 74, 241-249.	0.9	38
1062	Prediction of anaplastic transformation in low-grade oligodendrogliomas based on magnetic resonance spectroscopy and 1p/19q codeletion status. <i>Journal of Neuro-Oncology</i> , 2015, 122, 529-537.	1.4	12
1063	Molecular Markers in Low-Grade Glioma—Toward Tumor Reclassification. <i>Seminars in Radiation Oncology</i> , 2015, 25, 155-163.	1.0	62
1064	Genetics and imaging of oligodendroglial tumors. <i>CNS Oncology</i> , 2015, 4, 307-315.	1.2	4
1065	Prognostic significance of relative 1p/19q codeletion in oligodendroglial tumors. <i>Journal of Neuro-Oncology</i> , 2015, 125, 249-251.	1.4	37
1066	The role of neuropathology in the management of patients with diffuse low grade glioma. <i>Journal of Neuro-Oncology</i> , 2015, 125, 531-549.	1.4	120
1067	Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131. <i>Journal of Neuro-Oncology</i> , 2015, 124, 413-420.	1.4	27
1068	<i>inactivating mutations identify aggressive subset of 1p19q codeleted gliomas. <i>Annals of Neurology</i>, 2015, 78, 355-374.</i>	2.8	71
1069	IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy. <i>Journal of Neuro-Oncology</i> , 2015, 124, 493-500.	1.4	9
1070	Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1. <i>CNS Oncology</i> , 2015, 4, 287-294.	1.2	48
1071	Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen?. <i>CNS Oncology</i> , 2015, 4, 341-346.	1.2	25
1072	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Tumors of the Central Nervous System. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 1087-1093.	1.2	13

#	ARTICLE	IF	CITATIONS
1073	Paradoxical perfusion metrics of high-grade gliomas with an oligodendroglioma component: quantitative analysis of dynamic susceptibility contrast perfusion MR imaging. <i>Neuroradiology</i> , 2015, 57, 1111-1120.	1.1	9
1074	Molecular diagnostics: techniques and recommendations for 1p/19q assessment. <i>CNS Oncology</i> , 2015, 4, 295-306.	1.2	37
1076	ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. <i>Acta Neuropathologica</i> , 2015, 129, 133-146.	3.9	378
1077	Genetic Analysis of a Case of Glioblastoma with Oligodendroglial Component Arising During the Progression of Diffuse Astrocytoma. <i>Pathology and Oncology Research</i> , 2015, 21, 839-843.	0.9	1
1078	Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010. <i>Cancer</i> , 2015, 121, 102-112.	2.0	98
1079	Critical Molecular and Genetic Markers in Primary Brain Tumors with Their Clinical Importance. , 0, , .		1
1080	Chemotherapy for gliomas. , 0, , 76-90.		0
1081	Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients. <i>Neuro-Oncology</i> , 2016, 18, now100.	0.6	30
1082	Treatment Strategies for Low-Grade Glioma in Adults. <i>Journal of Oncology Practice</i> , 2016, 12, 1235-1241.	2.5	66
1083	World Health Organization grade "II" astrocytomas consist of genetically distinct tumor lineages. <i>Cancer Science</i> , 2016, 107, 1159-1164.	1.7	21
1084	Genetics of glioma. , 0, , 1-23.		1
1086	High Carbonic Anhydrase-9 Expression Identifies a Subset of 1p/19q Co-Deletion and Favorable Prognosis in Oligodendroglioma. <i>World Neurosurgery</i> , 2016, 91, 518-523.e1.	0.7	2
1087	Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide. <i>Journal of Neuro-Oncology</i> , 2016, 127, 505-514.	1.4	42
1088	Recent Advances on the Molecular Pathology of Glial Neoplasms in Children and Adults. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 620-634.	1.2	42
1089	Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community. <i>Neuro-Oncology</i> , 2016, 19, now181.	0.6	17
1090	Low-grade and anaplastic oligodendroglioma. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 361-380.	1.0	26
1091	Establishing a Robust Molecular Taxonomy for Diffuse Gliomas of Adulthood. <i>Surgical Pathology Clinics</i> , 2016, 9, 379-390.	0.7	4
1092	Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying). <i>Journal of Neuro-Oncology</i> , 2016, 130, 31-42.	1.4	35

#	ARTICLE	IF	CITATIONS
1093	Low-grade epilepsy-associated neuroepithelial tumours – the 2016 WHO classification. <i>Nature Reviews Neurology</i> , 2016, 12, 732-740.	4.9	113
1094	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009–2013. <i>Neuro-Oncology</i> , 2016, 18, v1-v75.	0.6	995
1095	Prevalence and profile of cognitive impairment in adult glioma: a sensitivity analysis. <i>Journal of Neuro-Oncology</i> , 2016, 129, 123-130.	1.4	30
1096	Neuroimaging Issues in Assessing Response to Brain Tumor Therapy. , 2016, , 667-680.		0
1097	Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: applying the –integrated–™ diagnosis approach. <i>Journal of Clinical Pathology</i> , 2016, 69, 686-694.	1.0	19
1098	Tumor cell–specific chromosomal abnormality in the vascular endothelial cells of anaplastic oligodendroglioma. <i>Journal of Neurosurgery</i> , 2016, 125, 995-1001.	0.9	1
1099	Special Techniques. , 2016, , 11-44.		0
1101	The Regulatory Role of Long Noncoding RNAs in Cancer Drug Resistance. <i>Methods in Molecular Biology</i> , 2016, 1395, 207-227.	0.4	20
1103	Biomarkers Applied to Specific Tumor Types. , 2016, , 59-98.		0
1104	Clinicopathologic features of small cell glioblastomas. <i>Journal of Neuro-Oncology</i> , 2016, 127, 337-344.	1.4	7
1105	Update on Brain Tumors: New Developments in Neuro–oncologic Diagnosis and Treatment, and Impact on Rehabilitation Strategies. <i>PM and R</i> , 2016, 8, 678-689.	0.9	14
1106	Survival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: A SEER-based analysis. <i>Neuro-Oncology Practice</i> , 2016, 3, 29-38.	1.0	22
1107	Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. <i>Clinical Cancer Research</i> , 2016, 22, 1632-1641.	3.2	127
1108	Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. <i>Neuro-Oncology</i> , 2016, 18, 388-400.	0.6	143
1109	Isocitrate dehydrogenase mutations in gliomas. <i>Neuro-Oncology</i> , 2016, 18, 16-26.	0.6	221
1110	Mild Malformation of Cortical Development with Oligodendroglial Hyperplasia in Frontal Lobe Epilepsy: A New Clinico–Pathological Entity. <i>Brain Pathology</i> , 2017, 27, 26-35.	2.1	81
1111	Radiation Therapy for Malignant Gliomas: Current Options. , 2017, , 217-231.		3
1112	Tumor-Specific Approach: Oligodendroglioma (IDH1 Mutated, 1p/19q Deleted). , 2017, , 251-263.		0

#	ARTICLE	IF	CITATIONS
1113	Glioma Subclassifications and Their Clinical Significance. <i>Neurotherapeutics</i> , 2017, 14, 284-297.	2.1	471
1115	Incidence and survival trends in oligodendrogliomas and anaplastic oligodendrogliomas in the United States from 2000 to 2013: a CBTRUS Report. <i>Journal of Neuro-Oncology</i> , 2017, 133, 17-25.	1.4	17
1116	Genomic Analysis in the Practice of Surgical Neuropathology: The Emory Experience. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 355-365.	1.2	2
1117	Survival trends of oligodendroglial tumor patients and associated clinical practice patterns: a SEER-based analysis. <i>Journal of Neuro-Oncology</i> , 2017, 133, 173-181.	1.4	14
1118	Treatment Outcomes in 1p19q Co-deleted/Partially Deleted Gliomas. <i>Canadian Journal of Neurological Sciences</i> , 2017, 44, 288-294.	0.3	12
1120	Citation classics in neuro-oncology: assessment of historical trends and scientific progress. <i>Neuro-Oncology</i> , 2017, 19, 1158-1172.	0.6	24
1121	Genetic and epigenetic stability of oligodendrogliomas at recurrence. <i>Acta Neuropathologica Communications</i> , 2017, 5, 18.	2.4	47
1122	A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics. <i>Neuro-Oncology</i> , 2017, 19, 614-624.	0.6	100
1123	Connectomic profile and clinical phenotype in newly diagnosed glioma patients. <i>NeuroImage: Clinical</i> , 2017, 14, 87-96.	1.4	64
1124	Contemporary management of low-Grade glioma: a paradigm shift in neuro-oncology. <i>Practical Neurology</i> , 2017, 17, 183-190.	0.5	14
1125	A comparison between oral chemotherapy combined with radiotherapy and radiotherapy for newly diagnosed glioblastoma. <i>Medicine (United States)</i> , 2017, 96, e8444.	0.4	9
1126	GRWD1, a new player among oncogenesis-related ribosomal/nucleolar proteins. <i>Cell Cycle</i> , 2017, 16, 1397-1403.	1.3	18
1127	Imaging Correlates of Adult Glioma Genotypes. <i>Radiology</i> , 2017, 284, 316-331.	3.6	160
1129	CLINICAL RELEVANCE OF MOLECULAR MARKERS IN GLIOMAS. <i>Revista Médica Clínica Las Condes</i> , 2017, 28, 343-351.	0.2	6
1130	Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. <i>Lancet, The</i> , 2017, 390, 1645-1653.	6.3	307
1131	AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma. <i>Nature Neuroscience</i> , 2017, 20, 1329-1341.	7.1	179
1132	From bench to clinical trials the EORTC experience in biology-based clinical cancer research. <i>Journal of the Egyptian National Cancer Institute</i> , 2017, 29, 171-176.	0.6	0
1134	Importance of biomarkers in glioblastomas patients receiving local BCNU wafer chemotherapy. <i>Molecular Cytogenetics</i> , 2017, 10, 16.	0.4	9

#	ARTICLE	IF	CITATIONS
1135	Prediction of genetic subgroups in adult supra tentorial gliomas by pre- and intraoperative parameters. <i>Journal of Neuro-Oncology</i> , 2017, 131, 403-412.	1.4	22
1136	Diagnostic revision of 206 adult gliomas (including 40 oligoastrocytomas) based on ATRX, IDH1/2 and 1p/19q status. <i>Journal of Neuro-Oncology</i> , 2017, 131, 213-222.	1.4	22
1137	CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. <i>Neuro-Oncology</i> , 2017, 19, v1-v88.	0.6	1,236
1138	Temozolomide Low-dose Chemotherapy in Newly Diagnosed Low-grade Gliomas: Activity, Safety, and Long-term Follow-up. <i>Tumori</i> , 2017, 103, 255-260.	0.6	5
1139	The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision. <i>Neurologia Medico-Chirurgica</i> , 2017, 57, 301-311.	1.0	196
1140	Differential Proteomics Analysis of Oligodendrogliomas and Astrocytomas Using iTRAQ Quantification. <i>Journal of Proteomics and Bioinformatics</i> , 2017, 10, .	0.4	0
1141	Patterns of diagnostic marker assessment in adult diffuse glioma: a survey of the European Confederation of Neuropathological Societies (Euro-CNS)., 2017, 36, 5-14.		6
1142	Insights From Molecular Profiling of Adult Glioma. <i>Journal of Clinical Oncology</i> , 2017, 35, 2386-2393.	0.8	53
1143	Diffuse Infiltrating Oligodendroglioma and Astrocytoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 2394-2401.	0.8	142
1144	Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics. <i>Advances in Anatomic Pathology</i> , 2018, 25, 143-171.	2.4	31
1145	Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. <i>Nature Communications</i> , 2018, 9, 1474.	5.8	106
1146	Reconstructing the molecular life history of gliomas. <i>Acta Neuropathologica</i> , 2018, 135, 649-670.	3.9	61
1147	Extent of BOLD Vascular Dysregulation Is Greater in Diffuse Gliomas without Isocitrate Dehydrogenase 1 R132H Mutation. <i>Radiology</i> , 2018, 287, 965-972.	3.6	15
1148	Current therapeutic approaches to diffuse grade II and III gliomas. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628561775203.	1.5	35
1149	The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology. <i>Neuro-Oncology</i> , 2018, 20, 1162-1172.	0.6	92
1150	Comparative analysis of histologically classified oligodendrogliomas reveals characteristic molecular differences between subgroups. <i>BMC Cancer</i> , 2018, 18, 399.	1.1	15
1151	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 310-320.	2.3	476
1152	Oligodendroglioma resection: a Surveillance, Epidemiology, and End Results (SEER) analysis. <i>Journal of Neurosurgery</i> , 2018, 128, 1076-1083.	0.9	38



#	ARTICLE	IF	CITATIONS
1153	Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications. <i>Neuro-Oncology</i> , 2018, 20, 608-620.	0.6	194
1154	Farewell to monomodality treatment in patients with WHO lower grade glioma?. <i>European Journal of Cancer</i> , 2018, 88, 109-114.	1.3	1
1155	Astrocytic and Oligodendroglial Tumors. , 2018, , 91-123.		1
1156	Outcomes and Prognostic Factors in Pediatric Oligodendroglioma: A Population-Based Study. <i>Pediatric Neurosurgery</i> , 2018, 53, 24-35.	0.4	19
1157	Integrating Genomics Into Neuro-Oncology Clinical Trials and Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 148-157.	1.8	2
1158	Determination of genetic aberrations and novel transcripts involved in the pathogenesis of oligodendroglioma using array comparative genomic hybridization and next generation sequencing. <i>Oncology Letters</i> , 2018, 17, 1675-1687.	0.8	1
1159	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. <i>Neuro-Oncology</i> , 2018, 20, iv1-iv86.	0.6	1,624
1160	Anaplastic oligodendroglioma with leptomeningeal dissemination in a french bulldog. <i>Journal of Veterinary Medical Science</i> , 2018, 80, 1590-1595.	0.3	8
1161	The post-surgical era of GBM: How molecular biology has impacted on our clinical management. A review. <i>Clinical Neurology and Neurosurgery</i> , 2018, 170, 120-126.	0.6	26
1162	The role of clinical and molecular factors in low-grade gliomas: what is their impact on survival?. <i>Future Oncology</i> , 2018, 14, 1559-1567.	1.1	17
1163	Clinical Pharmacology of Brain Tumor Chemotherapy. , 2018, , 21-44.		1
1164	An Overview of Molecular Genetics of Brain Tumors. , 2018, , 249-255.		1
1165	Chemotherapy of Oligodendrogliomas. , 2018, , 445-454.		0
1166	Issues in Response Assessment of Brain Tumor Chemotherapy. , 2018, , 715-727.		2
1167	<i>BCL3</i> expression promotes resistance to alkylating chemotherapy in gliomas. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	52
1168	Evolving Insights into the Molecular Neuropathology of Diffuse Gliomas in Adults. <i>Neurologic Clinics</i> , 2018, 36, 421-437.	0.8	9
1169	Epi-Detected Hyperspectral Stimulated Raman Scattering Microscopy for Label-Free Molecular Subtyping of Glioblastomas. <i>Analytical Chemistry</i> , 2018, 90, 10249-10255.	3.2	36
1170	Network-based analysis of oligodendrogliomas predicts novel cancer gene candidates within the region of the 1p/19q co-deletion. <i>Acta Neuropathologica Communications</i> , 2018, 6, 49.	2.4	30

#	ARTICLE	IF	CITATIONS
1171	Brain cancer genomics and epigenomics. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 148, 785-797.	1.0	5
1172	<i>IDH</i> -mutated astrocytomas with 19q loss constitute a subgroup that confers better prognosis. Cancer Science, 2018, 109, 2327-2335.	1.7	20
1173	Grade II and III Oligodendroglioma and Astrocytoma. Neurologic Clinics, 2018, 36, 467-484.	0.8	31
1174	A STAT3-based gene signature stratifies glioma patients for targeted therapy. Nature Communications, 2019, 10, 3601.	5.8	67
1175	Changing paradigms for targeted therapies against diffuse infiltrative gliomas: tackling a moving target. Expert Review of Neurotherapeutics, 2019, 19, 663-677.	1.4	3
1176	Defining Protein Pattern Differences Among Molecular Subtypes of Diffuse Gliomas Using Mass Spectrometry* [S]. Molecular and Cellular Proteomics, 2019, 18, 2029-2043.	2.5	19
1177	Primary central nervous system tumor treatment and survival in the United States, 2004-2015. Journal of Neuro-Oncology, 2019, 144, 179-191.	1.4	28
1178	Clinical presentation of spinal oligodendrogliomas. , 2019, , 11-21.		0
1179	The role of biomarkers in the diagnosis and treatment of oligodendrogliomas. , 2019, , 109-115.		1
1180	Bone metastases from a 1p/19q codeleted and IDH1-mutant anaplastic oligodendroglioma: a case report. Journal of Medical Case Reports, 2019, 13, 202.	0.4	6
1181	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. Neuro-Oncology, 2019, 21, v1-v100.	0.6	1,735
1182	Targeting Telomerase and ATRX/DAXX Inducing Tumor Senescence and Apoptosis in the Malignant Glioma. International Journal of Molecular Sciences, 2019, 20, 200.	1.8	30
1183	Accelerated progression of IDH mutant glioma after first recurrence. Neuro-Oncology, 2019, 21, 669-677.	0.6	38
1184	Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management. Journal of Medical Imaging and Radiation Oncology, 2019, 63, 272-280.	0.9	6
1185	Systematically profiling the expression of eIF3 subunits in glioma reveals the expression of eIF3i has prognostic value in IDH-mutant lower grade glioma. Cancer Cell International, 2019, 19, 155.	1.8	27
1186	Design and Validation of a Gene-Targeted, Next-Generation Sequencing Panel for Routine Diagnosis in Gliomas. Cancers, 2019, 11, 773.	1.7	18
1187	Molecular pathology of tumors of the central nervous system. Annals of Oncology, 2019, 30, 1265-1278.	0.6	129
1188	Polysomy is associated with poor outcome in 1p/19q codeleted oligodendroglial tumors. Neuro-Oncology, 2019, 21, 1164-1174.	0.6	12

#	ARTICLE	IF	CITATIONS
1189	Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma. <i>Carcinogenesis</i> , 2019, 40, 1229-1239.	1.3	60
1190	WHO II and III Gliomas. , 2019, , 217-236.		1
1191	Tumor Biology. , 2019, , 143-152.		0
1192	Neurosurgical patterns of care for diffuse low-grade gliomas in Sweden between 2005 and 2015. <i>Neuro-Oncology Practice</i> , 2019, 6, 124-133.	1.0	6
1193	An integrated genomic and metabolomic approach for defining survival time in adult oligodendrogliomas patients. <i>Metabolomics</i> , 2019, 15, 69.	1.4	5
1194	ATRX immunohistochemistry can help refine “not elsewhere classified” categorisation for grade II/III gliomas. <i>British Journal of Neurosurgery</i> , 2019, 33, 536-540.	0.4	1
1195	Pathology of Primary Brain Tumors“Gliomas. , 2019, , 121-137.		2
1196	Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entities. <i>Diagnostic Pathology</i> , 2019, 14, 29.	0.9	40
1197	Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus. <i>Neuro-Oncology</i> , 2019, 21, 837-853.	0.6	66
1198	PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 4375-4387.	3.2	26
1199	Overview of DNA methylation in adult diffuse gliomas. <i>Brain Tumor Pathology</i> , 2019, 36, 84-91.	1.1	45
1200	Biomarkers in tumors of the central nervous system “ a review. <i>Apms</i> , 2019, 127, 265-287.	0.9	9
1201	Widely metastatic IDH1-mutant glioblastoma with oligodendroglial features and atypical molecular findings: a case report and review of current challenges in molecular diagnostics. <i>Diagnostic Pathology</i> , 2019, 14, 16.	0.9	10
1202	Overall survival time prediction for high-grade glioma patients based on large-scale brain functional networks. <i>Brain Imaging and Behavior</i> , 2019, 13, 1333-1351.	1.1	37
1203	A little piece of mind: best practices for brain tumor intraoperative consultation. <i>Modern Pathology</i> , 2019, 32, 44-57.	2.9	10
1204	Neuro-Oncology Clinical Debate: PCV or temozolomide in combination with radiation for newly diagnosed high-grade oligodendroglioma. <i>Neuro-Oncology Practice</i> , 2019, 6, 17-21.	1.0	7
1205	Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual?. <i>Neuro-Oncology</i> , 2019, 21, 14-25.	0.6	69
1206	Genetic and epigenetic contribution to astrocytic gliomas pathogenesis. <i>Journal of Neurochemistry</i> , 2019, 148, 188-203.	2.1	82

#	ARTICLE	IF	CITATIONS
1207	Imaging scoring systems for preoperative molecular diagnoses of lower-grade gliomas. <i>Neurosurgical Review</i> , 2019, 42, 433-441.	1.2	19
1208	Pathology, Biomarkers, and Molecular Diagnostics. , 2020, , 225-253.e8.		4
1209	11C-Methionine Integrated PET/MRI-Based Texture Analysis Features May Have a Potential Ability to Distinguish Oligodendroglioma (IDH-Mutant and 1p/19q-Codeleted) From Varied Gliomas. <i>Academic Radiology</i> , 2020, 27, e159-e167.	1.3	7
1211	MRI and CT Identify Isocitrate Dehydrogenase (IDH)-Mutant Lower-Grade Gliomas Misclassified to 1p/19q Codeletion Status with Fluorescence in Situ Hybridization. <i>Radiology</i> , 2020, 294, 160-167.	3.6	19
1212	Imaging of Central Nervous System Tumors Based on the 2016 World Health Organization Classification. <i>Neurologic Clinics</i> , 2020, 38, 95-113.	0.8	21
1213	Imaging Gliomas After Treatment. , 2020, , .		0
1214	Frequency of false-positive FISH 1p/19q codeletion in adult diffuse astrocytic gliomas. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa109.	0.4	15
1215	CDKN2C-Null Leiomyosarcoma: A Novel, Genomically Distinct Class of TP53/RB1-Wild-Type Tumor With Frequent CIC Genomic Alterations and 1p/19q-Codeletion. <i>JCO Precision Oncology</i> , 2020, 4, 955-971.	1.5	6
1216	Epigenetic age acceleration and clinical outcomes in gliomas. <i>PLoS ONE</i> , 2020, 15, e0236045.	1.1	14
1217	Voxel-based strain tensors from near-field High Energy Diffraction Microscopy. <i>Current Opinion in Solid State and Materials Science</i> , 2020, 24, 100852.	5.6	15
1218	P.191 The impact of physical activity and fitness on resilience to modern-life stress and the role of brain-derived neurotrophic factor (BDNF). <i>European Neuropsychopharmacology</i> , 2020, 40, S110-S111.	0.3	0
1219	P.467 Safety, pharmacokinetics, and pharmacodynamics of LB-102, a selective D2 / 5-HT7 antagonist, in healthy volunteers. <i>European Neuropsychopharmacology</i> , 2020, 40, S265.	0.3	0
1220	Guided Internet-delivered cognitive behaviour therapy for perfectionism in a non-clinical sample of adolescents: A study protocol for a randomised controlled trial. <i>Internet Interventions</i> , 2020, 21, 100342.	1.4	0
1221	Comparison based on statistical thermodynamics between globule-to-coil transition of poly(N-isopropylacrylamide) and cold denaturation of a protein. <i>Journal of Molecular Liquids</i> , 2020, 317, 114129.	2.3	10
1224	Post COVID 19 acute acalculous cholecystitis raising the possibility of underlying dysregulated immune response, a case report. <i>Annals of Medicine and Surgery</i> , 2020, 60, 434-437.	0.5	25
1225	479P Open chromatin region (OCR) based model predicts advanced adenoma in plasma cell-free DNA whole-genome bisulfite sequencing data. <i>Annals of Oncology</i> , 2020, 31, S444.	0.6	0
1226	55P MOREL: Multicenter observational study on treatment and PD-L1 testing in patients (pts) with newly diagnosed stage IV NSCLC in Spain. <i>Annals of Oncology</i> , 2020, 31, S1437-S1438.	0.6	0
1227	Assessing mTBI Treatment Protocol for Latent Subgroups. <i>Archives of Physical Medicine and Rehabilitation</i> , 2020, 101, e129-e130.	0.5	0

#	ARTICLE	IF	CITATIONS
1228	Testicular hypertrophy as predictor of contralateral nonpalpable testis among Chinese boys: An 18-year retrospective study. <i>Archives De Pediatrie</i> , 2020, 27, 456-463.	0.4	5
1229	<i>Lactobacillus johnsonii</i> -activated chicken bone marrow-derived dendritic cells exhibit maturation and increased expression of cytokines and chemokines in vitro. <i>Cytokine</i> , 2020, 136, 155269.	1.4	4
1230	Î³-Aminobutyric acid found in fermented foods and beverages: current trends. <i>Heliyon</i> , 2020, 6, e05526.	1.4	51
1231	Influence of the interval length of hydraulic packer systems on thermally-induced pore pressure measurements in rock. <i>International Journal of Rock Mechanics and Minings Sciences</i> , 2020, 135, 104500.	2.6	6
1232	Linearized torsional problem of plastic thin wires. <i>Mechanics Research Communications</i> , 2020, 109, 103598.	1.0	1
1233	Bright and slip-proof engineered cementitious composites with visible light activated photo-catalysis property for pavement in tunnels. <i>Cement and Concrete Composites</i> , 2020, 114, 103788.	4.6	11
1235	Angelika Amon. <i>Developmental Cell</i> , 2020, 55, 525-528.	3.1	0
1236	Phase states, microstructure and dielectric characteristics of solid solutions $(1-x)\text{NaNbO}_3-x\text{Ca}_2\text{Nb}_2\text{O}_7$ and $(1-x)\text{NaNbO}_3-x\text{Sr}_2\text{Nb}_2\text{O}_7$ . <i>Heliyon</i> , 2020, 6, e05197.	1.4	3
1237	Molecular dynamic study of evaporation in nanoslit: Influence of slit geometry and wettability. <i>International Journal of Heat and Mass Transfer</i> , 2020, 163, 120463.	2.5	6
1238	Deep Markov models of multidimensional random fields. <i>Procedia Computer Science</i> , 2020, 176, 1289-1298.	1.2	3
1239	Custom optical imaging system for ex-vivo breast cancer detection based on spectral signature. <i>Surgical Oncology</i> , 2020, 35, 547-555.	0.8	14
1240	Tumor Phylogeny Topology Inference via Deep Learning. <i>IScience</i> , 2020, 23, 101655.	1.9	11
1241	Closed-loop optimized nanometal sintering method. <i>Journal of Manufacturing Processes</i> , 2020, 59, 403-410.	2.8	1
1243	Integrating yoga with psychological group-treatment for mixed depression and anxiety in primary healthcare: An explorative pilot study. <i>Complementary Therapies in Clinical Practice</i> , 2020, 41, 101250.	0.7	4
1244	A hybrid fractional optimal control for a novel Coronavirus (2019-nCov) mathematical model. <i>Journal of Advanced Research</i> , 2021, 32, 149-160.	4.4	29
1245	Reconstruction of the glacial history after the Last Glacial Maximum in the Italian Central Alps using Schmidt's hammer R-values and crystallinity ratio indices of soils. <i>Quaternary International</i> , 2020, 558, 19-27.	0.7	5
1247	Is the ALS a motor neuron disease or a hematopoietic stem cell disease?. <i>Progress in Brain Research</i> , 2020, 258, 381-396.	0.9	5
1248	Variation of CD4 count in pregnant women living with HIV. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 962-963.	0.7	1

#	ARTICLE	IF	CITATIONS
1249	Shear stress induced activation of von Willebrand factor may facilitate thrombotic events in coronary artery disease in young adults. <i>Atherosclerosis</i> , 2020, 315, e79.	0.4	0
1250	3PO inhibits glycolysis but does not bind to 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3). <i>Atherosclerosis</i> , 2020, 315, e87.	0.4	2
1251	Prognostic power of big endothelin-1 in noncompaction cardiomyopathy. <i>Atherosclerosis</i> , 2020, 315, e260.	0.4	0
1252	Association between added sugar intake and intima media thickness as a marker for atherosclerosis: A cross sectional study in the malmÅr diet and cancer study. <i>Atherosclerosis</i> , 2020, 315, e274.	0.4	0
1253	National OMFS specialty trainee recruitment – does an interview skills course help in preparation?. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2020, 58, e192.	0.4	0
1254	Management of lymphatic malformations of the head and neck region: our 6 year experience. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2020, 58, e192.	0.4	0
1255	Classification of crista galli pneumatization and clinical considerations for anterior skull base surgery. <i>Journal of Clinical Neuroscience</i> , 2020, 82, 225-230.	0.8	4
1262	Fear of negative evaluation and the concealment of their disease by epilepsy patients. <i>Epilepsy and Behavior</i> , 2020, 113, 107539.	0.9	9
1266	The role of oxidative stress on molybdenum enzymes and ischemic reperfusion injury in hyperuricaemic patients. An infrared spectroscopic study. <i>Atherosclerosis</i> , 2020, 315, e60-e61.	0.4	0
1267	Glypican-4 expression is reduced in the inflammatory plaque shoulder in human atherosclerotic lesions. <i>Atherosclerosis</i> , 2020, 315, e63.	0.4	0
1268	Arterial wall elasticity in Greek soccer athletes with and without family history of cardiovascular disease. <i>Atherosclerosis</i> , 2020, 315, e71.	0.4	0
1269	Percutaneous retrieval of an entrapped rotational atherectomy burr using novel technique of controlled traction and counter traction. <i>Cardiovascular Revascularization Medicine</i> , 2020, 28S, 132-135.	0.3	1
1270	Parametrized Fixed Points and Their Applications to Session Types. <i>Electronic Notes in Theoretical Computer Science</i> , 2020, 352, 149-172.	0.9	0
1273	Recycling for All Solid-State Lithium-Ion Batteries. <i>Matter</i> , 2020, 3, 1845-1861.	5.0	38
1276	Numerical investigation of an optimized plasmonic on-chip refractive index sensor for temperature and blood group detection. <i>Results in Physics</i> , 2020, 19, 103611.	2.0	29
1278	Interventions and Practice Implications for the Management of Endometriosis. <i>Nursing for Women's Health</i> , 2020, 24, 460-467.	0.3	2
1280	Multicenter transperineal MRI-TRUS fusion guided outpatient clinic prostate biopsies under local anesthesia. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 39, 432.e1-432.e7.	0.8	15
1281	14407 The Cancer Risk Among MITF E318K Mutation Carriers. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB23.	0.6	0

#	ARTICLE	IF	CITATIONS
1282	15120 Erdheim-Chester disease: Case report with multisystem manifestations. Journal of the American Academy of Dermatology, 2020, 83, AB30.	0.6	0
1283	15838 Autoimmune comorbidities of psoriasis in US adults and children. Journal of the American Academy of Dermatology, 2020, 83, AB48.	0.6	0
1284	15174 Risk of ischemic heart disease in patients with hidradenitis suppurativa: Analysis of real-world data within a large, urban, Midwestern US dermatology patient population. Journal of the American Academy of Dermatology, 2020, 83, AB143.	0.6	0
1285	Engineering lytic polysaccharide monoxygenases (LPMOs). Methods in Enzymology, 2020, 644, 1-34.	0.4	12
1286	First-principles study of binary and ternary alloys based on PdCu as oxygen reduction catalysts. Chemical Physics Letters, 2020, 758, 137932.	1.2	0
1288	Hernía interna relacionada con la derivación gástrica en Y de Roux: una complicación que representa un reto clínico y diagnóstico. Cirugía Española, 2020, 98, 559.	0.1	0
1289	High-speed video data for settling of dense liquid droplets through liquid media with different viscosities. Data in Brief, 2020, 33, 106428.	0.5	0
1290	Acidity and Nucleophilicity of Persulfides. Free Radical Biology and Medicine, 2020, 159, S18-S19.	1.3	0
1291	Generation of Glutaredoxin Mutants that Provide Resistance to Oxidative Inactivation and Promote Biological Activity. Free Radical Biology and Medicine, 2020, 159, S88.	1.3	0
1293	Comparison and suggestion of indicators of concentrations associated with CO <sub>2</sub> in seawater considering biological activity. International Journal of Greenhouse Gas Control, 2020, 102, 103152.	2.3	3
1294	Kocuria kristinae infection associated with short bowel syndrome: A case report. International Journal of Surgery Case Reports, 2020, 77, 276-278.	0.2	1
1295	A Pilot Longitudinal Study of 3-Dimensional Head and Neck Kinematics During Functional Tasks in Individuals With Chronic Idiopathic Neck Pain Either Wait-Listed for or Receiving Chiropractic Spinal Manipulative Therapy With Exercise. Journal of Manipulative and Physiological Therapeutics, 2020, 43, 490-505.	0.4	3
1296	Infographics Improve Comprehension and Recall at the Orthopaedic Journal Club. Journal of Surgical Education, 2021, 78, 1345-1349.	1.2	12
1297	A neural network based inverse system control strategy to decouple turbine power in multi-reactor and multi-turbine nuclear power plant. Progress in Nuclear Energy, 2020, 129, 103500.	1.3	6
1298	Landing Error Scoring System scores change with knowledge of scoring criteria and prior performance. Physical Therapy in Sport, 2020, 46, 155-161.	0.8	4
1299	Diazoalkane decay kinetics from UVA-active protein labelling molecules: Trifluoromethyl phenyl diazirines. Results in Chemistry, 2020, 2, 100066.	0.9	7
1300	Three-Dimensional Nuclear Telomere Profiling as a Biomarker for Recurrence in Oligodendrogliomas: A Pilot Study. International Journal of Molecular Sciences, 2020, 21, 8539.	1.8	2
1301	Comparison of using p-nc-SiO <sub>x</sub> :H and p-nc-Si:H as window layer in amorphous silicon based solar cells. Optik, 2020, 222, 165444.	1.4	3



#	ARTICLE	IF	CITATIONS
1302	Remotely sensed canopy resistance model for analyzing the stomatal behavior of environmentally-stressed winter wheat. <i>ISPRS Journal of Photogrammetry and Remote Sensing</i> , 2020, 168, 197-207.	4.9	11
1303	U-Pb zircon geochronology and geochemistry of metavolcanics and associated iron ores of the magnetite-rich BIF deposits in the Western Kunlun orogenic belt: Constraints on the depositional age, origin and tectonic setting. <i>Ore Geology Reviews</i> , 2020, 126, 103751.	1.1	9
1304	Traitement de la paralysie radiale par transferts tendineux avec r�animation de lâ™extensor carpi ulnaris: technique et r�sultats. <i>Revue De Chirurgie Orthopedique Et Traumatologique</i> , 2020, 106, 152-156.	0.0	0
1305	Physiological performance in aquaculture: Using physiology to help define optimal conditions for growth and environmental tolerance. <i>Fish Physiology</i> , 2020, , 83-121.	0.2	18
1306	Evidence on the neuroprotective properties of brimonidine in glaucoma. <i>Progress in Brain Research</i> , 2020, 257, 155-166.	0.9	6
1307	Botulinum toxin injections minimally affect modelled muscle forces during gait in children with cerebral palsy. <i>Gait and Posture</i> , 2020, 82, 54-60.	0.6	9
1308	Microstructure-based approach to the evaluation of welded joints of bainitic rails designed for high-speed railways. <i>Journal of Constructional Steel Research</i> , 2020, 175, 106372.	1.7	12
1309	Descripci3n de la cohorte PROCOAC (PROspective COhort of A Coru�a): Cohorte prospectiva espa�ola para el estudio de la osteoartritis. <i>Reumatolog�a Cl�nica</i> , 2022, 18, 100-104.	0.2	10
1311	A platform for initial testing of multiple camouflage patterns. <i>Defence Technology</i> , 2021, 17, 1833-1839.	2.1	5
1312	Altered hand proprioception following regional anesthesia as a cause of traumatic jersey finger: Report of two cases. <i>Hand Surgery and Rehabilitation</i> , 2020, 39, 582-584.	0.2	2
1313	Antitumor activity of an oncolytic measles virus against canine urinary bladder transitional cell carcinoma cells. <i>Research in Veterinary Science</i> , 2020, 133, 313-317.	0.9	4
1316	Quantitative estimates in reiterated homogenization. <i>Journal of Functional Analysis</i> , 2020, 279, 108759.	0.7	6
1317	Design of Gr/2024Al composite and Ti6Al4V titanium alloy joint brazed using AgCuSnTi filler and Ni/Nb/Ni composite interlayers. <i>Journal of Manufacturing Processes</i> , 2020, 58, 67-74.	2.8	2
1318	Removal of chromium from aqueous solution by porous Bi2MoO6@BiOCl nanostructure. <i>Journal of Solid State Chemistry</i> , 2020, 292, 121719.	1.4	28
1319	T-cell receptor antibodies expression in benign and malignant cutaneous lymphoid infiltrates in comparison with T-cell receptor gene rearrangement and its diagnostic utility in borderline cases. <i>Pathology Research and Practice</i> , 2020, 216, 153279.	1.0	0
1321	Novel Application for G Protein�Biased Mu Opioid Receptor Agonists in Opioid Relapse Prevention. <i>Biological Psychiatry</i> , 2020, 88, 896-897.	0.7	3
1322	Effect Of Low-Dose Radiotherapy On Abscopal Responses To Hypofractionated Radiotherapy And Anti-PD1 In Mice and NSCLC Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, e563.	0.4	3
1324	An advanced in silico drug discovery platform, 4HF Data Miner for identifying novel targets for tumors and tumor-stroma. <i>European Journal of Cancer</i> , 2020, 138, S27.	1.3	1

#	ARTICLE	IF	CITATIONS
1325	Fluorescent labeling of extracellular vesicles. <i>Methods in Enzymology</i> , 2020, 645, 15-42.	0.4	13
1326	A single amino acid substitution converts a histidine decarboxylase to an imidazole acetaldehyde synthase. <i>Archives of Biochemistry and Biophysics</i> , 2020, 693, 108551.	1.4	2
1327	Effect of Osteoarthritis on Prefrontal Cortical Activation Patterns During Dual Task Walking in Older Women. <i>Archives of Physical Medicine and Rehabilitation</i> , 2020, 101, e63.	0.5	0
1329	Hybrid engineered dental composites by multiscale reinforcements with chitosan-integrated halloysite nanotubes and S-glass fibers. <i>Composites Part B: Engineering</i> , 2020, 202, 108448.	5.9	19
1330	Brief communication: Impact of negative pressure dressing on surgical incisions following caesarean section. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 253, 343-344.	0.5	0
1331	How Sugar Affects Your Body. 2019. <i>Journal of Nutrition Education and Behavior</i> , 2020, 52, 1077-1078.	0.3	0
1332	A sensor framework for combined data streams and in-situ characterization of machining processes. <i>Procedia CIRP</i> , 2020, 93, 868-872.	1.0	2
1333	Spectrum Sensing for Smart Embedded Devices in Cognitive Networks using Machine Learning Algorithms. <i>Procedia Computer Science</i> , 2020, 176, 2404-2413.	1.2	12
1334	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. <i>Neuro-Oncology</i> , 2020, 22, iv1-iv96.	0.6	1,175
1335	Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications. <i>Biomedicines</i> , 2020, 8, 294.	1.4	39
1336	Recomendaciones para el tratamiento nutrometabólico especializado del paciente crónico: consecuencias de la desnutrición en el paciente crónico y valoración del estado nutricional. Grupo de Trabajo de Metabolismo y Nutrición de la Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC). <i>Medicina Intensiva</i> , 2020, 44, 19-23.	0.4	1
1337	Relationship between BRAF V600E and KRAS mutations in stool for identifying colorectal cancer: A cross-sectional study. <i>Annals of Medicine and Surgery</i> , 2020, 60, 121-125.	0.5	2
1338	Cell Biology: An Open Solution for Closed Mitosis. <i>Current Biology</i> , 2020, 30, R942-R944.	1.8	1
1340	White matter structural network disturbances in first-episode, drug-naïve adolescents with generalized anxiety disorder. <i>Journal of Psychiatric Research</i> , 2020, 130, 394-404.	1.5	9
1341	Large Subfoveal Vitelliform Lesions in a Case of Pentosan Polysulfate Maculopathy. <i>Ophthalmology</i> , 2020, 127, 1641.	2.5	7
1343	Follow the evacuation signs or surrounding people during building evacuation, an experimental study. <i>Physica A: Statistical Mechanics and Its Applications</i> , 2020, 560, 125156.	1.2	22
1345	39: Impact of Smoking Status and Pack Year History on Outcomes of Early Stage Non-Small Cell Lung Cancers Treated with Stereotactic Ablative Radiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 150, S20.	0.3	0
1346	Application cases of biological transformation in manufacturing technology. <i>CIRP Journal of Manufacturing Science and Technology</i> , 2020, 31, 68-77.	2.3	15

#	ARTICLE	IF	CITATIONS
1347	Thyroid function in adults patients undergoing cardiac surgery: A pilot study. <i>Clinical Nutrition ESPEN</i> , 2020, 40, 506-507.	0.5	0
1348	The impact of body composition on mortality in hematopoietic stem cell transplantation. <i>Clinical Nutrition ESPEN</i> , 2020, 40, 544.	0.5	0
1349	Frequency and determinants of malnutrition in hospitalised children with heart diseases. <i>Clinical Nutrition ESPEN</i> , 2020, 40, 577.	0.5	0
1350	Alteration in the profile of fecal bile acids after bypass in Y-Roux (RYGB) in patients with obesity and type 2 diabetes who did not undergo cholecystectomy may be involved with the improvement of postoperative glycemic homeostasis. <i>Clinical Nutrition ESPEN</i> , 2020, 40, 651.	0.5	0
1352	Ectopic pancreas: A rare cause of occult gastrointestinal bleeding. <i>Annals of Medicine and Surgery</i> , 2020, 59, 41-43.	0.5	3
1353	Arrhythmias Involving Variants of Accessory Pathways. <i>Cardiac Electrophysiology Clinics</i> , 2020, 12, 505-518.	0.7	1
1354	An efficient and modular modeling for launch dynamics of tubed rockets on a moving launcher. <i>Defence Technology</i> , 2021, 17, 2011-2026.	2.1	7
1355	Succession mechanism of microbial community with high species diversity in nutrient-deficient environments with low-dose ionizing radiation. <i>Ecological Modelling</i> , 2020, 435, 109270.	1.2	5
1356	Risk factors for stunting among children in Banggai Regency, Indonesia. <i>Enfermería Clínica</i> , 2020, 30, 149-152.	0.1	1
1357	Association of personal exposure to power-frequency magnetic fields with pregnancy outcomes among women seeking fertility treatment in a longitudinal cohort study. <i>Fertility and Sterility</i> , 2020, 114, 1058-1066.	0.5	2
1359	Maladaptation: When Adaptation to Climate Change Goes Very Wrong. <i>One Earth</i> , 2020, 3, 409-414.	3.6	166
1360	Blended Ag nanofluids with optimized optical properties to regulate the performance of PV/T systems. <i>Solar Energy</i> , 2020, 208, 623-636.	2.9	24
1361	Greenhouse gas emissions from high-speed rail infrastructure construction in Korea. <i>Transportation Research, Part D: Transport and Environment</i> , 2020, 87, 102514.	3.2	19
1362	Effect of moringa leaves during pregnancy on growth and morbidity in 0-5 months. <i>Enfermería Clínica</i> , 2020, 30, 61-65.	0.1	1
1363	Rerouting Europe's gas transit landscape - Effects of Russian natural gas infrastructure strategy on the V4. <i>Energy Policy</i> , 2020, 146, 111748.	4.2	12
1364	Core-shell Au@Se nanoparticles embedded in cellulose acetate/polyvinylidene fluoride scaffold for wound healing. <i>Journal of Materials Research and Technology</i> , 2020, 9, 15045-15056.	2.6	38
1367	Evaluating the properties of zinc production wastes as filler and their effects on asphalt mastic. <i>Construction and Building Materials</i> , 2020, 265, 120748.	3.2	14
1368	Snapshot of Equine Dentistry: Past, Present, and Future. <i>Veterinary Clinics of North America Equine Practice</i> , 2020, 36, xi-xiii.	0.3	0

#	ARTICLE	IF	CITATIONS
1373	Why Racial Justice Matters in Radiation Oncology. <i>Advances in Radiation Oncology</i> , 2020, 5, 7-14.	0.6	0
1374	The Practice of Anti-racist Science Requires an Internationalist Perspective. <i>American Journal of Human Genetics</i> , 2020, 107, 793-796.	2.6	5
1375	A Roadmap to Success – One Workgroup's Approach to Improving Internal Hand Hygiene Compliance in an Acute Care Medical Center. <i>American Journal of Infection Control</i> , 2020, 48, S10-S11.	1.1	0
1376	19 Factors Associated with County-Level SARS-CoV-2 Testing Volume in Nine States. <i>Annals of Emergency Medicine</i> , 2020, 76, S7-S8.	0.3	0
1377	303 Assessing Resident Communication With Faculty from Multiple Specialties in Pediatric Simulation Designed to Provide Multi-Source Feedback. <i>Annals of Emergency Medicine</i> , 2020, 76, S116-S117.	0.3	0
1378	343 Motivational Factors That Influence Adoption of Innovations. <i>Annals of Emergency Medicine</i> , 2020, 76, S132.	0.3	0
1380	Facile synthesis of three-dimensional porous graphene nanostructures from coordination complexes for supercapacitor electrode. <i>Advanced Powder Technology</i> , 2020, 31, 4157-4165.	2.0	4
1381	The Legacy of Hermann Staudinger: Covalently Linked Macromolecules. <i>CheM</i> , 2020, 6, 2855-2861.	5.8	11
1382	Learning rules. <i>Current Biology</i> , 2020, 30, R1289-R1290.	1.8	0
1383	Green tea ( <i>Camellia sinensis</i> ) extract inhibits biofilm formation in acyl homoserine lactone-producing, antibiotic-resistant <i>Morganella morganii</i> isolated from Pasig River, Philippines. <i>Heliyon</i> , 2020, 6, e05284.	1.4	7
1384	Using an extended Technology Acceptance Model to understand students' use of e-learning during Covid-19: Indonesian sport science education context. <i>Heliyon</i> , 2020, 6, e05410.	1.4	157
1385	A Softer Approach to Quantitative Blood Loss Measurement. <i>JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing</i> , 2020, 49, S24.	0.2	0
1386	Innovative Approach to Improving Efficiency Through an Early-Induction Unit. <i>JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing</i> , 2020, 49, S36.	0.2	0
1387	A Comparison Study of Patient Characteristics and Outcomes for Use of Nitrous Oxide During Labor. <i>JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing</i> , 2020, 49, S51.	0.2	0
1388	Challenging the Status Quo to Innovate the Future of Nurse Productivity and Benchmarking. <i>JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing</i> , 2020, 49, S82.	0.2	1
1392	Is enough, enough? SEND data processing considerations when changing the logging rate. <i>Journal of Pharmacological and Toxicological Methods</i> , 2020, 105, 106840.	0.3	0
1393	Effect of remote ischaemic conditioning on coagulation function as measured by rotational thromboelastometry and whole blood impedance aggregometry in off-pump coronary artery bypass surgery: a randomised controlled trial. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2020, 34, S14-S15.	0.6	0
1394	Resolution of strain abnormalities during extracorporeal rewarming from accidental hypothermic cardiac arrest: a case report. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2020, 34, S49-S50.	0.6	0

#	ARTICLE	IF	CITATIONS
1396	Infective endocarditis following transcatheter aortic valve implantation. <i>Annales De Cardiologie Et D'Angeiologie</i> , 2020, 69, 204-206.	0.3	0
1397	Impulsivity facets and cognitive distortions associated with problem gambling: Differences between ADHD and non-ADHD gamblers. <i>Revue Europeenne De Psychologie Appliquee</i> , 2020, 70, 100559.	0.4	5
1398	RIPK3 is a novel prognostic marker for lower grade glioma and further enriches IDH mutational status subgrouping. <i>Journal of Neuro-Oncology</i> , 2020, 147, 587-594.	1.4	16
1399	Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment. <i>Molecular Oncology</i> , 2020, 14, 1016-1027.	2.1	15
1400	Beyond IDH-Mutation: Emerging Molecular Diagnostic and Prognostic Features in Adult Diffuse Gliomas. <i>Cancers</i> , 2020, 12, 1817.	1.7	43
1401	DNA inhibitors for the treatment of brain tumors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 195-207.	1.5	3
1402	Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1004-1009.	1.0	16
1403	Educational Case: Histologic and Molecular Features of Diffuse Gliomas. <i>Academic Pathology</i> , 2020, 7, 2374289520914021.	0.7	2
1404	Observation versus radiotherapy with or without temozolomide in postoperative WHO grade II high-risk low-grade glioma: a retrospective cohort study. <i>Neurosurgical Review</i> , 2021, 44, 1447-1455.	1.2	11
1405	Fungal chitin-glucan nanopapers with heavy metal adsorption properties for ultrafiltration of organic solvents and water. <i>Carbohydrate Polymers</i> , 2021, 253, 117273.	5.1	43
1406	Analysis of gravel back-filled borehole heat exchanger in karst fractured limestone aquifer at local scale. <i>Geothermics</i> , 2021, 89, 101971.	1.5	7
1407	TO SHARE OR TO EXCHANGE: An analysis of the sharing economy characteristics of Airbnb and Fairbnb.coop. <i>International Journal of Hospitality Management</i> , 2021, 92, 102724.	5.3	10
1408	Preeclampsia and the crucial postpartum period for Covid-19 infected mothers: A case report. <i>Pregnancy Hypertension</i> , 2021, 23, 136-139.	0.6	9
1409	In-silico protein-ligand docking studies against the estrogen protein of breast cancer using pharmacophore based virtual screening approaches. <i>Saudi Journal of Biological Sciences</i> , 2021, 28, 400-407.	1.8	40
1410	Targeted quantification of B vitamins using ultra-performance liquid chromatography-selected reaction monitoring mass spectrometry in faba bean seeds. <i>Journal of Food Composition and Analysis</i> , 2021, 95, 103687.	1.9	8
1411	Choosing the right drug: status and future of endocannabinoid research for the prevention of drug-seeking reinstatement. <i>Current Opinion in Pharmacology</i> , 2021, 56, 29-38.	1.7	8
1412	Making legitimacy: Drug user representation in United Nations drug policy settings. <i>International Journal of Drug Policy</i> , 2021, 87, 103014.	1.6	13
1413	Diode-like rectification characteristics of BiFeO <sub>3</sub> -based /Zn <sub>1</sub> -Ni Fe <sub>2</sub> O <sub>4</sub> bilayered films for application of ferroelectric field effect transistors. <i>Journal of Alloys and Compounds</i> , 2021, 851, 156818.	2.8	4

#	ARTICLE	IF	CITATIONS
1414	Personality change during substance use disorder treatment is associated with improvements in abstinence self-efficacy post-treatment among U.S. military veterans. <i>Journal of Substance Abuse Treatment</i> , 2021, 120, 108187.	1.5	2
1415	One-equation model to assess population balance kernels in turbulent bubbly flows. <i>Chemical Engineering Science</i> , 2021, 229, 116096.	1.9	3
1416	Morphology-controllable cellulose/chitosan sponge for deep wound hemostasis with surfactant and pore-foaming agent. <i>Materials Science and Engineering C</i> , 2021, 118, 111408.	3.8	34
1417	Dissociation of proprioceptive drift and feelings of ownership in the somatic rubber hand illusion. <i>Acta Psychologica</i> , 2021, 212, 103192.	0.7	12
1418	Unravelling the effect of species mixing on water use and drought stress in Mediterranean forests: A modelling approach. <i>Agricultural and Forest Meteorology</i> , 2021, 296, 108233.	1.9	30
1419	Modelling the influence of the microstructure on the high cycle fatigue crack initiation in short fibre reinforced thermoplastics. <i>Composites Science and Technology</i> , 2021, 201, 108533.	3.8	9
1420	Measurement, simulation and uncertainty quantification of the neutron flux at the McMaster Nuclear Reactor. <i>Annals of Nuclear Energy</i> , 2021, 151, 107879.	0.9	7
1421	The mollification method based on a modified operator to the ill-posed problem for 3D Helmholtz equation with mixed boundary. <i>Applied Numerical Mathematics</i> , 2021, 160, 422-435.	1.2	0
1422	Surface strengthening and grain refinement of AZ31B magnesium alloy by ultrasonic cavitation modification. <i>Chinese Journal of Aeronautics</i> , 2021, 34, 508-517.	2.8	21
1423	Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. <i>European Urology</i> , 2021, 79, 200-211.	0.9	76
1424	Active headrests with selective delayless subband adaptive filters in an aircraft cabin. <i>Mechanical Systems and Signal Processing</i> , 2021, 148, 107164.	4.4	14
1425	Clinical Evaluation of Proline, Glutamic acid, and Leucine-Rich Protein 1 Expression in Astrocytomas and Correlations with the Proliferation Marker Ki-67. <i>Journal of Molecular Neuroscience</i> , 2021, 71, 724-733.	1.1	1
1426	Combining polarized Raman spectroscopy and micropillar compression to study microscale structure-property relationships in mineralized tissues. <i>Acta Biomaterialia</i> , 2021, 119, 390-404.	4.1	26
1427	Variable-rate control system for UAV-based granular fertilizer spreader. <i>Computers and Electronics in Agriculture</i> , 2021, 180, 105832.	3.7	25
1428	Novel non-destructive testing method using a two-electrode planar capacitive sensor based on measured normalized capacitance values. <i>Measurement: Journal of the International Measurement Confederation</i> , 2021, 167, 108455.	2.5	10
1431	The value of anti-neutrophil cytoplasmic antibodies (ANCA) testing for the diagnosis of ANCA-associated vasculitis, a systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2021, 20, 102716.	2.5	33
1432	Potential causal role of l-glutamine in sickle cell disease painful crises: A Mendelian randomization analysis. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 86, 102504.	0.6	14
1433	Major reduction of NKT cells in patients with severe COVID-19 pneumonia. <i>Clinical Immunology</i> , 2021, 222, 108630.	1.4	39



#	ARTICLE	IF	CITATIONS
1434	Investigation of the spontaneous nanoemulsification process with medium- and long-chain triglycerides. <i>Colloids and Surfaces B: Biointerfaces</i> , 2021, 197, 111432.	2.5	7
1435	High-performance and stable inverted perovskite solar cells using low-temperature solution-processed CuNbOx hole transport layer. <i>Journal of Power Sources</i> , 2021, 483, 229194.	4.0	12
1436	Authoritarian populism and emancipatory politics in the rural United States. <i>Journal of Rural Studies</i> , 2021, 82, 500-504.	2.1	11
1437	Facile preparation of worm-like mesoporous tin oxide films with super-hydrophilic surface. <i>Materials Science and Engineering B: Solid-State Materials for Advanced Technology</i> , 2021, 264, 114926.	1.7	5
1438	Speech frequency-following response in human auditory cortex is more than a simple tracking. <i>NeuroImage</i> , 2021, 226, 117545.	2.1	15
1439	No-till and carbon stocks: Is deep soil sampling necessary? Insights from long-term experiments. <i>Soil and Tillage Research</i> , 2021, 206, 104840.	2.6	13
1440	Knowledge and self-perception comparisons between students with and without prior technician experience in community pharmacy lab courses. <i>Currents in Pharmacy Teaching and Learning</i> , 2021, 13, 279-287.	0.4	0
1441	Sutura laparoscópica mecanizada con FlexDex Surgical System® para ubicaciones anatómicamente difíciles. <i>Cirugía Española</i> , 2021, 99, 222-228.	0.1	2
1442	A comparison of two types of electrospun chitosan membranes and a collagen membrane in vivo. <i>Dental Materials</i> , 2021, 37, 60-70.	1.6	13
1443	Integrated gene-based and pathway analyses using UK Biobank data identify novel genes for chronic respiratory diseases. <i>Gene</i> , 2021, 767, 145287.	1.0	7
1444	Multiple retrograde retinal artery emboli as a complication of coil embolization in the region of the ophthalmic artery. <i>Journal Français D'Ophthalmologie</i> , 2021, 44, e51-e54.	0.2	0
1445	Single-wired array light detector based on photoacoustic effect. <i>Optics and Lasers in Engineering</i> , 2021, 139, 106460.	2.0	2
1448	The role of nitrogen in achieving sustainable food systems for healthy diets. <i>Global Food Security</i> , 2021, 28, 100408.	4.0	11
1449	Fibrin clot properties to assess the bleeding phenotype in unrelated patients with hypodysfibrinogenemia due to novel fibrinogen mutations. <i>Thrombosis Research</i> , 2021, 197, 56-64.	0.8	6
1450	Anxiety Sensitivity and Arousal Symptom Implicit Association Task Performance: An Event-Related Potential Study of Cognitive Processing of Anxiety-Relevant Stimuli. <i>Journal of Affective Disorders</i> , 2021, 280, 7-15.	2.0	8
1451	Balanced QSAR analysis to identify the structural requirements of ABBV-075 (Mivebresib) analogues as bromodomain and extraterminal domain (BET) family bromodomain inhibitor. <i>Journal of Molecular Structure</i> , 2021, 1229, 129597.	1.8	5
1453	Neural mechanisms of language learning from social contexts. <i>Brain and Language</i> , 2021, 212, 104874.	0.8	13
1454	Adaptive rag-bull rider: A modified self-adaptive optimization algorithm for epileptic seizure detection with deep stacked autoencoder using electroencephalogram. <i>Biomedical Signal Processing and Control</i> , 2021, 64, 102322.	3.5	13



#	ARTICLE	IF	CITATIONS
1455	G protein-coupled estrogen receptor 1 mediates estrogen effect in red common carp ( <i>Cyprinus carpio</i> ). <i>Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology</i> , 2021, 239, 108868.	1.3	1
1456	A UAV-based framework for crop lodging assessment. <i>European Journal of Agronomy</i> , 2021, 123, 126201.	1.9	22
1457	Soil organic carbon stocks maintained despite intensification of shifting cultivation. <i>Geoderma</i> , 2021, 388, 114804.	2.3	17
1458	Assessment of the cascade of uncertainty in future snow depth projections across watersheds of mountainous, foothill, and plain areas in northern latitudes. <i>Journal of Hydrology</i> , 2021, 598, 125735.	2.3	12
1459	Regulating lithium deposition via bifunctional regular-random cross-linking network solid polymer electrolyte for Li metal batteries. <i>Journal of Power Sources</i> , 2021, 484, 229186.	4.0	28
1460	Opinion leadership vs. para-social relationship: Key factors in influencer marketing. <i>Journal of Retailing and Consumer Services</i> , 2021, 59, 102371.	5.3	92
1461	Effects of Y and Ni co-doping in Bi <sub>2</sub> Fe <sub>4</sub> O <sub>9</sub> - BiFeO <sub>3</sub> based multiferroic ceramics. <i>Materials Today: Proceedings</i> , 2021, 46, 4716-4719.	0.9	3
1462	The market-reach of pandemics: Evidence from female workers in Ethiopia's ready-made garment industry. <i>World Development</i> , 2021, 137, 105179.	2.6	12
1464	Development and verification of a simulation toolkit for Self-Powered Neutron Detector. <i>Annals of Nuclear Energy</i> , 2021, 150, 107784.	0.9	12
1466	ZnO decorated on low carbonate NiAl-layered double hydroxide as efficient photocatalyst for methyl orange degradation. <i>Applied Clay Science</i> , 2021, 201, 105927.	2.6	16
1467	Cellulosic fiber based hybrid composites: A comparative investigation into their structurally influencing mechanical properties. <i>Construction and Building Materials</i> , 2021, 271, 121587.	3.2	8
1468	Synthesis of hydrophobic fluoro-substituted polyaniline filler for the long-term anti-corrosion performance enhancement of epoxy coatings. <i>Corrosion Science</i> , 2021, 178, 109094.	3.0	58
1469	Strategies for supporting the transition from small-group activity to student learning: A possible role for beyond-group sharing. <i>Learning, Culture and Social Interaction</i> , 2021, 28, 100471.	1.1	3
1470	A continuous-flow catalytic process with natural hematite-alginate beads for effective water decontamination and disinfection: Peroxymonosulfate activation leading to dominant sulfate radical and minor non-radical pathways. <i>Chemical Engineering Journal</i> , 2021, 411, 127738.	6.6	32
1471	Emerging functions of the wellbeing concept in regional development scholarship: A review. <i>Environmental Science and Policy</i> , 2021, 115, 143-150.	2.4	18
1472	LES investigation of a Passively Excited Impinging Jet. <i>International Journal of Heat and Mass Transfer</i> , 2021, 165, 120705.	2.5	3
1473	Revisiting the use of the provocative acetylcholine test in patients with chest pain and nonobstructive coronary arteries: A five-year follow-up of the AChPOL registry, with special focus on patients with MINOCA. <i>Translational Research</i> , 2021, 231, 64-75.	2.2	11
1474	Drought monitoring of the maize planting areas in Northeast and North China Plain. <i>Agricultural Water Management</i> , 2021, 245, 106636.	2.4	33

#	ARTICLE	IF	CITATIONS
1475	Predictors of Colorectal Cancer Screening Modality Among Newly Age-Eligible Medicaid Enrollees. <i>American Journal of Preventive Medicine</i> , 2021, 60, 72-79.	1.6	4
1476	Lithium ion batteries with enhanced electrochemical performance by using carbon-coated SiO <sub>x</sub> /Ag composites as anode material. <i>Ceramics International</i> , 2021, 47, 1086-1094.	2.3	18
1477	New insight into the negative impact of imidazolium-based ionic liquid [C10mim]Cl on HeLa cells: From membrane damage to biochemical alterations. <i>Ecotoxicology and Environmental Safety</i> , 2021, 208, 111629.	2.9	21
1478	Influence of hydrogen addition on methane coupling in a moderate pressure microwave plasma. <i>Fuel</i> , 2021, 288, 119674.	3.4	15
1479	Interaction activated interfacial charge transfer in 2D g-C <sub>3</sub> N <sub>4</sub> /GaN nanorods heterostructure for self-powered UV photodetector and room temperature NO <sub>2</sub> gas sensor at ppb level. <i>Sensors and Actuators B: Chemical</i> , 2021, 329, 129175.	4.0	68
1481	Effect of pearlitic morphology with varying fineness on the cavitation erosion behavior of eutectoid rail steel. <i>Ultrasonics Sonochemistry</i> , 2021, 71, 105399.	3.8	17
1483	Tandem conversion of lignin to catechols via demethylation and catalytic hydrogenolysis. <i>Industrial Crops and Products</i> , 2021, 159, 113095.	2.5	27
1484	Efficient air epoxidation of cycloalkenes over bimetal-organic framework ZnCo-MOF materials. <i>Molecular Catalysis</i> , 2021, 499, 111300.	1.0	6
1485	Fractionation of <i>Cynara cardunculus</i> ethanolic extracts using dnanofiltration. <i>Separation and Purification Technology</i> , 2021, 256, 117856.	3.9	4
1486	Numerical investigation of conventional and tapered Savonius hydrokinetic turbines for low-velocity hydropower application in an irrigation channel. <i>Sustainable Energy Technologies and Assessments</i> , 2021, 43, 100871.	1.7	16
1487	Resource assessment of the Copahue geothermal field. <i>Geothermics</i> , 2021, 90, 101987.	1.5	8
1488	Mechanical response of a compressed novel 3D tetrachiral structure processed by MJF 3D printing process. <i>Materials Today: Proceedings</i> , 2021, 46, 4776-4781.	0.9	4
1489	A novel microbiome metabolic modulator improves the growth performance of broiler chickens in multiple trials and modulates targeted energy and amino acid metabolic pathways in the cecal metagenome. <i>Poultry Science</i> , 2021, 100, 100800.	1.5	8
1490	Effects of muscle activity on lumbar spinal stiffness in asymptomatic adults: An investigation using a novel rolling device. <i>Musculoskeletal Science and Practice</i> , 2021, 52, 102301.	0.6	1
1491	Plastic deformation and energy absorption of polycrystalline-like lattice structures. <i>Materials and Design</i> , 2021, 198, 109321.	3.3	33
1492	Irreversible incorporation of L-dopa into the C-terminus of $\alpha$ -tubulin inhibits binding of molecular motor KIF5B to microtubules and alters mitochondrial traffic along the axon. <i>Neurobiology of Disease</i> , 2021, 147, 105164.	2.1	9
1493	Climate change policy and entrepreneurial opportunities. <i>Technological Forecasting and Social Change</i> , 2021, 163, 120446.	6.2	29
1494	Evaluating couch polyurethane foam for a potential passive sampler of semivolatile organic compounds. <i>Chemosphere</i> , 2021, 271, 129349.	4.2	1

#	ARTICLE	IF	CITATIONS
1495	Message from the East About Anticoagulation After Deep Venous Stenting: The Agent Matters in Accomplishing the Mission. <i>European Journal of Vascular and Endovascular Surgery</i> , 2021, 61, 490.	0.8	0
1496	Decoupling hydrodynamic and entanglement effects on the modulus reinforcement of grafted silica filled nanocomposites through Thermal and rheological features. <i>Polymer</i> , 2021, 213, 123323.	1.8	12
1499	Exploring the multilevel effects of triclosan from development, reproduction to behavior using <i>Drosophila melanogaster</i> . <i>Science of the Total Environment</i> , 2021, 762, 144170.	3.9	13
1500	Does love become hate or forgiveness after a double deviation? The case of hotel loyalty program members. <i>Tourism Management</i> , 2021, 84, 104279.	5.8	24
1503	Comment on "Tunability of linear and nonlinear optical absorption in laterally coupled AlxGa1-As/GaAs quantum wires". <i>J. Alloys Compd.</i> 746 (2018) 653-659]. <i>Journal of Alloys and Compounds</i> , 2021, 850, 156302.	2.8	4
1504	Preliminary analyses on decontamination factors during pool scrubbing with bubble size distributions obtained from EPRI experiments. <i>Nuclear Engineering and Technology</i> , 2021, 53, 509-521.	1.1	6
1505	Overview of glioblastoma biological hallmarks and molecular pathology. , 2021, , 1-15.		0
1506	Tumors of the Central Nervous System. , 2021, , 121-145.		0
1507	FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab017.	0.4	6
1508	Structural variant detection in cancer genomes: computational challenges and perspectives for precision oncology. <i>Npj Precision Oncology</i> , 2021, 5, 15.	2.3	30
1510	Prognostic and predictive impact of MGMT promoter methylation in grade 3 gliomas. <i>Journal of Clinical Neuroscience</i> , 2021, 85, 115-121.	0.8	9
1511	Clinical significance of <i>CDKN2A</i> homozygous deletion in combination with methylated <i>MGMT</i> status for <i>IDH</i> wildtype glioblastoma. <i>Cancer Medicine</i> , 2021, 10, 3177-3187.	1.3	21
1512	A New Era of Neuro-Oncology Research Pioneered by Multi-Omics Analysis and Machine Learning. <i>Biomolecules</i> , 2021, 11, 565.	1.8	10
1513	In vivo Engineering of Chromosome 19 q-arm by Employing the CRISPR/AsCpf1 and ddAsCpf1 Systems in Human Malignant Gliomas (Hypothesis). <i>Journal of Molecular Neuroscience</i> , 2021, 71, 1648-1663.	1.1	2
1514	Classification of Diffuse Glioma Subtype from Clinical-Grade Pathological Images Using Deep Transfer Learning. <i>Sensors</i> , 2021, 21, 3500.	2.1	16
1515	Recent Advances in the Treatment of Gliomas: The Multimodal Care Therapy. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2020, 9, 503-508.	0.1	2
1516	Multi-parametric Z-spectral MRI may have a good performance for glioma stratification in clinical patients. <i>European Radiology</i> , 2022, 32, 101-111.	2.3	12
1517	Clinical implications of molecular analysis in diffuse glioma stratification. <i>Brain Tumor Pathology</i> , 2021, 38, 210-217.	1.1	6

#	ARTICLE	IF	CITATIONS
1518	Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study). <i>Cancer Research and Treatment</i> , 2022, 54, 396-405.	1.3	2
1519	Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas. <i>Cancer Research</i> , 2021, 81, 4861-4873.	0.4	7
1520	Prognostic stratification for IDH-wild-type lower-grade astrocytoma by Sanger sequencing and copy-number alteration analysis with MLPA. <i>Scientific Reports</i> , 2021, 11, 14408.	1.6	12
1521	Highly expressed of SERPINA3 indicated poor prognosis and involved in immune suppression in glioma. <i>Immunity, Inflammation and Disease</i> , 2021, 9, 1618-1630.	1.3	15
1522	Evaluation of the Oncomine Comprehensive Assay v3 panel for the detection of 1p/19q codeletion in oligodendroglial tumours. <i>Journal of Clinical Pathology</i> , 2021, , jclinpath-2021-207876.	1.0	1
1523	PICT1 is critical for regulating the Rps27a-Mdm2-p53 pathway by microtubule polymerization inhibitor against cervical cancer. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2021, 1868, 119084.	1.9	9
1524	18F-FET-PET-guided gross total resection improves overall survival in patients with WHO grade III/IV glioma: moving towards a multimodal imaging-guided resection. <i>Journal of Neuro-Oncology</i> , 2021, 155, 71-80.	1.4	9
1526	Chromosomal imbalances associated with response to chemotherapy and cytotoxic cytokines in human malignant glioma cell lines. <i>International Journal of Cancer</i> , 2001, 91, 213-218.	2.3	30
1527	Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. , 2008, , CD007104.		11
1529	Low-Grade Gliomas: Evidence-Based Treatment Options. , 2007, , 93-119.		1
1530	Gliomas. , 2007, , 299-304.		1
1531	Primary Brain Tumors: Characteristics, Practical Diagnostic and Treatment Approaches. , 2010, , 43-75.		4
1532	Chemotherapy Associated Central Nervous System Damage. <i>Advances in Experimental Medicine and Biology</i> , 2010, 678, 77-85.	0.8	36
1533	Adult High-Grade (Diffuse) Glioma. <i>Molecular Pathology Library</i> , 2015, , 77-93.	0.1	2
1534	Neuropathology and Molecular Pathogenesis of Primary Brain Tumors. , 2001, , 3-45.		2
1536	Transcription Profiling of Brain Tumors: Tumor Biology and Treatment Stratification. , 2009, , 529-551.		2
1537	Advances in imaging low-grade gliomas. <i>Advances and Technical Standards in Neurosurgery</i> , 2010, 35, 1-34.	0.2	31
1538	Molecular neuropathology of low-grade gliomas and its clinical impact. <i>Advances and Technical Standards in Neurosurgery</i> , 2010, 35, 35-64.	0.2	7

#	ARTICLE	IF	CITATIONS
1539	Treatment of High-Grade Gliomas in Adults. , 2009, , 355-382.		1
1540	Genetic Pathways to Human Cancer. Handbook of Experimental Pharmacology, 2003, , 25-39.	0.9	1
1541	Cancer of the Central Nervous System. , 2008, , 1075-1136.		1
1542	Cancer and the Nervous System. , 2008, , 1313-1333.		1
1543	Primary Tumors of the Central and Peripheral Nervous System. , 2003, , 827-863.		7
1544	Cancer of the Central Nervous System. , 2014, , 938-1001.e16.		1
1545	The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas. Academic Radiology, 2021, 28, e189-e198.	1.3	17
1548	MRS in brain tumors. , 0, , 61-90.		1
1549	Treatment of oligodendroglioma: An update. Neuro-Oncology, 1999, 1, 61-68.	0.6	12
1550	Transcription factor networks of oligodendrogliomas treated with adjuvant radiotherapy or observation inform prognosis. Neuro-Oncology, 2021, 23, 795-802.	0.6	3
1551	New chemotherapy options for the treatment of malignant gliomas. Current Opinion in Oncology, 1999, 11, 157.	1.1	49
1552	Molecular pathogenesis of malignant gliomas. Current Opinion in Oncology, 1999, 11, 162.	1.1	184
1555	Molecular Imaging of Gliomas. Molecular Imaging, 2002, 1, 309-335.	0.7	63
1556	CIC is a critical regulator of neuronal differentiation. JCI Insight, 2020, 5, .	2.3	21
1557	Adult Gliomas. CONTINUUM Lifelong Learning in Neurology, 2020, 26, 1452-1475.	0.4	8
1558	Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. Neurology, 1999, 53, 1141-1141.	1.5	70
1559	Neuro-oncology: Diagnosis and Management of Cerebral Gliomasâ€”Past, Present, and Future. Neurosurgery, 2000, 47, 1-8.	0.6	93
1560	Imaging biomarkers of angiogenesis and the microvascular environment in cerebral tumours. British Journal of Radiology, 2011, 84, S127-S144.	1.0	52

#	ARTICLE	IF	CITATIONS
1561	Loss of NOTCH2 Positively Predicts Survival in Subgroups of Human Glial Brain Tumors. PLoS ONE, 2007, 2, e576.	1.1	60
1562	Absence of Common Somatic Alterations in Genes on 1p and 19q in Oligodendrogliomas. PLoS ONE, 2011, 6, e22000.	1.1	13
1563	Genetic and Epigenetic Alterations in Primary Progressive Paired Oligodendroglial Tumors. PLoS ONE, 2013, 8, e67139.	1.1	6
1564	PCR-Based Simple Subgrouping Is Validated for Classification of Gliomas and Defines Negative Prognostic Copy Number Aberrations in IDH Mutant Gliomas. PLoS ONE, 2015, 10, e0142750.	1.1	10
1565	DEC1 expression in 1p-aberrant oligodendroglial neoplasms. Histology and Histopathology, 2005, 20, 1173-7.	0.5	12
1566	Genetic analysis to complement histopathological diagnosis of brain tumors. Histology and Histopathology, 2007, 22, 327-35.	0.5	15
1567	PICT-1 is a key nucleolar sensor in DNA damage response signaling that regulates apoptosis through the RPL11-MDM2-p53 pathway. Oncotarget, 2016, 7, 83241-83257.	0.8	12
1568	Remote intracranial recurrence of IDH mutant gliomas is associated with TP53 mutations and an 8q gain. Oncotarget, 2017, 8, 84729-84742.	0.8	9
1569	Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity. Oncotarget, 2014, 5, 7960-7979.	0.8	35
1570	Procarbazine, CCNU and vincristine (PCV) versus temozolomide chemotherapy for patients with low-grade glioma: a systematic review. Oncotarget, 2018, 9, 33623-33633.	0.8	28
1571	Molecular-genetic and clinical characteristics of gliomas with astrocytic appearance and total 1p19q loss in a single institutional consecutive cohort. Oncotarget, 2015, 6, 15871-15881.	0.8	9
1572	Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study. Oncotarget, 2015, 6, 29456-29468.	0.8	23
1573	Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget, 2012, 3, 1194-1203.	0.8	241
1574	Driver or passenger effects of augmented c-Myc and Cdc20 in gliomagenesis. Oncotarget, 2016, 7, 23521-23529.	0.8	5
1575	Chromosomal abnormalities subdivide neuroepithelial tumors into clinically relevant groups. Keio Journal of Medicine, 2006, 55, 52-58.	0.5	4
1576	Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications. Frontiers in Bioscience - Landmark, 2000, 5, d213.	3.0	135
1577	Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging. Journal of Neurosurgery, 2007, 107, 600-609.	0.9	63
1578	Chromosome arm 1q gain associated with good response to chemotherapy in a malignant glioma. Journal of Neurosurgery, 2007, 106, 488-494.	0.9	14

#	ARTICLE	IF	CITATIONS
1579	Malignant Glioma with Neuronal Marker Expression : A Clinicopathological Study of 18 Cases. Journal of Korean Neurosurgical Society, 2015, 59, 44.	0.5	4
1580	Oligodendrogliomas: Impact of molecular genetics on treatment. Neurology India, 2005, 53, 140.	0.2	2
1581	Role of natural killer cells in isocitrate dehydrogenase 1/2 mutant glioma pathogenesis and emerging therapies. Glioma (Mumbai, India), 2019, 2, 133.	0.0	2
1582	Clinical Targeted Next-Generation sequencing Panels for Detection of Somatic Variants in Gliomas. Cancer Research and Treatment, 2020, 52, 41-50.	1.3	14
1583	Neuropathological biomarker candidates in brain tumors: key issues for translational efficiency. , 2010, 29, 41-54.		13
1584	FISH-based detection of 1p 19q codeletion in oligodendroglial tumors: procedures and protocols for neuropathological practice " a publication under the auspices of the Research Committee of the		



#	ARTICLE	IF	CITATIONS
1599	Oligodendroglial Tumors. , 2005, , 167-176.		0
1600	Möglichkeiten und Bedeutung der Neuropathologie für die Neurologie. , 2005, , 127-133.		0
1601	Chemotherapy of Oligoastrocytomas. , 2006, , 382-394.		0
1602	Glioblastoma Multiforme – Past, Present, and Future. Oncology & Hematology Review, 2006, 00, 1.	0.2	1
1604	Chemotherapy for Malignant Gliomas : Randomized Controlled Study and Taylor-made Therapy. Japanese Journal of Neurosurgery, 2006, 15, 3-9.	0.0	0
1605	Primäre Hirntumoren bei Erwachsenen. , 2006, , 3219-3260.		1
1606	Recent advances in the medical therapy of high-grade gliomas. Future Neurology, 2006, 1, 831-842.	0.9	0
1607	Malignome des zentralen Nervensystems (ZNS). , 2007, , 937-954.		0
1610	Neuroimaging Issues in Assessing Response to Brain Tumor Therapy. , 2008, , 504-514.		0
1611	Primary Brain Tumors. , 2008, , 487-493.		0
1613	Malignant Glioma: Chemotherapy Perspective. , 2008, , 223-231.		0
1615	Dendritic Cell Vaccines for Gliomas. Translational Medicine Series, 2008, , 83-108.	0.0	0
1616	Protocol for the Examination of Specimens From Patients With Tumors of the Brain/Spinal Cord. Archives of Pathology and Laboratory Medicine, 2008, 132, 907-912.	1.2	6
1617	Gliomas. , 2009, , 131-136.		0
1618	The Future of Molecular Neuro-Oncology. , 2009, , 3201-3228.		0
1620	Genomic Medicine, Brain Tumors and Gliomas. , 2009, , 956-966.		0
1621	Molecular Markers of Gliomas. , 2009, , 157-177.		0
1622	Tumors of the Brain and Spinal Cord. , 2009, , 601-720.		2

#	ARTICLE	IF	CITATIONS
1624	Intracranial Neoplasms. , 2009, , 49-144.		3
1625	Comprehensive Brain Tumor Management. , 2009, , 735-748.		0
1627	Update on Diagnostic Practice: Tumors of the Nervous System. Archives of Pathology and Laboratory Medicine, 2009, 133, 1062-1077.	1.2	18
1628	Molecular Mechanisms of Pathogenesis in Glioblastoma and Current Therapeutic Strategies. , 2010, , 85-93.		0
1630	Low-Grade Gliomas. Pediatric Oncology, 2010, , 1-35.	0.5	1
1631	Irinotecan and BCNU-Impregnated Wafers Used in Combination, for the Treatment of Patients with Recurrent Glioblastoma Multiforme. Journal of Carcinogenesis & Mutagenesis, 2010, 01, .	0.3	1
1632	Anaplastic Oligodendrogliomas and Mixed Gliomas. , 2011, , 233-248.		0
1633	Low-Grade Gliomas. , 2011, , 173-194.		0
1635	Gliomagenesis: Advantages and Limitations of Biomarkers. , 2011, , 11-24.		1
1636	Oligodendroglioma. , 2011, , 227-232.		0
1640	Brain Tumor Angiogenesis and Glioma Grading: Role of Tumor Blood Volume and Permeability Estimates Using Perfusion CT. , 2011, , 81-91.		0
1643	ProgrÃ©s rÃ©cents dans la gÃ©nÃ©tique et dans le traitement mÃ©dical des gliomes cÃ©rÃ©braux. Bulletin De L'Academie Nationale De Medecine, 2011, 195, 11-21.	0.0	0
1644	Radical Resection of Adult Low Grade Oligodendroglioma without Adjuvant Therapy: Results of a Prospective Treatment Protocolâ€”Surgical Treatment of Low-Grade Oligodendroglioma. Journal of Cancer Therapy, 2011, 02, 235-242.	0.1	1
1646	Genomic Abnormalities in Gliomas. , 0, , .		0
1647	Somatic Alterations and Targeted Therapy. , 2012, , 51-101.		0
1648	Cancer and the Nervous System. , 2012, , 1116-1136.		0
1649	Management of Recurrent Gliomas. , 2012, , 127-140.		0
1650	Malignome des zentralen Nervensystems (ZNS). , 2012, , 919-945.		0

#	ARTICLE	IF	CITATIONS
1651	Management of recurrent gliomas and meningiomas. , 2012, , 347-371.		0
1652	Anaplastic Oligodendroglioma Metastasized to Extraneural Sites. , 2012, , 241-254.		0
1653	Primary Spinal Oligodendroglioma: Diagnosis, Outcome, and Prognosis. , 2012, , 61-70.		0
1654	Cancer and the Nervous System. , 2012, , 1141-1157.		0
1655	Análisis de la codeleción 1p19q como marcador pronóstico en pacientes con glioblastoma primario.. Revista Colombiana De Hematología Y Oncología, 2012, 1, 25-32.	0.0	0
1656	Fluorescence In Situ Hybridization (FISH). , 2013, , 415-439.		0
1657	Managing the Elderly Patient. , 2013, , 171-196.		0
1658	How to Use Molecular Markers When Caring for a Patient with Brain Cancer: 1P/19Q as a Predictive and Prognostic Marker in the Neuro-oncology Clinic. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 114-116.	1.8	0
1659	Bridging Science and Clinical Practice: How to Use Molecular Markers When Caring for a Patient with Brain Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 108-113.	1.8	0
1660	Oligodendroglial Tumors: Intra-arterial Chemotherapy. Tumors of the Central Nervous System, 2014, , 15-22.	0.1	0
1661	Molecular Testing in CNS tumors. , 2014, , 243-255.		0
1663	Integrated Diagnostic Approach for Adult Oligodendroglioma and Oligoastrocytoma. Brain Disorders & Therapy, 2015, 04, .	0.1	2
1664	CIC Mutation as Signature Alteration in Oligodendroglioma. , 2015, , 423-440.		0
1665	Refined Glioma Classification based on Molecular Pathology. Japanese Journal of Neurosurgery, 2015, 24, 366-377.	0.0	0
1666	Techniques in the Resection of Gliomas. Neuro-Oncology Practice, 2015, 5, 3-12.	1.0	0
1667	Targeted Therapies in Brain Tumours: An Overview. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 1-23.	0.1	0
1668	Gliomas. , 2016, , 507-514.		0
1669	Title is missing!. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
1670	THE IMPACT OF THE 2016 WORLD HEALTH ORGANIZATION CLASSIFICATION OF TUMOURS OF THE CENTRAL NERVOUS SYSTEM UPON DIAGNOSIS AND PROGNOSIS. Australasian Medical Journal, 2017, 10, .	0.1	0
1671	Molecular Testing for Glioblastoma. , 2017, , 339-347.		0
1674	Histopathology of Primary Tumors of the Central Nervous System. , 2018, , 21-53.		1
1675	High-Grade Gliomas. , 2018, , 580-585.e2.		0
1676	Primary Brain Tumors in Adults. , 2019, , 869-889.		0
1677	The Applicability of Haarlem Integrated Diagnostic System in Diffuse Glial Tumors and Molecular Methods Affecting Prognosis. Balkan Medical Journal, 2019, 36, 222-228.	0.3	0
1679	Imaging Markers of Lower-Grade Diffuse Glioma. , 2020, , 139-159.		0
1680	Chemotherapy and Future Developments. , 2020, , 29-37.		0
1682	Overview of Modern Surgical Management of Central Nervous System Tumors: North American Experience. Current Cancer Therapy Reviews, 2020, 16, 207-220.	0.2	0
1683	Updates Treatment of Low-Grade Glioma. , 2021, , 437-454.		0
1685	Tumoren des zentralen Nervensystems. , 2005, , 1246-1253.		0
1686	Neoplastic Disorders. , 2005, , 411-439.		0
1688	Histologic Classification of High-Grade Gliomas. , 2007, , 3-35.		0
1691	Molecular Classifications. , 2007, , 37-42.		1
1693	Hirntumorerkrankungen. , 2007, , 139-181.		0
1694	Tumoren des Nervensystems. , 0, , 458-487.		0
1695	Tumoren des zentralen Nervensystems. , 2007, , 1400-1408.		0
1696	Imaging in neurooncology. Neurotherapeutics, 2005, 2, 333-347.	2.1	1

#	ARTICLE	IF	CITATIONS
1697	Factors that affect survival in low grade gliomas and the prognostic significance of the Ki -67 proliferation index. Cumhuriyet Medical Journal, 0, , .	0.1	0
1699	Molecular biology of gliomas: present and future challenges. Translational Medicine @ UniSa, 2014, 10, 29-37.	0.8	33
1700	Management and treatment recommendations for World Health Organization Grade III and IV gliomas. International Journal of Health Sciences, 2017, 11, 54-62.	0.4	4
1701	Multiple Extranodal Metastases of Anaplastic Oligodendroglioma. Journal of Innovative Optical Health Sciences, 2018, 13, 830-833.	0.5	1
1702	VHA Practice Guideline Recommendations for Diffuse Gliomas. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2018, 35, S28-S35.	0.6	1
1703	Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. American Journal of Neuroradiology, 2005, 26, 266-73.	1.2	178
1705	Multiple extraneural metastases of anaplastic oligodendroglioma. Journal of Innovative Optical Health Sciences, 2018, 13, 830.	0.5	3
1706	Short-term outcomes associated with temozolomide or PCV chemotherapy for 1p/19q-codeleted WHO grade 3 oligodendrogliomas: A national evaluation. Neuro-Oncology Practice, 2022, 9, 201-207.	1.0	3
1707	FISH analyses for 1p and 19q status on gliomas: Reporting an 8Âyears' experience from a tertiary care center in the Middle East. Annals of Diagnostic Pathology, 2022, 57, 151899.	0.6	3
1709	Galectin-9/TIM-3 as a Key Regulator of Immune Response in Gliomas With Chromosome 1p/19q Codeletion. Frontiers in Immunology, 2021, 12, 800928.	2.2	6
1712	Cerebral Mass Lesions. , 0, , 151-221.		0
1715	Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma. American Journal of Clinical Pathology, 2005, 124, 755-68.	0.4	25
1716	Integrated proteomic analysis of low-grade gliomas reveals contributions of 1p-19q co-deletion to oligodendroglioma. Acta Neuropathologica Communications, 2022, 10, 70.	2.4	4
1717	What the eyes cannot seeâ€”Limitations of current molecular neuropathological interpretations: A primer. International Journal of Neurooncology, 2021, 4, 46.	0.1	0
1718	Advanced MR (MR Spectroscopy, Diffusion Imaging, Diffusion Tensor Imaging, and Perfusion Imaging). , 2011, , 79-125.		0
1719	Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort. BMC Cancer, 2022, 22, .	1.1	18
1720	Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. Journal of Clinical Oncology, 2022, 40, 2539-2545.	0.8	23
1721	Allelic Losses at 1p36 and 19q13 in Gliomas: Correlation with Histologic Classification, Definition of a 150-kb Minimal Deleted Region on 1p36, and Evaluation of <i>CAMTA1</i> as a Candidate Tumor Suppressor Gene. Clinical Cancer Research, 2005, 11, 1119-1128.	3.2	153

#	ARTICLE	IF	CITATIONS
1722	Identifying Differential Expression Genes and Prognostic Signature Based on Subventricular Zone Involved Glioblastoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
1723	The Tropomyosin Family as Novel Biomarkers in Relation to Poor Prognosis in Glioma. <i>Biology</i> , 2022, 11, 1115.	1.3	4
1724	PTPRD and CNTNAP2 as markers of tumor aggressiveness in oligodendrogliomas. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
1725	Identification of the Prognostic Signatures for Isocitrate Dehydrogenase Mutant Glioma. , 2022, , .		0
1726	The role of Calmodulin Binding Transcription Activator 1 (<sc><i>CAMTA1</i></sc>) gene and its putative genetic partners in the human nervous system. <i>Psychogeriatrics</i> , 2022, 22, 869-878.	0.6	1
1727	New Frontiers in Translational Research in Neuro-oncology and the Blood-Brain Barrier: Report of the Tenth Annual Blood-Brain Barrier Disruption Consortium Meeting. <i>Clinical Cancer Research</i> , 2005, 11, 421-428.	3.2	42
1728	Loss of the AP-2 $\beta$ Transcription Factor Is Associated with the Grade of Human Gliomas. <i>Clinical Cancer Research</i> , 2005, 11, 267-272.	3.2	33
1729	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015â€“2019. <i>Neuro-Oncology</i> , 2022, 24, v1-v95.	0.6	385
1730	Adjuvant Chemoradiation therapy Versus Chemotherapy Alone for Resected Oligodendroglioma: A Surveillance, Epidemiology and End Results (SEER) Analysis. <i>World Neurosurgery</i> , 2022, , .	0.7	0
1731	Successful diffusible brachytherapy (dBT) of a progressive low-grade astrocytoma using the locally injected peptidic vector and somatostatin analogue [90Y] - DOTA 0-D-Phe 1-Tyr 3-octreotide (DOTATOC). <i>Swiss Medical Weekly</i> , 0, , .	0.8	4
1732	Glioma Stem Cells: Novel Data Obtained by Single-Cell Sequencing. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14224.	1.8	10
1733	Molecular Neuropathology versus Histopathology in the Diagnosis of Central Nervous System Tumors: Review Article about Novel Diagnostic and Investigative Technologies. <i>Journal of Biosciences and Medicines</i> , 2022, 10, 55-72.	0.1	0
1734	Central Nervous System Neoplasms in Microgravity. , 2022, , 107-121.		1
1735	Identification of therapeutic targets and prognostic biomarkers among frizzled family genes in glioma. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	1
1736	Review Article: Genetic Polymorphism Studies and Insurgence of Human Genetic Diseases. , 2022, 1, 161-178.		0
1737	Management of Patients with High-Grade Glioma. <i>European Medical Journal Oncology</i> , 0, , 91-99.	0.0	1
1738	Entering a new era of molecular classification of brain tumors: An update of 2021 World Health Organization classification in adult gliomas. <i>Formosan Journal of Surgery</i> , 2023, 56, 43-46.	0.1	0
1739	Intra-Axial Neoplasms. , 2013, , 692-727.		1

#	ARTICLE	IF	CITATIONS
1740	SRSF4 Confers Temozolomide Resistance of Glioma via Accelerating Double Strand Break Repair. Journal of Molecular Neuroscience, 2023, 73, 259-268.	1.1	1
1741	Thirty years of progress in the management of low-grade gliomas. Revue Neurologique, 2023, 179, 425-429.	0.6	2
1745	Quantitative and Physiological Magnetic Resonance Imaging in Glioma. , 2023, , 433-457.		0
1748	Malignant Glioma. Advances in Experimental Medicine and Biology, 2023, , 1-30.	0.8	8
1755	Molecular testing for gliomas. , 2024, , 385-396.		0